GT,Diagnosis 1,ERN Category
['Vitamin B12-unresponsive methylmalonic acidemia'],"+1. Methylmalonic acidemia: Consistent with metabolic acidosis, decreased methylmalonyl-CoA mutase activity, and early death. Key symptoms not reported include developmental delay, lethargy, vomiting, and failure to thrive.

+2. Propionic acidemia: Consistent with metabolic acidosis and early death. However, decreased methylmalonyl-CoA mutase activity is more specific to methylmalonic acidemia.

+3. Isovaleric acidemia: Consistent with metabolic acidosis and early death. However, the key enzyme deficiency (isovaleryl-CoA dehydrogenase) is different from the reported decreased methylmalonyl-CoA mutase activity.

+4. Glutaric acidemia type II: Consistent with metabolic acidosis and early death. However, the key enzyme deficiency (electron transfer flavoprotein or electron transfer flavoprotein:ubiquinone oxidoreductase) is different from the reported decreased methylmalonyl-CoA mutase activity.

+5. Maple syrup urine disease: Consistent with metabolic acidosis and early death. However, the key enzyme deficiency (branched-chain alpha-keto acid dehydrogenase complex) is different from the reported decreased methylmalonyl-CoA mutase activity.",Hereditary metabolic disorders
['Succinic semialdehyde dehydrogenase deficiency'],"+1. Glutaric acidemia type II (Multiple acyl-CoA dehydrogenase deficiency): Consistent with generalized hypotonia, death in infancy, and elevated urinary carboxylic acid. Key symptoms not reported: metabolic acidosis, hypoglycemia, and cardiomyopathy.

+2. Propionic acidemia: Consistent with generalized hypotonia, motor delay, and elevated urinary carboxylic acid. Key symptoms not reported: metabolic acidosis, vomiting, and lethargy.

+3. Methylmalonic acidemia: Consistent with generalized hypotonia, motor delay, and elevated urinary carboxylic acid. Key symptoms not reported: metabolic acidosis, vomiting, and lethargy.

+4. Spinal muscular atrophy (SMA): Consistent with motor delay and generalized hypotonia. Key symptoms not reported: progressive muscle weakness, respiratory distress, and fasciculations.

+5. Leigh syndrome: A mitochondrial disorder that can present with hypotonia, developmental delays, and elevated lactate (a carboxylic acid). Key symptoms not reported: seizures, respiratory distress, and neuroimaging findings.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Tyrosinemia type I: Characterized by hypertyrosinemia, abnormal prenatal development, and neonatal death if untreated. Key symptoms present.

+2. Phenylketonuria (PKU): Characterized by hyperphenylalaninemia, which can lead to developmental abnormalities and intellectual disability if untreated. Key symptoms present.

+3. Tyrosinemia type II: Characterized by hypertyrosinemia, eye and skin abnormalities, and neurological symptoms. Neonatal death is less common than in type I.

+4. Tyrosinemia type III: Characterized by hypertyrosinemia and mild developmental delay. Neonatal death is rare.

+5. Maple syrup urine disease: Characterized by elevated levels of branched-chain amino acids (leucine, isoleucine, and valine), which can lead to neonatal death if untreated. Hypertyrosinemia and hyperphenylalaninemia are not typical symptoms.",Hereditary metabolic disorders
['PMM2-CDG'],"+1. Congenital disorder of glycosylation (CDG): Consistent with congenital diaphragmatic hernia, cerebellar atrophy, failure to thrive, and abnormal muscle physiology. Some types of CDG can present with this combination of symptoms.

+2. Mitochondrial disorder: Consistent with cerebellar atrophy, failure to thrive, abnormal muscle physiology, and potentially the diaphragmatic hernia. Mitochondrial disorders can affect multiple organ systems.

+3. Peroxisomal disorder: Consistent with cerebellar abnormalities, lipodystrophy, and potentially the diaphragmatic hernia and abnormal muscle physiology. Peroxisomal disorders can cause a wide range of symptoms due to their role in lipid metabolism.

+4. Congenital muscular dystrophy: Consistent with the motor delay, abnormal muscle physiology, and potentially the diaphragmatic hernia and cerebellar atrophy. Some forms of congenital muscular dystrophy can involve the brain and diaphragm.

+5. Severe combined malformation syndrome: This is a non-specific diagnosis for a combination of severe congenital malformations affecting multiple organ systems, which could explain the patient's presentation. However, a more specific diagnosis would be preferable if possible.",Hereditary metabolic disorders
['Maple syrup urine disease'],"+1. Maple syrup urine disease (MSUD): Consistent with hypervalinemia, hyperleucinemia, hyperisoleucinemia, developmental delays, neurological symptoms, and elevated urinary carboxylic acid. Key symptom not reported: Maple syrup odor in urine/body fluids.

+2. Methylmalonic acidemia: Consistent with developmental delays, neurological symptoms, and elevated urinary carboxylic acid. Key symptoms not reported: Metabolic acidosis, hyperammonemia, and ketosis.

+3. Propionic acidemia: Consistent with developmental delays, neurological symptoms, and elevated urinary carboxylic acid. Key symptoms not reported: Metabolic acidosis, hyperammonemia, and ketosis.

+4. Glutaric aciduria type II: Consistent with developmental delays, neurological symptoms, and elevated urinary carboxylic acid. Key symptoms not reported: Metabolic acidosis, hypoglycemia, and organic aciduria.

+5. Mitochondrial disorder: Consistent with developmental delays, neurological symptoms, and elevated urinary carboxylic acid. Key symptoms not reported: Lactic acidosis, muscle weakness, and specific organ involvement (e.g., cardiomyopathy, vision/hearing loss).",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Tyrosinemia: Consistent with hypertyrosinemia, skin rash, gastrointestinal inflammation, and potential liver involvement. Key symptoms not reported: neurological symptoms, kidney dysfunction.

+2. Phenylketonuria (PKU): Consistent with hyperphenylalaninemia and potential intellectual disability (if left untreated). Key symptoms not reported: neurological symptoms, musty odor.

+3. Severe combined immunodeficiency (SCID): Consistent with recurrent viral infections, failure to thrive, and potential gastrointestinal involvement. Key symptoms not reported: lymphopenia, opportunistic infections.

+4. Inflammatory bowel disease (IBD): Consistent with gastrointestinal inflammation, diarrhea, and potential skin manifestations. Key symptoms not reported: abdominal pain, bloody stools, weight loss.

+5. Leaky gut syndrome: Consistent with gastrointestinal inflammation, diarrhea, and potential skin manifestations. Key symptoms not reported: food intolerances, nutrient deficiencies.",Hereditary metabolic disorders
['Biotinidase deficiency'],"+1. Mitochondrial disorder: Skin rash, alopecia, increased lactate levels in blood and CSF, potentially leading to death in infancy. Key symptoms not reported: neurological manifestations, developmental delays.

+2. Organic acidemia: Skin rash, alopecia, increased lactate levels in blood and CSF, potentially leading to death in infancy. Key symptoms not reported: metabolic acidosis, vomiting, failure to thrive.

+3. Leukodystrophy (e.g., Krabbe disease, metachromatic leukodystrophy): Skin rash, alopecia, increased lactate levels in CSF, potentially leading to death in infancy. Key symptoms not reported: neurological deficits, developmental regression.

+4. Severe combined immunodeficiency (SCID): Skin rash, alopecia, recurrent infections potentially leading to death in infancy. Key symptoms not reported: increased susceptibility to infections, failure to thrive.

+5. Congenital disorder of glycosylation (CDG): Skin rash, alopecia, potentially leading to death in infancy. Key symptoms not reported: developmental delays, neurological manifestations, coagulopathy.",Hereditary metabolic disorders
['PMM2-CDG'],"+1. Niemann-Pick disease type C: Rod-cone dystrophy, intellectual disability, cerebellar atrophy, thromboembolism, abnormal facial shape, lipodystrophy, acute and chronic hepatitis. Key symptoms not reported: Hepatosplenomegaly, vertical supranuclear gaze palsy.

+2. Chronic visceral acid sphingomyelinase deficiency: Intellectual disability, cerebellar atrophy, thromboembolism, abnormal facial shape, lipodystrophy, acute and chronic hepatitis. Key symptoms not reported: Hepatosplenomegaly, pancytopenia, cherry-red spot on the macula.

+3. Mitochondrial disorder: Rod-cone dystrophy, intellectual disability, cerebellar atrophy, acute and chronic hepatitis. Key symptoms not reported: Muscle weakness, lactic acidosis, seizures.

+4. Congenital disorder of glycosylation (CDG): Intellectual disability, abnormal facial shape, acute and chronic hepatitis. Key symptoms not reported: Hypoglycemia, coagulopathy, protein-losing enteropathy.

+5. Peroxisomal disorder (e.g., Zellweger syndrome): Intellectual disability, abnormal facial shape, acute and chronic hepatitis. Key symptoms not reported: Hypotonia, seizures, hearing loss, renal cysts.",Hereditary metabolic disorders
['Glutaryl-CoA dehydrogenase deficiency'],"+1. Glutaric acidemia type 1 (GA1): Consistent with macrocephaly, generalized hypotonia, dystonia, glutaric aciduria, and decreased plasma free carnitine. Key symptom not reported: subdural hemorrhage.

+2. Carnitine deficiency disorders: Consistent with generalized hypotonia, lethargy, and decreased plasma free carnitine. Key symptoms not reported: cardiomyopathy, skeletal muscle weakness.

+3. Fatty acid oxidation disorders: Consistent with generalized hypotonia, lethargy, and decreased plasma free carnitine. Key symptoms not reported: hepatomegaly, hypoglycemia.

+4. Glutaric acidemia type 2: Consistent with generalized hypotonia, lethargy, and glutaric aciduria. Key symptoms not reported: congenital anomalies, metabolic acidosis.

+5. Organic acidemias (other than glutaric acidemias): Consistent with generalized hypotonia, lethargy, and metabolic decompensation. Key symptoms not reported: specific metabolic markers for each disorder.",Hereditary metabolic disorders
['Isovaleric acidemia'],"+1. Urea cycle disorder: Consistent with hyperammonemia, lethargy, and potential for neonatal or early childhood death. Key symptoms not reported: vomiting, seizures, coma.

+2. Organic acidemia: Matches hyperammonemia, lethargy, and potential for neonatal or early childhood death. Key symptoms not reported: metabolic acidosis, ketosis, vomiting.

+3. Fatty acid oxidation disorder: Consistent with lethargy, feeding difficulties, and potential for metabolic decompensation. Key symptoms not reported: hypoglycemia, hepatomegaly, cardiomyopathy.

+4. Glycine encephalopathy: Aligns with abnormal circulating glycine concentration, lethargy, and potential for neonatal or early childhood death. Key symptoms not reported: seizures, respiratory distress, hypotonia.

+5. Carnitine deficiency: Matches abnormal circulating carnitine concentration, lethargy, and potential for metabolic decompensation. Key symptoms not reported: cardiomyopathy, skeletal muscle weakness, hypoglycemia.",Hereditary metabolic disorders
['PMM2-CDG'],"+1. Congenital disorders of glycosylation (CDGs): Consistent with intellectual disability, ataxia, hypotonia, cerebellar atrophy, and other neurological manifestations. Some forms of CDGs can also present with microcephaly and growth delay.

+2. Mucolipidosis type IV: Matches the symptoms of microcephaly, strabismus, nystagmus, intellectual disability, cerebellar atrophy, hypotonia, and early death. This disorder is characterized by severe neurological impairment and developmental delay.

+3. Pontocerebellar hypoplasia: Consistent with the cerebellar agenesis or hypoplasia, intellectual disability, ataxia, hypotonia, and other neurological manifestations. Different subtypes of pontocerebellar hypoplasia can present with varying degrees of cerebellar involvement and additional features.

+4. Congenital muscular dystrophies (e.g., Walker-Warburg syndrome, muscle-eye-brain disease): These disorders can present with brain malformations, including cerebellar hypoplasia or atrophy, along with intellectual disability, hypotonia, and eye abnormalities like strabismus and nystagmus. However, the patient's symptoms may not fully align with the typical presentation of these conditions.

+5. Inherited metabolic disorders affecting brain development: Other inherited metabolic disorders, such as peroxisomal disorders, mitochondrial disorders, or leukodystrophies, can sometimes present with a similar constellation of neurological symptoms, including microcephaly, intellectual disability, ataxia, hypotonia, and cerebellar abnormalities. Additional testing may be required to identify the specific disorder.",Hereditary metabolic disorders
"['Methylmalonic acidemia with homocystinuria, type cblC']","+1. Methylmalonic acidemia: Consistent with methylmalonic aciduria, hyperammonemia, and developmental delays. Key symptoms not reported: metabolic acidosis, lethargy, vomiting.

+2. Propionic acidemia: Consistent with hyperammonemia, developmental delays, and elevated urinary carboxylic acids. Key symptoms not reported: metabolic acidosis, ketosis, protein avoidance.

+3. Glutaric acidemia type II: Consistent with hyperalaninemia, elevated urinary carboxylic acids, hypotonia, and developmental delays. Key symptoms not reported: metabolic acidosis, macrocephaly, dystonia.

+4. Mitochondrial disorder: Consistent with neurological symptoms (strabismus, nystagmus, optic atrophy), developmental delays, hypotonia, and metabolic abnormalities. Specific type cannot be determined without additional testing.

+5. Carnitine deficiency: Consistent with abnormal circulating carnitine concentration, which can lead to metabolic decompensation and developmental delays. Key symptoms not reported: cardiomyopathy, hypoglycemia, hepatic encephalopathy.",Hereditary metabolic disorders
['Medium chain acyl-CoA dehydrogenase deficiency'],"+1. Fatty acid oxidation disorder: Consistent with hypoglycemia, elevated liver enzymes, and abnormal carnitine levels. Key symptom not reported: metabolic acidosis.

+2. Organic acidemia: Consistent with vomiting, elevated liver enzymes, and potential metabolic crises. Key symptoms not reported: lethargy, metabolic acidosis, hyperammonemia.

+3. Galactosemia: Consistent with vomiting, diarrhea, hypoglycemia, and liver dysfunction. Key symptom not reported: jaundice.

+4. Hereditary fructose intolerance: Consistent with hypoglycemia, vomiting, and liver dysfunction. Key symptom not reported: aversion to sweet foods.

+5. Mitochondrial disorder: Consistent with multi-organ involvement and potential energy deficiency. Key symptoms not reported: neurological manifestations, lactic acidosis.",Hereditary metabolic disorders
['Succinic semialdehyde dehydrogenase deficiency'],"+1. Organic acidemia: Consistent with coma, respiratory acidosis, and elevated urinary carboxylic acid. Key symptoms not reported: specific metabolic derangements or organ involvement.

+2. Fatty acid oxidation disorder: Consistent with coma, respiratory acidosis, and potential metabolic decompensation. Key symptoms not reported: hypoglycemia, hepatic involvement, or specific metabolic markers.

+3. Mitochondrial disorder: Consistent with multi-organ dysfunction, respiratory acidosis, and potential lactic acidosis (not explicitly reported). Key symptoms not reported: specific neurological or muscular manifestations.

+4. Severe sepsis or septic shock: Consistent with electrolyte imbalances, respiratory acidosis, and potential multi-organ failure. Key symptoms not reported: fever, specific infectious source, or other signs of sepsis.

+5. Neonatal hyperammonemia: Consistent with coma and potential metabolic derangement. Key symptoms not reported: specific ammonia levels or other metabolic markers.",Hereditary metabolic disorders
['Homocystinuria due to cystathionine beta-synthase deficiency'],"+1: Homocystinuria due to cystathionine beta-synthase deficiency: Consistent with ectopia lentis, intellectual disability, motor delay, large hands, long feet, hyperhomocystinemia, and hypermethioninemia.

+2: Marfan syndrome: Consistent with ectopia lentis, large hands, and long feet. However, the patient does not report other typical features like aortic dilation or skeletal abnormalities.

+3: Fabry disease: Consistent with fatigue and potential intellectual disability. However, the patient does not report other characteristic symptoms like neuropathic pain, angiokeratomas, or renal involvement.

+4: Niemann-Pick disease type C: Consistent with intellectual disability and potential motor delay. However, the patient does not report other typical features like hepatosplenomegaly, vertical supranuclear gaze palsy, or ataxia.

+5: Chronic visceral acid sphingomyelinase deficiency: Consistent with intellectual disability and potential motor delay. However, the patient does not report other characteristic symptoms like hepatosplenomegaly, pulmonary involvement, or hematological abnormalities.",Hereditary metabolic disorders
[],"+1. Congenital disorder of glycosylation (CDG): Wide mouth, epicanthus, seizures, hypoglycemia, and death in infancy/childhood are consistent with a CDG. Sparse hair and carious teeth can also be seen in some types of CDGs.

+2. Galactosemia: Seizures, hypoglycemia, feeding difficulties, and abnormal hemoglobin can occur in galactosemia. However, the patient lacks classic symptoms like jaundice, vomiting, and liver problems.

+3. Glycogen storage disease: Seizures, hypoglycemia, and failure to thrive can be seen in some types of glycogen storage diseases. The lack of hepatomegaly makes this less likely.

+4. Mitochondrial disorder: Seizures, hypoglycemia, and death in infancy/childhood can occur in severe mitochondrial disorders. However, the patient does not have the typical features like lactic acidosis, muscle weakness, or neurological regression.

+5. Amino acid disorder: Certain amino acid disorders, such as maple syrup urine disease, can present with seizures, feeding difficulties, and abnormal laboratory findings. However, the patient does not have the characteristic maple syrup odor or other specific symptoms.",Hereditary metabolic disorders
['Propionic acidemia'],"+1. Glycine encephalopathy (non-ketotic hyperglycinemia): Consistent with intellectual disability, seizures, hyperglycinemia, and early death. Does not typically cause anemia or hepatomegaly.

+2. Urea cycle disorder (e.g., citrullinemia, argininosuccinic aciduria): Consistent with hyperammonemia, intellectual disability, seizures, and hepatomegaly. Does not explain hyperglycinemia or hypoglycinemia.

+3. Methylmalonic acidemia: Consistent with metabolic decompensation, hyperammonemia, seizures, developmental delay, anemia, and abnormal circulating carnitine concentration. Hyperglycinemia and hypoglycinemia are not typical features.

+4. Propionic acidemia: Consistent with metabolic decompensation, hyperammonemia, seizures, developmental delay, anemia, and abnormal circulating carnitine concentration. Hyperglycinemia and hypoglycinemia are not typical features.

+5. Glutaric aciduria type II: Consistent with metabolic decompensation, seizures, developmental delay, and hypoglycinemia. Does not typically cause hyperammonemia, hyperglycinemia, anemia, or hepatomegaly.",Hereditary metabolic disorders
['Vitamin B12-unresponsive methylmalonic acidemia'],"+1. Methylmalonic acidemia (MMA): Consistent with generalized hypotonia, metabolic acidosis, methylmalonic aciduria, decreased methylmalonyl-CoA mutase activity, and abnormal nervous system physiology. Key symptoms not reported: developmental delay, lethargy, and failure to thrive.

+2. Propionic acidemia: Consistent with metabolic acidosis, thrombocytopenia, and abnormal nervous system physiology. However, the presence of methylmalonic aciduria and decreased methylmalonyl-CoA mutase activity is more specific for MMA.

+3. Isovaleric acidemia: Consistent with metabolic acidosis and abnormal nervous system physiology. However, the presence of methylmalonic aciduria and decreased methylmalonyl-CoA mutase activity is not typical for this disorder.

+4. Glutaric acidemia type II: Consistent with metabolic acidosis and abnormal nervous system physiology. However, the presence of methylmalonic aciduria and decreased methylmalonyl-CoA mutase activity is not typical for this disorder.

+5. Maple syrup urine disease: Consistent with metabolic acidosis and abnormal nervous system physiology. However, the presence of methylmalonic aciduria and decreased methylmalonyl-CoA mutase activity is not typical for this disorder.",Hereditary metabolic disorders
['Systemic primary carnitine deficiency'],"+1. Organic acidemia: Consistent with abnormal amino acid levels, hypoglycemia, vomiting, and potential metabolic crises. Key symptoms not reported: specific aciduria, ketoacidosis.

+2. Fatty acid oxidation disorder: Consistent with hypoglycemia, elevated liver enzymes, and potential metabolic decompensation. Key symptoms not reported: hypoketotic hypoglycemia, cardiomyopathy.

+3. Mitochondrial disorder: Consistent with multi-system involvement, elevated lactate dehydrogenase, and potential metabolic crises. Key symptoms not reported: lactic acidosis, neurological manifestations.

+4. Glycogen storage disease: Consistent with hypoglycemia, elevated liver enzymes, and potential metabolic decompensation. Key symptoms not reported: hepatomegaly, growth retardation.

+5. Urea cycle disorder: Consistent with hyperammonemia (suggested by abnormal amino acid levels), vomiting, and potential metabolic crises. Key symptoms not reported: specific orotic aciduria, neurological manifestations.",Hereditary metabolic disorders
['3-methylcrotonyl-CoA carboxylase deficiency'],"+1. Organic acidemia: Lethargy, drowsiness, poor feeding, and decreased plasma free carnitine are consistent with this group of inborn errors of metabolism. Key symptoms not reported: metabolic acidosis, vomiting, failure to thrive.

+2. Fatty acid oxidation disorder: Lethargy, clumsiness, poor coordination, and decreased plasma free carnitine could fit with a disorder of fatty acid metabolism. Key symptoms not reported: hypoglycemia, liver dysfunction, cardiomyopathy.

+3. Mitochondrial disorder: Lethargy, poor coordination, feeding difficulties, and potential multi-system involvement could suggest a mitochondrial disease. Key symptoms not reported: seizures, vision or hearing loss, lactic acidosis.

+4. Leukodystrophy: Progressive neurological symptoms, such as lethargy, clumsiness, and poor coordination, could be seen in certain leukodystrophies. Key symptoms not reported: vision or hearing loss, spasticity, cognitive decline.

+5. Neuronal ceroid lipofuscinosis: This group of neurodegenerative disorders can present with lethargy, clumsiness, seizures, and eventual death in childhood. Key symptoms not reported: vision loss, seizures, cognitive decline.",Hereditary metabolic disorders
[],"+1. Mitochondrial disorder: Consistent with neurological symptoms, encephalopathy, muscle involvement (cytochrome C oxidase-negative fibers), and metabolic abnormalities. Key symptoms not reported: lactic acidosis, stroke-like episodes.

+2. Organic acidemia (e.g., ethylmalonic acidemia, methylmalonic acidemia): Consistent with ethylmalonic aciduria, metabolic abnormalities, and neurological symptoms. Key symptoms not reported: specific metabolic derangements associated with the specific disorder.

+3. Leukodystrophy (e.g., X-linked adrenoleukodystrophy, metachromatic leukodystrophy): Consistent with neurological symptoms, developmental delays, and potential metabolic disturbances. Key symptoms not reported: specific white matter changes on neuroimaging.

+4. Glycine encephalopathy: Consistent with abnormal circulating glycine concentration, neurological symptoms, and encephalopathy. Key symptoms not reported: specific metabolic derangements associated with the disorder.

+5. Combined oxidative phosphorylation defect: Consistent with neurological symptoms, encephalopathy, muscle involvement (cytochrome C oxidase-negative fibers), and metabolic abnormalities. Key symptoms not reported: lactic acidosis, specific enzyme deficiencies.",Hereditary metabolic disorders
['Medium chain acyl-CoA dehydrogenase deficiency'],"+1 Fatty acid oxidation disorder: Abnormal circulating carnitine concentration, potentially fatal neonatal presentation. Key symptoms not reported: hypoglycemia, metabolic acidosis, hyperammonemia.

+2 Carnitine transporter deficiency: Abnormal circulating carnitine concentration, potentially fatal neonatal presentation. Key symptoms not reported: hypoglycemia, metabolic acidosis, cardiomyopathy.

+3 Severe congenital malformation or chromosomal abnormality: Abnormality of prenatal development or birth, neonatal death. Key symptoms not reported: specific structural defects or dysmorphic features.

+4 Mitochondrial disorder: Abnormality of prenatal development or birth, neonatal death, potentially abnormal circulating carnitine concentration. Key symptoms not reported: lactic acidosis, multi-organ dysfunction.

+5 Peroxisomal disorder: Abnormal circulating carnitine concentration, potentially fatal neonatal presentation. Key symptoms not reported: hypoglycemia, hepatic dysfunction, neurological abnormalities.",Hereditary metabolic disorders
['Glutaryl-CoA dehydrogenase deficiency'],"+1. Glutaric aciduria type 1 (GA1): Matches the patient's macrocephaly, metabolic acidosis, glutaric aciduria, decreased plasma free carnitine, neurological symptoms (hypotonia, dystonia, lethargy), and potentially life-threatening encephalopathic crises. Key symptoms not reported: dystonic movements, subdural hemorrhages.

+2. Methylmalonic acidemia: A possible alternative organic acidemia, but the patient's symptoms do not specifically point to this condition. Key symptoms not reported: developmental delay, recurrent vomiting, lethargy, dehydration, and metabolic acidosis.

+3. Propionic acidemia: Another organic acidemia to consider, but the patient's symptoms are not entirely specific for this condition. Key symptoms not reported: developmental delay, lethargy, vomiting, protein avoidance, and metabolic acidosis.

+4. Mitochondrial encephalomyopathy: A group of disorders that could potentially explain some of the patient's symptoms, such as hypotonia, metabolic acidosis, and neurological manifestations. However, the specific finding of glutaric aciduria is not typically seen in mitochondrial disorders.

+5. Leigh syndrome: A severe mitochondrial disorder that can present with hypotonia, dystonia, and metabolic acidosis. However, the presence of glutaric aciduria and macrocephaly are not typical features of this condition.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Phenylketonuria (PKU): Hyperphenylalaninemia, potential brain damage and developmental abnormalities.
+2. Tyrosinemia type I: Hypertyrosinemia, liver disease, kidney disease, neurological problems. Key symptom of elevated tyrosine levels is present.
+3. Tyrosinemia type II: Hypertyrosinemia, eye problems, skin problems, neurological issues. Also matches the elevated tyrosine levels.
+4. Tyrosinemia type III: Hypertyrosinemia, neurological problems, intellectual disability. Another type of tyrosinemia consistent with the elevated tyrosine levels.
+5. Maple syrup urine disease (MSUD): Elevated levels of leucine, isoleucine, valine, and sometimes tyrosine and phenylalanine. Can lead to metabolic crisis and death if untreated.",Hereditary metabolic disorders
['L-2-hydroxyglutaric aciduria'],"+1. Leukodystrophy: Delayed speech and language development, intellectual disability, hyperreflexia, difficulty walking and climbing stairs, abnormal cerebral white matter morphology, and early death are consistent with this group of disorders affecting the brain's white matter.

+2. Mitochondrial disorder: The progressive course, intellectual disability, motor difficulties, and early death could be explained by a severe mitochondrial disorder affecting energy production in cells.

+3. Neuronal ceroid lipofuscinosis (NCL): Intellectual disability, hyperreflexia, and abnormal white matter are consistent with NCLs, but the lack of reported seizures or vision problems makes this less likely.

+4. Neurodegenerative disorder: Conditions like infantile neuroaxonal dystrophy or Pelizaeus-Merzbacher disease can present with intellectual disability, motor difficulties, and white matter abnormalities, along with a progressive course.

+5. Organic acidemia: Although metabolic acidosis or other metabolic abnormalities are not reported, some organic acidemias can lead to developmental delays, seizures, and progressive neurological decline, which could potentially fit the patient's presentation.",Hereditary metabolic disorders
['Maple syrup urine disease'],"+1. Maple syrup urine disease (MSUD): Consistent with generalized hypotonia, hypoglycemia, hypervalinemia, hyperleucinemia, and hyperisoleucinemia. Classic symptoms include a distinctive maple syrup odor (not mentioned).

+2. Propionic acidemia: Consistent with hypoglycemia, hypotonia, and elevated BCAA levels. However, the patient does not exhibit metabolic acidosis or ketosis, which are common features of this disorder.

+3. Isovaleric acidemia: Consistent with hypoglycemia and elevated BCAA levels. However, the characteristic ""sweaty feet"" odor is not mentioned.

+4. Methylmalonic acidemia: A disorder of organic acid metabolism that can present with hypotonia, developmental delay, and metabolic acidosis. However, the patient does not exhibit the typical elevated methylmalonic acid levels or other characteristic features.

+5. Glutaric aciduria type II: A disorder of fatty acid and amino acid metabolism that can present with hypotonia, hypoglycemia, and metabolic acidosis. However, the patient does not exhibit the characteristic elevated glutaric acid levels or other specific features.",Hereditary metabolic disorders
['Classic galactosemia'],"+1: Classic galactosemia: Delayed speech and language development, death in infancy/adolescence, increased total bilirubin, abnormality of galactoside metabolism, hypergalactosemia. Key symptoms not reported: hepatomegaly, failure to thrive, vomiting.

+2: Maple syrup urine disease (MSUD): Hyperalaninemia, aminoaciduria, abnormal circulating aspartate family amino acid concentration, abnormal circulating tyrosine concentration. Key symptoms not reported: maple syrup odor, lethargy, seizures.

+3: Combined disorder of galactose and amino acid metabolism: Delayed speech and language development, obesity, death in infancy/adolescence, hyperalaninemia, aminoaciduria, increased total bilirubin, abnormality of galactoside metabolism, abnormal circulating aspartate family amino acid concentration, abnormal circulating tyrosine concentration, hypergalactosemia.

+4: Urea cycle disorder: Hyperalaninemia, aminoaciduria, increased total bilirubin. Key symptoms not reported: lethargy, vomiting, respiratory distress, protein intolerance.

+5: Organic acidemia: Aminoaciduria, abnormal circulating aspartate family amino acid concentration, abnormal circulating tyrosine concentration. Key symptoms not reported: metabolic acidosis, ketosis, vomiting, lethargy.",Hereditary metabolic disorders
['3-hydroxy-3-methylglutaric aciduria'],"+1. Methylmalonic acidemia: Consistent with metabolic acidosis, hyperammonemia, and elevated methylmalonic acid levels. Key symptom not reported: Hyperglycinemia.

+2. Isovaleric acidemia: Consistent with metabolic acidosis, vomiting, and elevated isovaleric acid levels (dicarboxylic aciduria). Key symptoms not reported: Sweaty feet odor, neutropenia.

+3. Glutaric acidemia type II: Consistent with metabolic acidosis, dicarboxylic aciduria (elevated glutaric and 3-methylglutaconic acids), and abnormal glycine levels. Key symptoms not reported: Hypoglycemia, lactic acidosis.

+4. Propionic acidemia: Consistent with metabolic acidosis, hyperammonemia, and elevated propionic acid levels (dicarboxylic aciduria). Key symptoms not reported: Ketosis, pancytopenia.

+5. Maple syrup urine disease: Consistent with metabolic acidosis, hyperammonemia, and abnormal amino acid levels (elevated branched-chain amino acids). Key symptoms not reported: Maple syrup odor, lethargy.",Hereditary metabolic disorders
['Homocystinuria due to cystathionine beta-synthase deficiency'],"+1. Homocystinuria due to cystathionine beta-synthase deficiency: Consistent with hyperhomocystinemia, hypomethioninemia, and progressive neurologic deterioration. Does not typically present with jaundice or recurrent viral infections.

+2. Methylenetetrahydrofolate reductase deficiency: Consistent with hyperhomocystinemia, anemia, and neurologic symptoms. Does not fully explain jaundice or recurrent viral infections.

+3. Disorders of cobalamin (vitamin B12) metabolism: Consistent with hyperhomocystinemia, anemia, and neurologic deterioration. Do not typically cause jaundice or hypomethioninemia.

+4. Hereditary coproporphyria: A disorder of porphyrin metabolism that can cause jaundice, neurologic symptoms, and abnormal circulating porphyrin concentration. However, it does not explain the hyperhomocystinemia or hypomethioninemia.

+5. Combined disorder of folate and cobalamin metabolism: A potential explanation for the combination of symptoms, but specific genetic or metabolic defects would need to be identified.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Phenylketonuria (PKU): Consistent with hyperphenylalaninemia, potentially leading to developmental abnormalities, neurological issues, and early death if untreated. Key symptom not reported: intellectual disability or developmental delay.

+2. Tyrosinemia type I: Consistent with hypertyrosinemia, potentially causing liver disease, kidney dysfunction, neurological issues, and respiratory failure. Key symptoms not reported: liver dysfunction, renal tubular dysfunction, or neurological symptoms.

+3. Maple syrup urine disease (MSUD): A branched-chain amino acid metabolism disorder that can cause respiratory distress, developmental delay, and early death if untreated. Key symptoms not reported: maple syrup odor, lethargy, or neurological symptoms.

+4. Methylmalonic acidemia: An organic acid disorder that can cause respiratory distress, developmental delay, and early death if untreated. Key symptoms not reported: metabolic acidosis, lethargy, or neurological symptoms.

+5. Propionic acidemia: An organic acid disorder that can cause respiratory distress, developmental delay, and early death if untreated. Key symptoms not reported: metabolic acidosis, lethargy, or neurological symptoms.",Hereditary metabolic disorders
['Biotinidase deficiency'],"+1. Organic acidemia: Consistent with seizures, spasticity, apathy, elevated urinary carboxylic acid. May not explain alopecia or dyspnea.

+2. Mitochondrial disorder: Consistent with seizures, spasticity, apathy, fatigue, dyspnea, elevated urinary carboxylic acid. May not explain alopecia or death in infancy.

+3. Fatty acid oxidation disorder: Consistent with seizures, apathy, fatigue, dyspnea, elevated urinary carboxylic acid. May not explain alopecia, spasticity, or death in infancy.

+4. Peroxisomal disorder: Consistent with seizures, apathy, fatigue, dyspnea, elevated urinary carboxylic acid. May not explain alopecia, spasticity, or death in infancy.

+5. Leukodystrophy: Consistent with seizures, spasticity, apathy, fatigue. May not explain alopecia, dyspnea, or elevated urinary carboxylic acid.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Tyrosinemia type I: Consistent with hypertyrosinemia, gastrointestinal inflammation, and potential fatal complications. Key symptoms not reported: liver disease, liver cancer.

+2. Maple syrup urine disease (MSUD): Consistent with potentially fatal metabolic decompensation and neonatal/childhood death. Key symptoms not reported: maple syrup odor, neurological symptoms.

+3. Phenylketonuria (PKU): Consistent with hyperphenylalaninemia. Key symptoms not reported: neurological impairment, developmental delays.

+4. Urea cycle disorder: Consistent with potentially fatal metabolic decompensation and neonatal/childhood death. Key symptoms not reported: hyperammonemia, neurological symptoms.

+5. Organic acidemia: A group of disorders that can present with metabolic decompensation, vomiting, and potentially fatal complications. Key symptoms not reported: specific organic acid elevations, neurological symptoms.",Hereditary metabolic disorders
['Biotinidase deficiency'],"+1. Glycine encephalopathy (non-ketotic hyperglycinemia): Abnormal circulating glycine concentration, metabolic acidosis, aminoaciduria. Key symptoms not reported: seizures, developmental delay, hypotonia.

+2. Propionic acidemia: Metabolic acidosis, aminoaciduria, elevated urinary carboxylic acid. Key symptoms not reported: vomiting, lethargy, developmental delay, protein avoidance.

+3. Methylmalonic acidemia: Metabolic acidosis, aminoaciduria, elevated urinary carboxylic acid. Key symptoms not reported: vomiting, lethargy, developmental delay, protein avoidance.

+4. Mitochondrial disorder (e.g., Leigh syndrome, MELAS): Metabolic acidosis, increased CSF lactate, potential multi-system involvement. Key symptoms not reported: developmental delay, seizures, hypotonia, neurological deficits.

+5. Biotinidase deficiency: Metabolic acidosis, skin rash, alopecia, aminoaciduria. Key symptoms not reported: seizures, developmental delay, hearing loss, ataxia.",Hereditary metabolic disorders
['Vitamin B12-unresponsive methylmalonic acidemia'],"+1. Methylmalonic acidemia: Matches the decreased methylmalonyl-CoA mutase activity, and can present with neonatal death, dehydration, and feeding difficulties.

+2. Propionic acidemia: Another inherited disorder of amino acid metabolism that can present with similar severe neonatal symptoms.

+3. Isovaleric acidemia: An organic acidemia that can lead to neonatal metabolic decompensation, dehydration, and feeding difficulties.

+4. Glutaric acidemia type II: An inherited disorder of multiple acyl-CoA dehydrogenases, which can present with neonatal metabolic decompensation and early death.

+5. Multiple carboxylase deficiency: A disorder affecting several enzymes involved in amino acid and organic acid metabolism, which can present with severe neonatal symptoms.",Hereditary metabolic disorders
['Biotinidase deficiency'],"+1. Propionic acidemia (PA): Consistent with propionyl-CoA carboxylase deficiency, metabolic acidosis, lethargy, hypotonia, and elevated urinary carboxylic acids. Key symptoms not reported: vomiting, poor feeding, and developmental delays.

+2. Methylmalonic acidemia (MMA): Consistent with metabolic acidosis, lethargy, hypotonia, and elevated urinary carboxylic acids. Key symptoms not reported: vomiting, developmental delays, and failure to thrive.

+3. Pyruvate carboxylase deficiency: Consistent with decreased pyruvate carboxylase activity, lactic acidosis, hypotonia, and lethargy. Key symptoms not reported: developmental delays and neurological abnormalities.

+4. Organic acidemia (unspecified): Consistent with metabolic acidosis, lethargy, hypotonia, and elevated urinary carboxylic acids. Additional information is needed to specify the exact type of organic acidemia.

+5. Aminoacidopathy (unspecified): Consistent with aminoaciduria and abnormal circulating glycine concentration. Additional information is needed to specify the exact type of aminoacidopathy.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Tyrosinemia type I: Characterized by hypertyrosinemia, abnormality of prenatal development, and potential neonatal or early childhood death if untreated. Key symptoms present.

+2. Phenylketonuria (PKU): Characterized by hyperphenylalaninemia, intellectual disability, seizures, and potential developmental abnormalities if untreated. Key symptoms present.

+3. Maple syrup urine disease (MSUD): Characterized by accumulation of branched-chain amino acids, neurological damage, coma, and potential death if untreated. Hypertyrosinemia and hyperphenylalaninemia may be present.

+4. Homocystinuria: A rare inherited disorder caused by a deficiency of the enzyme cystathionine beta-synthase, leading to accumulation of homocysteine and other metabolites. Can cause developmental delays, intellectual disability, and other neurological problems. Hypertyrosinemia and hyperphenylalaninemia may be present.

+5. Organic acidemias: A group of inherited metabolic disorders characterized by the accumulation of organic acids, including methylmalonic acidemia and propionic acidemia. Can cause developmental delays, seizures, and potentially life-threatening complications. Hypertyrosinemia and hyperphenylalaninemia may be present.",Hereditary metabolic disorders
['3-hydroxy-3-methylglutaric aciduria'],"+1. 3-Methylglutaconic aciduria type I: Consistent with dicarboxylic aciduria, 3-methylglutaric aciduria, and elevated urinary carboxylic acid. Typically presents in infancy with metabolic acidosis and other life-threatening complications.

+2. Glutaric aciduria type II: Consistent with dicarboxylic aciduria, 3-methylglutaric aciduria, and elevated urinary carboxylic acid. Can present with similar metabolic abnormalities as 3-methylglutaconic aciduria.

+3. Isovaleric acidemia: Consistent with dicarboxylic aciduria and elevated urinary carboxylic acid. However, the patient did not report the characteristic ""sweaty feet"" odor associated with this disorder.

+4. Propionic acidemia: Consistent with dicarboxylic aciduria and elevated urinary carboxylic acid. However, the patient did not report other common symptoms such as vomiting, lethargy, and developmental delay.

+5. Methylmalonic acidemia: Consistent with dicarboxylic aciduria and elevated urinary carboxylic acid. However, the patient did not report other common symptoms such as vomiting, lethargy, and developmental delay.",Hereditary metabolic disorders
['Wilson disease'],"+1. Wilson's disease: Carious teeth, obesity, elevated circulating hepatic transaminase concentration, death in childhood, abnormal circulating porphyrin concentration, decreased circulating ceruloplasmin concentration, increased urinary copper concentration, decreased circulating copper concentration. Key symptoms not reported: neurological manifestations (tremors, dysarthria, dystonia), Kayser-Fleischer rings.

+2. Menkes disease: Decreased circulating ceruloplasmin concentration, decreased circulating copper concentration. Key symptoms not reported: kinky or steely hair, hypothermia, seizures, developmental delay.

+3. Hereditary fructose intolerance: Obesity, elevated circulating hepatic transaminase concentration, death in childhood, abnormal circulating aspartate family amino acid concentration, abnormal circulating alanine concentration. Key symptoms not reported: vomiting, abdominal pain, hypoglycemia after fructose ingestion.

+4. Maple syrup urine disease: Abnormal circulating aspartate family amino acid concentration, abnormal circulating alanine concentration. Key symptoms not reported: maple syrup odor, lethargy, poor feeding, developmental delay.

+5. Tyrosinemia type I: Elevated circulating hepatic transaminase concentration, death in childhood, abnormal circulating aspartate family amino acid concentration, abnormal circulating alanine concentration. Key symptoms not reported: failure to thrive, rickets, hepatic failure, neurological crises.",Hereditary metabolic disorders
['Medium chain acyl-CoA dehydrogenase deficiency'],"+1. Fatty acid oxidation disorder: Abnormal circulating carnitine concentration, potentially leading to metabolic decompensation and neonatal death. Key symptoms not reported: hypoglycemia, metabolic acidosis, hyperammonemia.

+2. Carnitine transporter deficiency: Abnormal circulating carnitine concentration, potentially leading to metabolic crises and neonatal death. Key symptoms not reported: hypoglycemia, metabolic acidosis, cardiomyopathy.

+3. Severe congenital malformation or chromosomal abnormality: Abnormality of prenatal development or birth, potentially incompatible with life and leading to neonatal death. Key symptoms not reported: specific structural defects or dysmorphic features.

+4. Mitochondrial disorder: Abnormality of prenatal development or birth, potentially leading to energy deficiency, metabolic crises, and neonatal death. Key symptoms not reported: lactic acidosis, multi-organ dysfunction, neurological manifestations.

+5. Congenital disorder of glycosylation: Abnormality of prenatal development or birth, potentially affecting multiple organ systems and leading to neonatal death. Key symptoms not reported: specific dysmorphic features, neurological manifestations, coagulopathy.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Tyrosinemia type I: Hypertyrosinemia, death in infancy/childhood. Key symptoms not reported: liver disease, kidney disease, neurological problems.

+2. Phenylketonuria (PKU): Hyperphenylalaninemia. Key symptoms not reported: intellectual disability, seizures, neurological problems.

+3. Maple syrup urine disease (MSUD): Recurrent infections, death in infancy/childhood. Key symptoms not reported: accumulation of branched-chain amino acids, neurological problems, coma.

+4. Urea cycle disorders: Death in infancy/childhood. Key symptoms not reported: hyperammonemia, neurological problems.

+5. Organic acidemias: Death in infancy/childhood, recurrent infections. Key symptoms not reported: specific organic acid accumulation, metabolic acidosis, neurological problems.",Hereditary metabolic disorders
['3-methylcrotonyl-CoA carboxylase deficiency'],"+1. Organic acidemia: Consistent with elevated urinary carboxylic acid and potential aminoaciduria. Key symptoms not reported: metabolic acidosis, vomiting, lethargy.

+2. Urea cycle disorder: Consistent with aminoaciduria and potential abnormal glycine levels. Key symptoms not reported: hyperammonemia, lethargy, vomiting.

+3. Fatty acid oxidation disorder: Consistent with abnormal circulating carnitine concentration and potential elevated urinary organic acids. Key symptoms not reported: hypoglycemia, lethargy, liver dysfunction.

+4. Amino acid metabolism disorder: Consistent with aminoaciduria and abnormal circulating amino acid levels. Key symptoms not reported: specific clinical manifestations depending on the disorder (e.g., neurological symptoms in PKU, maple syrup odor in MSUD).

+5. Glycine encephalopathy: Consistent with abnormal circulating glycine concentration and potential aminoaciduria. Key symptoms not reported: neurological symptoms, seizures, developmental delay.",Hereditary metabolic disorders
['Carbamoyl-phosphate synthetase 1 deficiency'],"+1. Mitochondrial disorder: Generalized hypotonia, hepatomegaly, tachypnea, 3-methylglutaconic aciduria, neonatal death, and feeding difficulties are consistent with a mitochondrial disorder. Key symptoms not reported include seizures, lactic acidosis, and neuroimaging abnormalities.

+2. Organic acidemia (e.g., 3-methylglutaconic aciduria type I or II): The presence of 3-methylglutaconic aciduria suggests an organic acidemia, which can also cause hypotonia, hepatomegaly, and feeding difficulties. Additional symptoms like metabolic acidosis, seizures, or developmental delay may be expected but were not reported.

+3. Glycogen storage disorder: Hepatomegaly and hypotonia are consistent with certain glycogen storage disorders, but the other reported symptoms are less typical for this group of disorders.

+4. Congenital disorder of glycosylation (CDG): Some forms of CDG can present with hypotonia, hepatomegaly, and feeding difficulties, although the 3-methylglutaconic aciduria is not a common feature.

+5. Severe congenital neuromuscular disorder: The generalized hypotonia, feeding difficulties, and neonatal death could potentially be explained by a severe congenital neuromuscular disorder, although the other reported symptoms are not typical for this category.",Hereditary metabolic disorders
['Citrullinemia type I'],"+1. Citrullinemia type I: Consistent with elevated plasma citrulline, oroticaciduria, hyperammonemia, and liver dysfunction. Key symptoms not reported: cerebral edema, hypoargininemia, hyperprolinemia.

+2. Methylmalonic acidemia: Consistent with metabolic disturbances, developmental delays, and lethargy. Key symptoms not reported: metabolic acidosis, ketosis, and specific organic aciduria.

+3. Propionic acidemia: Consistent with metabolic disturbances, developmental delays, and lethargy. Key symptoms not reported: metabolic acidosis, ketosis, and specific organic aciduria.

+4. Mitochondrial disorder: Consistent with multi-system involvement, metabolic disturbances, and developmental delays. Key symptoms not reported: specific biochemical markers or organ involvement.

+5. Fatty acid oxidation disorder: Consistent with hypoglycemia, lethargy, and metabolic decompensation. Key symptoms not reported: specific biochemical markers or organ involvement.",Hereditary metabolic disorders
['Glutaryl-CoA dehydrogenase deficiency'],"+1. Glutaryl-CoA dehydrogenase deficiency: Consistent with macrocephaly, seizures, hypotonia, athetosis, and glutaric aciduria. Key symptoms not reported include encephalopathic crises and subdural hemorrhages.

+2. Organic aciduria: Consistent with seizures, hypotonia, and metabolic abnormalities. However, the specific finding of glutaric aciduria makes this a less likely diagnosis.

+3. Disorder of amino acid metabolism: Consistent with neurological symptoms and metabolic abnormalities. However, the presence of glutaric aciduria is more specific for certain organic acidurias.

+4. Leukodystrophy: Consistent with macrocephaly, seizures, and neurological symptoms. However, the presence of glutaric aciduria is not typical for leukodystrophies.

+5. Mitochondrial disorder: Consistent with neurological symptoms and metabolic abnormalities. However, the specific finding of glutaric aciduria is not commonly seen in mitochondrial disorders.",Hereditary metabolic disorders
['Tyrosinemia type 1'],"+1. Tyrosinemia type III (4-hydroxyphenylpyruvic dioxygenase deficiency): Consistent with 4-hydroxyphenylpyruvic aciduria, hypertyrosinemia, and developmental delay. Key symptom not reported: liver disease.

+2. Tyrosinemia type I (fumarylacetoacetate hydrolase deficiency): Consistent with hypertyrosinemia, developmental delay, and potential early mortality. Key symptom not reported: liver failure.

+3. Acute intermittent porphyria: Consistent with elevated urinary delta-aminolevulinic acid. Key symptoms not reported: abdominal pain, neurological symptoms.

+4. Phenylketonuria (PKU): Consistent with abnormal circulating phenylalanine concentration and developmental delay. Key symptom not reported: hypopigmentation.

+5. Combined disorder of tyrosine and porphyrin metabolism: Consistent with multiple reported symptoms, but rare and would require further investigation.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Phenylketonuria (PKU): Hyperphenylalaninemia, intellectual disability (if untreated), and other neurological symptoms. The patient did not report intellectual disability or neurological symptoms.

+2. Maple syrup urine disease (MSUD): Elevated levels of branched-chain amino acids (leucine, isoleucine, valine), maple syrup odor in urine, and severe metabolic crises. The patient did not report a maple syrup odor or specific amino acid elevations.

+3. Methylmalonic acidemia: An organic acidemia characterized by elevated methylmalonic acid levels, metabolic acidosis, and other severe symptoms. The patient did not report metabolic acidosis or specific organic acid elevations.

+4. Propionic acidemia: An organic acidemia with elevated propionic acid levels, metabolic acidosis, and other severe symptoms. The patient did not report metabolic acidosis or specific organic acid elevations.

+5. Isovaleric acidemia: An organic acidemia with elevated isovaleric acid levels, a sweaty feet odor, and other severe symptoms. The patient did not report a sweaty feet odor or specific organic acid elevations.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Succinic semialdehyde dehydrogenase deficiency (SSADHD): Consistent with intellectual disability, seizures, hyperactivity, and obesity. Key symptom not reported: delayed language development.

+2. Tyrosinemia type I: Consistent with hypertyrosinemia, hyperphenylalaninemia, elevated urinary carboxylic acid, and early mortality. Key symptoms not reported: liver disease, renal tubular dysfunction.

+3. Methylmalonic acidemia: Consistent with severe short stature, early mortality, and elevated urinary carboxylic acid. Key symptoms not reported: metabolic acidosis, hyperammonemia, developmental delay.

+4. Propionic acidemia: Consistent with severe short stature, early mortality, and elevated urinary carboxylic acid. Key symptoms not reported: metabolic acidosis, hyperammonemia, developmental delay.

+5. Glutaric aciduria type I: Consistent with intellectual disability, seizures, and elevated urinary carboxylic acid. Key symptoms not reported: macrocephaly, dystonia, metabolic acidosis.",Hereditary metabolic disorders
['Vitamin B12-unresponsive methylmalonic acidemia'],"+1. Methylmalonic acidemia (MMA): Consistent with seizures, generalized hypotonia, metabolic acidosis, hyperammonemia, vomiting, methylmalonic acidemia, and methylmalonic aciduria. Neonatal death can occur in severe cases.

+2. Propionic acidemia: Consistent with metabolic acidosis, hyperammonemia, and elevated methylmalonic acid levels. May also present with seizures, vomiting, and hypotonia.

+3. Cobalamin (vitamin B12) deficiency: Can lead to methylmalonic acidemia and related symptoms like seizures, hypotonia, and metabolic acidosis. Deficiency may be inherited or acquired.

+4. Holocarboxylase synthetase deficiency: A rare disorder that can cause methylmalonic acidemia and metabolic acidosis due to impaired biotin metabolism. May also present with seizures, hypotonia, and developmental delay.

+5. Succinyl-CoA ligase deficiency: A mitochondrial disorder that can cause methylmalonic acidemia, metabolic acidosis, and hyperammonemia. May also present with seizures, hypotonia, and developmental delay.",Hereditary metabolic disorders
['Medium chain acyl-CoA dehydrogenase deficiency'],"+1. Fatty acid oxidation disorder: Abnormal circulating carnitine concentration, potentially leading to metabolic decompensation and neonatal death. Key symptoms may include hypoglycemia, metabolic acidosis, and cardiomyopathy.

+2. Organic acidemia: Abnormal circulating carnitine concentration, potentially leading to metabolic decompensation and neonatal death. Key symptoms may include metabolic acidosis, hyperammonemia, and neurological manifestations.

+3. Primary carnitine deficiency: Abnormal circulating carnitine concentration, potentially leading to metabolic decompensation and neonatal death. Key symptoms may include cardiomyopathy, hypoglycemia, and metabolic acidosis.

+4. Mitochondrial disorder: Abnormal circulating carnitine concentration, potentially leading to metabolic decompensation and neonatal death. Key symptoms may include lactic acidosis, multisystem involvement, and neurological manifestations.

+5. Carnitine palmitoyltransferase I deficiency: Abnormal circulating carnitine concentration, potentially leading to metabolic decompensation and neonatal death. Key symptoms may include hypoketotic hypoglycemia, liver dysfunction, and cardiomyopathy.",Hereditary metabolic disorders
['Vitamin B12-unresponsive methylmalonic acidemia'],"+1: Methylmalonic acidemia: Consistent with metabolic acidosis, hyperammonemia, vomiting, and methylmalonic aciduria. This group of disorders involves defects in the metabolism of methylmalonic acid, leading to its accumulation.

+2: Propionic acidemia: Consistent with metabolic acidosis, hyperammonemia, vomiting, and methylmalonic aciduria. This disorder involves a defect in the metabolism of propionyl-CoA, which can lead to the accumulation of methylmalonic acid as a secondary metabolite.

+3: Isovaleric acidemia: Consistent with metabolic acidosis, vomiting, and methylmalonic aciduria. This disorder involves a defect in the metabolism of isovaleric acid, which can lead to the accumulation of other organic acids, including methylmalonic acid.

+4: Glutaric acidemia type II: Consistent with metabolic acidosis, hyperammonemia, and methylmalonic aciduria. This disorder involves a defect in the metabolism of multiple organic acids, including glutaric acid and methylmalonic acid.

+5: Recurrent metabolic encephalomyopathic crises-rhabdomyolysis-cardiac arrhythmia-intellectual disability syndrome: Consistent with metabolic acidosis and hyperammonemia. This rare disorder involves defects in energy metabolism and can lead to various metabolic disturbances, including acidosis and hyperammonemia.",Hereditary metabolic disorders
['Ornithine transcarbamylase deficiency'],"+1. Citrullinemia type I: Seizures, hyperammonemia, cerebral edema, oroticaciduria, and neonatal death are consistent with this urea cycle disorder caused by a deficiency of argininosuccinate synthetase. Key missing symptom: Hypoargininemia.

+2. Ornithine transcarbamylase deficiency: Seizures, hyperammonemia, cerebral edema, and neonatal death fit this urea cycle disorder. Key missing symptoms: Elevated glutamine, orotic aciduria (sometimes present).

+3. Methylmalonic acidemia: Seizures, hyperammonemia, and cerebral edema can occur in this organic acidemia. Key missing symptoms: Metabolic acidosis, ketosis, elevated methylmalonic acid levels.

+4. Propionic acidemia: Seizures, hyperammonemia, and cerebral edema are seen in this organic acidemia. Key missing symptoms: Metabolic acidosis, ketosis, elevated propionylcarnitine levels.

+5. Argininosuccinic aciduria: Seizures, hyperammonemia, and cerebral edema can present in this urea cycle disorder. Key missing symptoms: Argininosuccinic aciduria, hypoargininemia.",Hereditary metabolic disorders
['Biotinidase deficiency'],"+1. Glutaric aciduria type 1: Seizures, hypotonia, alopecia, and elevated urinary carboxylic acids are consistent with this disorder. However, death in infancy is not a typical feature.

+2. Maple syrup urine disease (MSUD): Seizures, hypotonia, growth delay, and elevated urinary carboxylic acids are consistent with this disorder. Alopecia and fasciculations are not common symptoms.

+3. Mitochondrial disorder (e.g., Leigh syndrome, mtDNA depletion syndrome): Seizures, hypotonia, growth delay, and elevated lactate (a carboxylic acid) are consistent with these disorders. Alopecia and fasciculations are not typical symptoms.

+4. Peroxisomal disorder (e.g., Zellweger syndrome, D-bifunctional protein deficiency): Seizures, hypotonia, growth delay, and elevated urinary carboxylic acids are consistent with these disorders. Alopecia and fasciculations are not common symptoms.

+5. Organic acidemia or fatty acid oxidation disorder (unspecified): The combination of symptoms suggests a metabolic disorder involving organic acids or fatty acid metabolism, but the specific diagnosis is unclear based on the provided information.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Phenylketonuria (PKU): Hyperphenylalaninemia, consistent with other symptoms.
+2. Tyrosinemia: Hypertyrosinemia, consistent with other symptoms.
+3. Homocystinuria: Hyperphenylalaninemia, consistent with other symptoms. Key symptom of homocystinuria (elevated homocysteine levels) not reported.
+4. Maple syrup urine disease (MSUD): Obesity, consistent with other symptoms. Key symptom of maple syrup odor not reported.
+5. Niemann-Pick disease type C: Hypercholesterolemia, consistent with other symptoms. Key symptoms of neurological involvement and hepatosplenomegaly not reported.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Phenylketonuria (PKU): Characterized by hyperphenylalaninemia, consistent with the patient's symptoms. Premature birth and severe short stature can be associated complications.

+2. Tyrosinemia type I: Characterized by hypertyrosinemia, liver disease, renal tubular dysfunction (possibly explaining the hypospadias), growth failure, and neonatal death, consistent with the patient's symptoms.

+3. Maple syrup urine disease (MSUD): A disorder of branched-chain amino acid metabolism, which can present with hypospadias, growth failure, and neonatal death in severe cases, consistent with the patient's symptoms.

+4. Homocystinuria: A disorder of methionine metabolism, which can present with hypospadias, growth failure, and intellectual disability. However, the patient's symptoms do not specifically mention the characteristic features of homocystinuria.

+5. Methylmalonic acidemia: A disorder of organic acid metabolism, which can present with growth failure, developmental delay, and metabolic acidosis. However, the patient's symptoms do not specifically mention the characteristic features of methylmalonic acidemia.",Hereditary metabolic disorders
['Smith-Lemli-Opitz syndrome'],"+1. Smith-Lemli-Opitz syndrome (SLOS): Characterized by microcephaly, intellectual disability, delayed development, dysmorphic features (low-set ears, wide nasal bridge, syndactyly), and elevated 7/8-dehydrocholesterol levels due to a defect in cholesterol biosynthesis.

+2. Congenital disorder of glycosylation (CDG): A group of inherited metabolic disorders affecting protein glycosylation, some forms can present with developmental delays, intellectual disability, and dysmorphic features, but cholesterol abnormalities are not typically seen.

+3. Peroxisomal disorder (e.g., Zellweger syndrome): Can involve developmental delays, dysmorphic features, and hearing loss, but cholesterol abnormalities are not a common finding.

+4. Chromosomal abnormality (e.g., trisomy 18 or 13): Can present with intellectual disability, growth delays, and physical malformations, but cholesterol abnormalities would not be expected.

+5. Severe combined malformation syndrome: A non-specific diagnosis for patients with multiple congenital anomalies and developmental delays, without a clear underlying cause identified.",Hereditary metabolic disorders
['Glutaryl-CoA dehydrogenase deficiency'],"+1. Glutaric acidemia type 1 (GA1): Consistent with ataxia, opisthotonus, athetosis, progressive neurologic deterioration, glutaric aciduria, elevated circulating glutaric acid concentration, and early death. Key symptoms not reported include macrocephaly and subdural hemorrhage.

+2. Methylmalonic acidemia: Consistent with ataxia, progressive neurologic deterioration, and elevated circulating acylcarnitine concentration. However, no specific mention of methylmalonic aciduria or elevated methylmalonic acid levels.

+3. Propionic acidemia: Consistent with ataxia, progressive neurologic deterioration, and elevated circulating acylcarnitine concentration. However, no specific mention of propionic aciduria or elevated propionic acid levels.

+4. Mitochondrial disorders: Consistent with ataxia, progressive neurologic deterioration, and elevated circulating lactate concentration (not reported). However, no specific mitochondrial dysfunction symptoms mentioned.

+5. Neurodegenerative disorders (e.g., Leigh syndrome, NARP syndrome): Consistent with ataxia, progressive neurologic deterioration, and early death. However, no specific neuroimaging or biochemical findings suggestive of these disorders are reported.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Tyrosinemia type I: Characterized by hypertyrosinemia, liver disease, renal tubular dysfunction, neurological symptoms (hypotonia, motor delay), and potentially fatal if untreated. The patient's hypertyrosinemia and severe outcomes are consistent with this diagnosis.

+2. Phenylketonuria (PKU): An inborn error of phenylalanine metabolism, leading to hyperphenylalaninemia, intellectual disability, and other neurological symptoms if untreated. The patient's hyperphenylalaninemia and motor delay/hypotonia are consistent with this condition.

+3. Maple syrup urine disease (MSUD): A branched-chain amino acid disorder characterized by elevated levels of leucine, isoleucine, and valine. While not specifically mentioned, MSUD can present with hypotonia, developmental delay, and potentially fatal outcomes in severe cases.

+4. Glutaric aciduria type I: An organic acidemia that can present with hypotonia, motor delay, and metabolic crises in infancy. The patient's symptoms are consistent, but specific metabolic testing would be needed to confirm this diagnosis.

+5. Nonketotic hyperglycinemia: A rare inborn error of glycine metabolism that can present with hypotonia, seizures, and developmental delay in infancy. While not specifically mentioned, it should be considered in the differential diagnosis for this patient's presentation.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Tyrosinemia type I: Consistent with hypertyrosinemia, hyperphenylalaninemia, seizures, and liver/kidney dysfunction. Key symptoms not reported: liver failure, cirrhosis, renal tubular dysfunction.

+2. Maple syrup urine disease (MSUD): Consistent with seizures, hypotonia, and metabolic abnormalities. Key symptoms not reported: maple syrup odor, lethargy, poor feeding.

+3. Nonketotic hyperglycinemia: Consistent with seizures, hypotonia, and apnea. Key symptoms not reported: elevated glycine levels, developmental delays.

+4. Mitochondrial disorder: Consistent with seizures, hypotonia, apnea, and metabolic abnormalities. Key symptoms not reported: lactic acidosis, muscle weakness, developmental delays.

+5. Organic acidemia: Consistent with seizures, hypotonia, and metabolic abnormalities. Key symptoms not reported: specific organic acid elevations, metabolic acidosis, vomiting.",Hereditary metabolic disorders
['Tyrosinemia type 1'],"+1: Tyrosinemia type I: Consistent with hypertyrosinemia, elevated alkaline phosphatase, elevated alpha-fetoprotein, intellectual disability, seizures, and potential for early death. Key symptom not reported: liver failure or cirrhosis.

+2: Phenylketonuria (PKU): Consistent with hyperphenylalaninemia, intellectual disability, seizures, and developmental delay. Key symptoms not reported: musty odor, fair skin/hair.

+3: Autism spectrum disorder: Consistent with autistic behavior, intellectual disability, and developmental delay. Does not explain metabolic abnormalities.

+4: Maple syrup urine disease: Consistent with intellectual disability, seizures, and abnormal amino acid levels. Does not explain hypertyrosinemia or elevated alkaline phosphatase.

+5: Homocystinuria: Consistent with intellectual disability, seizures, and abnormal amino acid levels. Does not explain hypertyrosinemia or elevated alkaline phosphatase.",Hereditary metabolic disorders
['Classic galactosemia'],"+1: Classic galactosemia: Consistent with hypergalactosemia, neonatal death/death in infancy, vomiting, and increased bilirubin. Key symptom not reported: jaundice, hepatomegaly, failure to thrive.

+2: Hereditary fructose intolerance: Consistent with vomiting, increased bilirubin, and potential neonatal complications. However, hypergalactosemia is not a typical feature.

+3: Maple syrup urine disease: Consistent with neonatal death/death in infancy and potential metabolic crisis. However, hypergalactosemia and increased bilirubin are not typical symptoms.

+4: Tyrosinemia type I: Consistent with neonatal death/death in infancy, vomiting, and increased bilirubin (due to liver dysfunction). However, hypergalactosemia is not a typical feature.

+5: Galactokinase deficiency: Consistent with hypergalactosemia and potential neonatal complications. However, neonatal death/death in infancy is less common compared to classic galactosemia.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Phenylketonuria (PKU): Hyperphenylalaninemia, abnormal circulating tyrosine concentration. Neonatal death and abnormality of prenatal development or birth can occur in severe, untreated cases.

+2. Tetrahydrobiopterin deficiency: Can cause hyperphenylalaninemia and abnormal tyrosine levels, similar to PKU. May present with developmental abnormalities and early death in severe cases.

+3. Liver disorder affecting amino acid metabolism: Liver dysfunction can lead to abnormal amino acid levels, including hyperphenylalaninemia and altered tyrosine levels. Prenatal/neonatal complications are possible in severe cases.

+4. Genetic syndrome with hyperphenylalaninemia: Certain genetic syndromes, such as biopterin deficiency disorders or disorders of biogenic amine metabolism, can present with hyperphenylalaninemia and other metabolic abnormalities.

+5. Transient neonatal hyperphenylalaninemia: A temporary elevation of phenylalanine levels in newborns, often resolving within a few weeks. However, the reported neonatal death and prenatal abnormalities suggest a more severe underlying condition.",Hereditary metabolic disorders
['Biotinidase deficiency'],"+1. Fatty acid oxidation disorder: Consistent with obesity, abnormal carnitine levels, and potential early death. Key symptoms not reported: hypoglycemia, cardiomyopathy, liver dysfunction.

+2. Carnitine deficiency disorder: Consistent with obesity, abnormal carnitine levels, and potential early death. Key symptoms not reported: hypoglycemia, cardiomyopathy, muscle weakness.

+3. Mitochondrial disorder: Consistent with obesity, abnormal carnitine levels, and potential early death. Key symptoms not reported: neurological involvement, multi-system dysfunction.

+4. Glycogen storage disease type II (Pompe disease): Consistent with obesity, potential early death. Key symptoms not reported: hypotonia, respiratory distress, cardiomyopathy.

+5. Glycogen storage disease (other types): Consistent with obesity, potential early death. Key symptoms not reported: hepatomegaly, hypoglycemia, muscle weakness.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Phenylketonuria (PKU): Hyperphenylalaninemia, intellectual disability, potential for early death if untreated. Key symptom not reported: fair skin, blue eyes, musty odor.

+2. Tyrosinemia: Hypertyrosinemia, intellectual disability, potential for early death if untreated. Key symptoms not reported: liver disease, kidney disease, rickets.

+3. Maple syrup urine disease (MSUD): Intellectual disability, potential for early death if untreated. Key symptoms not reported: maple syrup odor, lethargy, poor feeding.

+4. Urea cycle disorders (e.g., ornithine transcarbamylase deficiency): Intellectual disability, potential for early death if untreated. Key symptoms not reported: hyperammonemia, vomiting, lethargy.

+5. Non-ketotic hyperglycinemia: Intellectual disability, potential for early death if untreated. Key symptoms not reported: seizures, hypotonia, respiratory distress.",Hereditary metabolic disorders
['Smith-Lemli-Opitz syndrome'],"+1. Smith-Lemli-Opitz syndrome (SLOS): Consistent with microcephaly, intellectual disability, motor delay, hypotonia, syndactyly, feeding difficulties, hypocholesterolemia, elevated 8-dehydrocholesterol, elevated circulating 7-dehydrocholesterol concentration. Key symptom not reported: Characteristic facial features (e.g., ptosis, anteverted nares, micrognathia).

+2. Zellweger spectrum disorders (ZSDs): Consistent with developmental delays, hypotonia, seizures, hearing impairment, feeding difficulties, vomiting, hypoxemia. Key symptoms not reported: Hepatic dysfunction, renal cysts, calcific stippling of the patellae.

+3. Congenital disorders of glycosylation (CDGs): Consistent with developmental delays, hypotonia, seizures, feeding difficulties, vomiting, skin rash. Key symptoms not reported: Coagulopathy, hepatic dysfunction, cerebellar hypoplasia.

+4. Fetal Gaucher disease: Consistent with developmental delays, hypotonia, skin rash, hepatosplenomegaly (not reported), thrombocytopenia (not reported). Key symptoms not reported: Ichthyosiform erythroderma, death in infancy.

+5. Niemann-Pick disease type C: Consistent with developmental delays, hypotonia, seizures, feeding difficulties, vomiting, hepatosplenomegaly (not reported). Key symptoms not reported: Vertical supranuclear gaze palsy, gelastic cataplexy.",Hereditary metabolic disorders
['Canavan disease'],"+1. Leukodystrophy: Strabismus, hyporeflexia, generalized hypotonia, cerebral atrophy, and death in infancy are consistent with a progressive leukodystrophy. Key symptoms not reported include developmental regression and specific neurological deficits.

+2. Neuronal ceroid lipofuscinosis: The combination of neurological symptoms (strabismus, hyporeflexia, hypotonia), cerebral atrophy, and early death could indicate a neuronal ceroid lipofuscinosis. However, the patient did not report seizures or visual impairment, which are common in these disorders.

+3. Organic acidemia: The abnormal circulating aspartate family amino acid concentration could suggest an organic acidemia. However, the patient did not report metabolic acidosis, vomiting, or other typical metabolic symptoms.

+4. Aminoacidopathy: Similar to organic acidemias, the abnormal amino acid levels could indicate an aminoacidopathy. However, the neurological symptoms and cerebral atrophy are not typical of most aminoacidopathies.

+5. Congenital muscular dystrophy: The generalized hypotonia and death in infancy could be explained by a severe congenital muscular dystrophy. However, the cerebral atrophy, strabismus, and hyporeflexia are less common in these disorders.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Tyrosinemia: Characterized by hypertyrosinemia, which is consistent with the patient's symptoms. Different types of tyrosinemia have varying severity and associated features.

+2. Phenylketonuria (PKU): A disorder of phenylalanine metabolism, consistent with the hyperphenylalaninemia reported. However, hypertyrosinemia is not a typical feature of classic PKU.

+3. Maple syrup urine disease (MSUD): A disorder of branched-chain amino acid metabolism. While hypertyrosinemia and hyperphenylalaninemia are not typical, it could potentially explain some of the patient's symptoms.

+4. Organic acidemia: A group of disorders affecting the metabolism of organic acids, which can present with a broad range of symptoms, including metabolic abnormalities and multi-organ involvement.

+5. Fatty acid oxidation disorder: Disorders affecting the breakdown of fatty acids, which can lead to metabolic decompensation and various complications, including liver dysfunction and cardiomyopathy.",Hereditary metabolic disorders
['Homocystinuria due to cystathionine beta-synthase deficiency'],"+1. Homocystinuria due to cystathionine beta-synthase deficiency: Consistent with hyperhomocystinemia, hypermethioninemia, and aminoaciduria. A severe form can lead to neonatal death. Key symptom not reported: Ectopia lentis (dislocation of the eye lens).

+2. Methylmalonic acidemia: Consistent with aminoaciduria and neonatal death in severe cases. Key symptoms not reported: Metabolic acidosis, ketosis, and elevated methylmalonic acid levels.

+3. Maple syrup urine disease: Consistent with aminoaciduria and neonatal death in severe cases. Key symptoms not reported: Maple syrup odor, lethargy, and elevated branched-chain amino acids.

+4. Propionic acidemia: Consistent with aminoaciduria and neonatal death in severe cases. Key symptoms not reported: Metabolic acidosis, ketosis, and elevated propionic acid levels.

+5. Isovaleric acidemia: Consistent with aminoaciduria and neonatal death in severe cases. Key symptoms not reported: Metabolic acidosis, ketosis, and a sweaty feet odor.",Hereditary metabolic disorders
[],"+1. Dihydropyrimidine dehydrogenase (DPD) deficiency: Consistent with ataxia, hypotonia, abnormal pyrimidine levels, and uraciluria. Early death is a common outcome.

+2. Pyrimidine 5'-nucleotidase deficiency: Also presents with ataxia, hypotonia, abnormal pyrimidine metabolism, and uraciluria. Can be life-threatening in severe cases.

+3. Hereditary orotic aciduria: A disorder of pyrimidine metabolism that can cause neurological symptoms like ataxia and hypotonia, as well as other systemic issues. Uraciluria may be present.

+4. Lesch-Nyhan syndrome: An X-linked disorder of purine metabolism that can also affect pyrimidine levels. Presents with neurological symptoms like ataxia, hypotonia, and self-mutilating behavior. Usually fatal in childhood.

+5. Mitochondrial DNA depletion syndrome: A group of disorders that can cause various neurological and systemic symptoms, including ataxia and hypotonia. Some forms may involve abnormal pyrimidine metabolism.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Tyrosinemia type I (Fumarylacetoacetate hydrolase deficiency): Consistent with hypertyrosinemia and early death if untreated. Key symptoms not reported: liver dysfunction, kidney dysfunction, neurological problems, increased risk of liver cancer.

+2. Phenylketonuria (PKU): Consistent with hyperphenylalaninemia. Key symptoms not reported: intellectual disability, seizures, neurological problems.

+3. Maple syrup urine disease (MSUD): A metabolic disorder involving the breakdown of branched-chain amino acids, including leucine, isoleucine, and valine. While not directly consistent with the reported symptoms, it could potentially cause hypertyrosinemia and hyperphenylalaninemia as secondary effects. Key symptoms not reported: maple syrup odor in urine, vomiting, lethargy, developmental delay.

+4. Homocystinuria: An inherited metabolic disorder caused by a deficiency of the enzyme cystathionine beta-synthase, which is involved in the metabolism of methionine and homocysteine. While not directly related to tyrosine or phenylalanine metabolism, it could potentially cause hypertyrosinemia and hyperphenylalaninemia as secondary effects. Key symptoms not reported: developmental delay, intellectual disability, skeletal abnormalities, thrombosis.

+5. Alkaptonuria: A rare inherited metabolic disorder caused by a deficiency of the enzyme homogentisate 1,2-dioxygenase, which is involved in the breakdown of tyrosine. Patients with this condition have elevated levels of homogentisic acid in the blood and tissues, leading to darkening of urine and connective tissues. While not directly consistent with the reported symptoms, it could potentially cause hypertyrosinemia as a secondary effect. Key symptoms not reported: dark urine, ochronosis (bluish-black pigmentation of connective tissues).",Hereditary metabolic disorders
[],"+1. Dihydropyrimidine dehydrogenase (DPD) deficiency: Consistent with neonatal death, respiratory insufficiency, abnormal circulating pyrimidine concentration, and uraciluria.
+2. Hereditary orotic aciduria: Consistent with neonatal death, abnormal circulating pyrimidine concentration, and uraciluria. May also present with developmental delays and failure to thrive.
+3. Pyrimidine nucleotidase deficiency: Consistent with neonatal death, respiratory insufficiency, abnormal circulating pyrimidine concentration, and uraciluria. May also present with developmental delays and seizures.
+4. Severe combined immunodeficiency (SCID) with pyrimidine metabolic defect: Consistent with neonatal death and respiratory insufficiency. May also present with recurrent infections and failure to thrive.
+5. Lesch-Nyhan syndrome: Consistent with abnormal circulating pyrimidine concentration and uraciluria. May also present with self-mutilating behavior, neurological symptoms, and developmental delays.",Hereditary metabolic disorders
['Tyrosinemia type 1'],"+1. Tyrosinemia type I: Hypertyrosinemia, aminoaciduria, elevated alpha-fetoprotein, liver dysfunction (ascites, hypoalbuminemia, elevated alkaline phosphatase), anemia, thrombocytosis. Key missing symptoms: neurological manifestations, renal tubular dysfunction.

+2. Hereditary fructose intolerance: Aminoaciduria, ascites, hypoalbuminemia, elevated alkaline phosphatase, failure to thrive (death in infancy). Key missing symptoms: vomiting, hypoglycemia, aversion to sweet foods.

+3. Niemann-Pick disease type C: Thrombocytosis, anemia, hypoalbuminemia, elevated alkaline phosphatase, abnormal porphyrin levels, hernia. Key missing symptoms: neurological manifestations, hepatosplenomegaly, vertical supranuclear gaze palsy.

+4. Zellweger syndrome: Elevated alkaline phosphatase, abnormal porphyrin levels, hernia, failure to thrive (death in infancy). Key missing symptoms: characteristic facial features, neurological abnormalities, liver dysfunction.

+5. Crigler-Najjar syndrome type I: Jaundice (pallor), elevated bilirubin levels (abnormal porphyrin levels), elevated alkaline phosphatase, failure to thrive (death in infancy). Key missing symptoms: kernicterus, neurological manifestations.",Hereditary metabolic disorders
['Canavan disease'],"+1. Maple syrup urine disease (MSUD): Seizures, motor delay, and abnormal circulating aspartate family amino acid concentration (elevated branched-chain amino acids) are consistent with this disorder. Key symptoms not reported: maple syrup odor, metabolic decompensation.

+2. Urea cycle disorders: Seizures, motor delay, and abnormal circulating aspartate family amino acid concentration (elevated ammonia and other metabolites) are consistent with these disorders. Key symptoms not reported: hyperammonemia, lethargy, vomiting.

+3. Nonketotic hyperglycinemia: Seizures, motor delay, and abnormal circulating aspartate family amino acid concentration (elevated glycine) are consistent with this disorder. Key symptoms not reported: hypotonia, apnea, hiccups.

+4. Mitochondrial disorders: Seizures, motor delay, and death in infancy are consistent with severe mitochondrial disorders. Key symptoms not reported: lactic acidosis, multisystem involvement.

+5. Early infantile epileptic encephalopathy (EIEE): Seizures, motor delay, and death in infancy are consistent with severe epileptic encephalopathies. Key symptoms not reported: specific seizure types, developmental regression.",Hereditary metabolic disorders
['Isovaleric acidemia'],"+1. Organic acidemia: Consistent with vomiting, diarrhea, abdominal pain, abnormal glycine and carnitine levels, and potential for early death. Key symptoms not reported: metabolic acidosis, hyperammonemia, lethargy.

+2. Fatty acid oxidation disorder: Consistent with vomiting, abnormal carnitine levels, and potential for early death. Key symptoms not reported: hypoglycemia, hepatomegaly, cardiomyopathy.

+3. Primary immunodeficiency: Consistent with recurrent viral infections and potential for early death. Key symptoms not reported: lymphopenia, chronic diarrhea, failure to thrive.

+4. Mitochondrial disorder: Consistent with multi-system involvement, gastrointestinal symptoms, and potential for early death. Key symptoms not reported: neurological manifestations, lactic acidosis, muscle weakness.

+5. Inflammatory bowel disease: Consistent with gastrointestinal inflammation, diarrhea, abdominal pain, and potential for early death in severe cases. Key symptoms not reported: bloody stools, weight loss, extraintestinal manifestations.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Tyrosinemia type I: Consistent with hypertyrosinemia, hyperphenylalaninemia, elevated urinary carboxylic acid, intellectual disability, and early death. Key symptoms not reported: liver disease, kidney disease, increased risk of liver cancer.

+2. Phenylketonuria (PKU): Consistent with hyperphenylalaninemia and intellectual disability if untreated. Key symptoms not reported: musty odor, eczema, fair skin and hair.

+3. Tyrosinemia type II: Consistent with hypertyrosinemia. Key symptoms not reported: eye and skin problems.

+4. Tyrosinemia type III: Consistent with hypertyrosinemia and intellectual disability. Key symptoms not reported: seizures, ataxia.

+5. Hawkinsinuria: Consistent with hypertyrosinemia and elevated hawkinsin levels (not reported). Key symptoms not reported: seizures, developmental delay.",Hereditary metabolic disorders
['Medium chain acyl-CoA dehydrogenase deficiency'],"+1. Organic acidemia: Consistent with abnormal prenatal development, small for gestational age, death in infancy/childhood, hyperalaninemia, and abnormal circulating carnitine concentration. Key symptoms not reported: metabolic acidosis, ketosis, hypoglycemia.

+2. Fatty acid oxidation disorder: Consistent with abnormal prenatal development, small for gestational age, death in infancy/childhood, and abnormal circulating carnitine concentration. Key symptoms not reported: hypoglycemia, metabolic acidosis, cardiomyopathy.

+3. Mitochondrial disorder: Consistent with abnormal prenatal development, small for gestational age, death in infancy/childhood, and severe hearing impairment. Key symptoms not reported: lactic acidosis, seizures, neurological abnormalities.

+4. Peroxisomal disorder (e.g., Zellweger syndrome): Consistent with abnormal prenatal development, small for gestational age, death in infancy/childhood, and severe hearing impairment. Key symptoms not reported: dysmorphic features, liver dysfunction, neurological abnormalities.

+5. Aminoacidopathy (e.g., maple syrup urine disease): Consistent with abnormal prenatal development, small for gestational age, death in infancy/childhood, and hyperalaninemia. Key symptoms not reported: maple syrup odor, metabolic acidosis, neurological symptoms.",Hereditary metabolic disorders
['Ornithine transcarbamylase deficiency'],"+1. Ornithine transcarbamylase deficiency (OTC deficiency): Consistent with lethargy, drowsiness, oroticaciduria, and abnormal circulating ornithine concentration. May also present with hyperammonemia and death in infancy if untreated.

+2. Citrullinemia: Consistent with lethargy, drowsiness, oroticaciduria, and abnormal ornithine levels. May also present with hyperammonemia and other neurological symptoms.

+3. Arginase deficiency: Consistent with lethargy, drowsiness, oroticaciduria, and abnormal ornithine levels. May also present with neurological symptoms and hyperammonemia.

+4. Carbamoyl phosphate synthetase I (CPS1) deficiency: Consistent with lethargy, drowsiness, oroticaciduria, and hyperammonemia. May not have abnormal ornithine levels.

+5. Organic acidemia (e.g., propionic acidemia, methylmalonic acidemia): Consistent with lethargy, drowsiness, and metabolic abnormalities. Oroticaciduria and abnormal ornithine levels may not be typical features.",Hereditary metabolic disorders
['Glutaryl-CoA dehydrogenase deficiency'],"+1. Glutaric acidemia type 1 (GA1): Consistent with ataxia, dystonia, abnormal cerebral morphology, glutaric aciduria, decreased plasma free carnitine, and abnormal myelination. Key symptoms not reported: macrocephaly, seizures, and developmental delay.

+2. Organic acidemia: Consistent with glutaric aciduria, abnormal cerebral morphology, and decreased plasma free carnitine. However, the specific neurological symptoms (ataxia, dystonia) are more suggestive of GA1.

+3. Leukodystrophy: Consistent with abnormal cerebral morphology and abnormal myelination. However, the presence of glutaric aciduria and decreased plasma free carnitine are more specific to metabolic disorders like GA1.

+4. Mitochondrial disorder: Consistent with abnormal cerebral morphology, ataxia, and decreased plasma free carnitine. However, the presence of glutaric aciduria is more specific to GA1.

+5. Aminoacidopathy: Consistent with abnormal cerebral morphology and ataxia. However, the presence of glutaric aciduria and decreased plasma free carnitine are more specific to GA1.",Hereditary metabolic disorders
['Phenylketonuria'],"+1: Phenylketonuria (PKU): Characterized by hyperphenylalaninemia, which is consistent with the patient's symptoms. PKU is an inherited metabolic disorder caused by a deficiency of the enzyme phenylalanine hydroxylase, leading to a buildup of phenylalanine in the body.

+2: Maple syrup urine disease (MSUD): A rare inherited disorder of branched-chain amino acid metabolism, which can present with neonatal death or death in infancy. However, the patient does not have the characteristic maple syrup odor or other typical symptoms of MSUD.

+3: Mitochondrial disorders: A group of inherited conditions affecting energy production in cells, which can lead to severe, life-threatening symptoms in infancy. However, the patient does not have the typical multisystem involvement seen in mitochondrial disorders.

+4: Severe congenital malformations or genetic disorders: Various congenital anomalies or genetic syndromes can be life-threatening in infancy. However, the presence of hyperphenylalaninemia suggests a metabolic disorder like PKU as the more likely diagnosis.

+5: Organic acidemias: A group of inherited metabolic disorders characterized by the accumulation of organic acids, which can present with neonatal or infantile death. However, the patient does not have the typical metabolic acidosis or other symptoms associated with organic acidemias.",Hereditary metabolic disorders
['Systemic primary carnitine deficiency'],"+1. Organic acidemia: Consistent with encephalopathy, hypoglycemia, vomiting, elevated liver enzymes, and abnormal amino acid levels. May not fully explain cardiomyopathy or anemia.

+2. Fatty acid oxidation disorder: Consistent with hypoglycemia, hepatomegaly, cardiomyopathy, and elevated liver enzymes. May not fully explain neurological symptoms or anemia.

+3. Mitochondrial disorder: Consistent with multi-organ involvement (neurological, cardiac, liver), metabolic abnormalities, and elevated liver enzymes. Anemia and specific metabolic findings may not be typical.

+4. Lysosomal storage disorder (e.g., Gaucher disease, Niemann-Pick disease): Consistent with hepatomegaly, neurological symptoms, and metabolic abnormalities. Cardiomyopathy and specific metabolic findings may not be typical.

+5. Porphyria: Consistent with neurological symptoms, abdominal pain (vomiting), and abnormal porphyrin levels. May not fully explain cardiomyopathy, hepatomegaly, or metabolic abnormalities.",Hereditary metabolic disorders
['PMM2-CDG'],"+1. Congenital disorder of glycosylation (CDG): Consistent with generalized hypotonia, cerebellar atrophy, encephalopathy, and growth delay. Some CDGs can also cause strabismus, nystagmus, and motor delays.
+2. Mitochondrial disorder: Consistent with ataxia, hypotonia, encephalopathy, motor delay, and cerebellar atrophy. Mitochondrial disorders can also lead to growth delays and death in severe cases.
+3. Leukodystrophy: Consistent with ataxia, hyporeflexia, motor delay, and encephalopathy. Some leukodystrophies can also cause nystagmus, hypotonia, and cerebellar atrophy.
+4. Congenital muscular dystrophy: Consistent with generalized hypotonia, motor delay, and respiratory complications (which can lead to death in infancy). Some forms can also cause cerebellar involvement and ataxia.
+5. Congenital brain malformation (e.g., cerebellar agenesis/hypoplasia): Consistent with cerebellar agenesis/atrophy, ataxia, hypotonia, and motor delays. Other symptoms like strabismus and nystagmus can also occur.",Hereditary metabolic disorders
['Homocystinuria due to cystathionine beta-synthase deficiency'],"+1. Homocystinuria due to cystathionine beta-synthase deficiency: Consistent with myopia, ectopia lentis, intellectual disability, hyperhomocystinemia, hypermethioninemia, aminoaciduria. Key symptom not reported: arachnodactyly.

+2. Methylmalonic acidemia: Consistent with intellectual disability, delayed speech and language development, aminoaciduria, abnormal circulating alanine concentration. Key symptoms not reported: metabolic acidosis, ketosis, hyperammonemia.

+3. Maple syrup urine disease: Consistent with intellectual disability, delayed speech and language development, aminoaciduria, abnormal circulating alanine concentration. Key symptoms not reported: maple syrup odor, lethargy, poor feeding.

+4. Glutaric aciduria type 1: Consistent with intellectual disability, delayed speech and language development, dyskinesia. Key symptoms not reported: macrocephaly, metabolic acidosis, organic aciduria.

+5. Propionic acidemia: Consistent with intellectual disability, delayed speech and language development, aminoaciduria, abnormal circulating alanine concentration. Key symptoms not reported: metabolic acidosis, ketosis, hyperammonemia.",Hereditary metabolic disorders
['Ornithine transcarbamylase deficiency'],"+1. Urea cycle disorder: Consistent with hyperammonemia, metabolic acidosis, oroticaciduria, and potential neurological symptoms. Key symptoms like seizures and ataxia may not be as prominent.

+2. Organic acidemia: Consistent with metabolic acidosis, lethargy, and potential neurological symptoms. Hyperammonemia and oroticaciduria are less common.

+3. Mitochondrial disorder or disorder of energy metabolism: Consistent with metabolic acidosis, seizures, ataxia, and potential multi-organ involvement. Hyperammonemia and oroticaciduria are not typical features.

+4. Leukodystrophy: Consistent with neurological symptoms like seizures and ataxia. Metabolic abnormalities like hyperammonemia, metabolic acidosis, and oroticaciduria are less consistent.

+5. Unspecified inherited metabolic disorder: The combination of symptoms suggests an underlying inherited metabolic disorder, but the specific diagnosis remains unclear based on the provided information.",Hereditary metabolic disorders
['Smith-Lemli-Opitz syndrome'],"+1. Smith-Lemli-Opitz syndrome (SLOS): Microcephaly, intellectual disability, ataxia, generalized hypotonia, dysmorphic features (pointed chin, short chin, strabismus, ptosis, syndactyly), hypocholesterolemia, elevated 8-dehydrocholesterol, elevated circulating 7-dehydrocholesterol concentration, feeding difficulties, failure to thrive, and potential death in infancy/childhood are consistent with this disorder of cholesterol biosynthesis.

+2. Zellweger spectrum disorder: Microcephaly, intellectual disability, hypotonia, failure to thrive, and dysmorphic features can be seen in this peroxisomal disorder, but the elevated 7-dehydrocholesterol levels are not typical.

+3. Congenital disorder of glycosylation (CDG): Intellectual disability, hypotonia, failure to thrive, and dysmorphic features can occur in CDGs, but the cholesterol abnormalities are not characteristic.

+4. Mitochondrial disorder: Intellectual disability, hypotonia, failure to thrive, and potential death in infancy/childhood can be seen in mitochondrial disorders, but the dysmorphic features and cholesterol abnormalities are not typical.

+5. Lysosomal storage disorder: Intellectual disability, hypotonia, failure to thrive, and dysmorphic features can occur in some lysosomal storage disorders, but the cholesterol abnormalities are not characteristic.",Hereditary metabolic disorders
['Glycogen storage disease due to glycogen debranching enzyme deficiency'],"+1. Mitochondrial disorder: Generalized hypotonia, increased lactate, elevated lactate dehydrogenase and creatine kinase, and neonatal death are consistent with a severe mitochondrial disease. Key symptoms not reported: seizures, developmental delay, and specific organ involvement.

+2. Fatty acid oxidation defect: Hypertriglyceridemia, hepatomegaly, hypotonia, and neonatal death can occur in disorders of fatty acid metabolism. Key symptoms not reported: hypoglycemia, cardiomyopathy, and specific metabolic abnormalities.

+3. Gaucher disease (fetal form): Generalized hypotonia, hepatomegaly, and death in infancy are seen in the severe, fetal form of Gaucher disease. Key symptoms not reported: thrombocytopenia, anemia, and specific enzyme deficiency.

+4. Niemann-Pick disease type C: Hepatomegaly, hypotonia, and neonatal death can occur in this lysosomal storage disorder. Key symptoms not reported: splenomegaly, neurological manifestations, and specific biochemical abnormalities.

+5. Congenital lactic acidosis: Increased lactate, hypotonia, and early death are consistent with severe congenital lactic acidosis. Key symptoms not reported: specific metabolic abnormalities, acidosis, and organ involvement.",Hereditary metabolic disorders
['Glutaryl-CoA dehydrogenase deficiency'],"+1. Glutaric acidemia type I (GA1): Consistent with glutaric aciduria, microcephaly, generalized hypotonia, athetosis, and cerebral cortical atrophy. May not explain the decreased plasma free carnitine and abnormal circulating acylcarnitine concentrations.

+2. Methylmalonic acidemia: An organic acidemia that can present with hypotonia, developmental delay, seizures, and metabolic abnormalities like acidosis and abnormal acylcarnitine levels. Glutaric aciduria is not a typical feature.

+3. Propionic acidemia: Another organic acidemia that can cause hypotonia, developmental delay, seizures, and metabolic abnormalities. Glutaric aciduria is not a typical feature.

+4. Medium-chain acyl-CoA dehydrogenase deficiency (MCADD): A fatty acid oxidation disorder that can present with hypoglycemia, metabolic acidosis, and abnormal acylcarnitine levels. However, the neurological symptoms like microcephaly and athetosis are not typical.

+5. Mitochondrial disorders (e.g., Leigh syndrome, MELAS): Can cause a wide range of symptoms, including hypotonia, seizures, developmental delay, and metabolic abnormalities. Glutaric aciduria and abnormal acylcarnitine levels may or may not be present, depending on the specific disorder.",Hereditary metabolic disorders
['Propionic acidemia'],"+1. Non-ketotic hyperglycinemia: Consistent with hyperglycinemia, hyperglycinuria, and other metabolic abnormalities. May not explain all symptoms like ichthyosis or death in infancy.

+2. Propionic acidemia: Consistent with hyperammonemia, vomiting, and elevated urinary carboxylic acids. May not explain hyperglycinemia or hyperalaninemia.

+3. Methylmalonic acidemia: Consistent with hyperammonemia, vomiting, and elevated urinary carboxylic acids. May not explain hyperglycinemia or hyperalaninemia.

+4. Urea cycle disorders (e.g., ornithine transcarbamylase deficiency): Consistent with hyperammonemia and abnormal amino acid levels. May not explain ichthyosis or death in infancy.

+5. Organic acidemias (e.g., isovaleric acidemia): Consistent with vomiting, hyperammonemia, and elevated urinary carboxylic acids. May not explain hyperglycinemia or hyperalaninemia.",Hereditary metabolic disorders
['Succinic semialdehyde dehydrogenase deficiency'],"+1. Glutaric aciduria type 1 (GA1): Consistent with intellectual disability, motor delay, abnormal facial shape, abnormal calvaria morphology, and elevated urinary carboxylic acid. Key symptom not reported: macrocephaly.

+2. Methylmalonic acidemia: Consistent with intellectual disability, motor delay, abnormal facial shape, and elevated urinary carboxylic acid. Key symptoms not reported: metabolic acidosis, hyperammonemia.

+3. Propionic acidemia: Consistent with intellectual disability, motor delay, abnormal facial shape, and elevated urinary carboxylic acid. Key symptoms not reported: metabolic acidosis, hyperammonemia, ketosis.

+4. Isovaleric acidemia: Consistent with intellectual disability, motor delay, abnormal facial shape, and elevated urinary carboxylic acid. Key symptom not reported: a characteristic ""sweaty feet"" odor.

+5. Chronic visceral acid sphingomyelinase deficiency (Niemann-Pick disease type C): Consistent with intellectual disability, motor delay, abnormal facial shape, and death in childhood. However, the reported abnormal circulating monocarboxylic acid and elevated urinary carboxylic acid levels are not typical features of this condition.",Hereditary metabolic disorders
['Classic galactosemia'],"+1. Classic galactosemia: Consistent with intellectual disability, hepatic failure, hypergalactosemia, and abnormal galactoside metabolism. Key symptoms not reported: cataracts, vomiting, failure to thrive.

+2. Galactokinase deficiency: Consistent with intellectual disability, hypergalactosemia, and abnormal galactoside metabolism. Key symptoms not reported: cataracts, failure to thrive.

+3. UDP-galactose 4'-epimerase deficiency: Consistent with intellectual disability, hypergalactosemia, and abnormal galactoside metabolism. Key symptoms not reported: cataracts, failure to thrive.

+4. Recurrent metabolic encephalomyopathic crises-rhabdomyolysis-cardiac arrhythmia-intellectual disability syndrome: Consistent with intellectual disability and motor delay, but does not explain the hepatic failure, hypergalactosemia, or abnormal galactoside metabolism.

+5. Citrullinemia type I: Consistent with intellectual disability and hepatic failure, but does not explain the hypergalactosemia or abnormal galactoside metabolism.",Hereditary metabolic disorders
['Neonatal intrahepatic cholestasis due to citrin deficiency'],"+1. Citrullinemia type I: Elevated plasma citrulline, hyperammonemia, neonatal/infantile death. Key symptoms not reported: oroticaciduria, hypoargininemia, hyperprolinemia.

+2. Argininosuccinic aciduria: Hyperammonemia, aminoaciduria. Key symptoms not reported: elevated argininosuccinic acid levels.

+3. Propionic acidemia: Hyperammonemia, aminoaciduria, neonatal/infantile death. Key symptoms not reported: ketoacidosis, hyperglycinemia, elevated propionyl carnitine.

+4. Methylmalonic acidemia: Hyperammonemia, aminoaciduria, neonatal/infantile death. Key symptoms not reported: ketoacidosis, hyperglycinemia, elevated methylmalonic acid.

+5. Ornithine transcarbamylase deficiency: Hyperammonemia, neonatal/infantile death. Key symptoms not reported: orotic aciduria, elevated glutamine levels.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Hereditary tyrosinemia type I: Consistent with hypertyrosinemia, elevated urinary carboxylic acid, and potential for liver failure and early death. Key symptoms not reported: hepatomegaly, coagulopathy, neurological symptoms.

+2. Phenylketonuria: Consistent with hyperphenylalaninemia, but does not fully explain other symptoms like abnormal porphyrin levels or recurrent infections.

+3. Acute intermittent porphyria: Could account for abnormal porphyrin levels, but may not fully fit the clinical picture with hypertyrosinemia and hyperphenylalaninemia.

+4. Hereditary coproporphyria: Another porphyria that could explain abnormal porphyrin levels, but may not fully account for other metabolic abnormalities.

+5. Primary immunodeficiency (e.g., severe combined immunodeficiency): Could explain recurrent viral infections and decreased ferritin, but may not account for metabolic abnormalities like hypertyrosinemia and hyperphenylalaninemia.",Hereditary metabolic disorders
['Maple syrup urine disease'],"+1. Maple syrup urine disease (MSUD): Consistent with lethargy, hypotonia, tremor, abnormal circulating leucine concentration, and body odor. Key symptom not reported: Maple syrup odor.

+2. Methylmalonic acidemia: Consistent with lethargy, hypotonia, elevated urinary carboxylic acid, and metabolic acidosis (if present). Key symptoms not reported: Vomiting, failure to thrive, developmental delay.

+3. Propionic acidemia: Consistent with lethargy, hypotonia, elevated urinary carboxylic acid, and metabolic acidosis (if present). Key symptoms not reported: Vomiting, failure to thrive, developmental delay.

+4. Mitochondrial disorder: Consistent with lethargy, hypotonia, and potentially elevated lactate levels (if present). Key symptoms not reported: Seizures, developmental delay, failure to thrive.

+5. Glutaric aciduria type I: Consistent with lethargy, hypotonia, and elevated urinary organic acids. Key symptoms not reported: Macrocephaly, dystonia, cerebral atrophy.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Mitochondrial disorder: Consistent with generalized hypotonia, premature birth, anemia, and early death. Key symptoms not reported: lactic acidosis, seizures, developmental delays.

+2. Congenital disorder of glycosylation (CDG): Consistent with generalized hypotonia, abnormality of vitamin D metabolism, and multi-system involvement. Key symptoms not reported: developmental delays, coagulopathy, neurological abnormalities.

+3. Tyrosinemia type I: Consistent with hypertyrosinemia, anemia, and liver involvement (suggested by abnormal vitamin D metabolism). Key symptoms not reported: liver failure, renal tubular dysfunction, rickets.

+4. Phenylketonuria (PKU): Consistent with hyperphenylalaninemia and potential neurological complications. Key symptoms not reported: developmental delays, seizures, musty odor.

+5. Gaucher disease (perinatal lethal form): Consistent with generalized hypotonia, anemia, and early death. Key symptoms not reported: hepatosplenomegaly, thrombocytopenia, ichthyosis.",Hereditary metabolic disorders
['Smith-Lemli-Opitz syndrome'],"+1. Smith-Lemli-Opitz syndrome (SLOS): Consistent with hypertelorism, anteverted nares, syndactyly, abnormal foot morphology, delayed speech and language development, intellectual disability, motor delay, seizures, self-mutilation, hyperactivity, hypocholesterolemia, elevated 8-dehydrocholesterol, elevated circulating 7-dehydrocholesterol concentration, and severe hearing impairment. Key symptoms not reported: Photosensitivity rash, failure to thrive, microcephaly.

+2. Peroxisomal biogenesis disorder (e.g., Zellweger syndrome): Consistent with dysmorphic features, developmental delay, seizures, and hearing impairment. Key symptoms not reported: Hypotonia, liver dysfunction, renal cysts, and other organ involvement.

+3. Chromosomal abnormality (e.g., trisomy, deletion): Consistent with multiple congenital anomalies, developmental delay, and intellectual disability. Key symptoms not reported: Specific dysmorphic features and biochemical abnormalities associated with SLOS.

+4. Congenital disorder of glycosylation (CDG): Consistent with developmental delay, seizures, and dysmorphic features. Key symptoms not reported: Specific biochemical markers for CDG.

+5. Inborn error of metabolism (e.g., organic acidemia, aminoacidopathy): Consistent with developmental delay, seizures, and intellectual disability. Key symptoms not reported: Specific biochemical markers and other organ involvement.",Hereditary metabolic disorders
['Vitamin B12-unresponsive methylmalonic acidemia'],"+1. Methylmalonic acidemia (MMA): Consistent with methylmalonic acidemia, methylmalonic aciduria, and decreased methylmalonyl-CoA mutase activity. Key symptoms not reported: specific neurological or hematological abnormalities associated with different MMA subtypes.

+2. Propionic acidemia: Consistent with metabolic acidosis, hyperglycinemia, hyperglycinuria, and methylmalonic acidemia. Key symptoms not reported: pancytopenia, thrombocytopenia, and specific neurological manifestations.

+3. Glutaric aciduria type II: Consistent with metabolic acidosis, hypoglycemia, hyperammonemia, and increased lactate. Key symptoms not reported: specific neurological manifestations like dystonia or brain abnormalities.

+4. Mitochondrial disorder: Consistent with lactic acidosis, hypoglycemia, and multi-organ involvement. Key symptoms not reported: specific neurological or muscular manifestations associated with mitochondrial disorders.

+5. Urea cycle disorder: Consistent with hyperammonemia and elevated amino acid levels. Key symptoms not reported: specific neurological manifestations or biochemical abnormalities associated with different urea cycle defects.",Hereditary metabolic disorders
[],"+1. Dihydropyrimidine dehydrogenase (DPD) deficiency: Consistent with ataxia, hypotonia, lethargy, abnormal pyrimidine concentration, and uraciluria. Key symptom not reported: seizures.

+2. Orotic aciduria: Consistent with ataxia, hypotonia, lethargy, abnormal pyrimidine concentration, and uraciluria. Key symptom not reported: developmental delay.

+3. Mitochondrial disorder or oxidative phosphorylation defect: Consistent with ataxia, hypotonia, lethargy, and death in infancy. Key symptoms not reported: lactic acidosis, muscle weakness, and failure to thrive.

+4. Leukodystrophy (e.g., Krabbe disease, metachromatic leukodystrophy): Consistent with ataxia, hypotonia, lethargy, and death in infancy. Key symptoms not reported: developmental regression, vision problems, and seizures.

+5. Neurodegenerative disorder (e.g., infantile neuroaxonal dystrophy): Consistent with ataxia, hypotonia, lethargy, and death in infancy. Key symptoms not reported: developmental regression, seizures, and vision problems.",Hereditary metabolic disorders
['Isovaleric acidemia'],"+1. Urea cycle disorder: Consistent with hyperammonemia, abnormal prenatal development, and early mortality. Key symptoms of specific urea cycle defects (e.g., lethargy, vomiting, seizures) are not mentioned.

+2. Organic acidemia: Matches hyperammonemia, abnormal prenatal development, and potential for neonatal/childhood death. Specific organic acids causing the disorder are not identified.

+3. Glycine encephalopathy: Aligns with abnormal circulating glycine concentration and potential for severe outcomes. Neurological symptoms (e.g., seizures, developmental delay) are not reported.

+4. Fatty acid oxidation disorder: Can present with hyperammonemia, abnormal carnitine levels, and potential for neonatal/childhood mortality. Specific symptoms (e.g., hypoglycemia, cardiomyopathy) are not mentioned.

+5. Mitochondrial disorder: Some mitochondrial disorders can cause hyperammonemia, abnormal metabolite levels, and severe outcomes. Specific symptoms (e.g., lactic acidosis, muscle weakness) are not reported.",Hereditary metabolic disorders
['Biotinidase deficiency'],"+1. Glutaric aciduria type 1 (glutaryl-CoA dehydrogenase deficiency): Consistent with seizures, hypotonia, and elevated urinary organic acids. Key symptom not reported: macrocephaly (enlarged head size).

+2. Methylmalonic acidemia: Consistent with seizures, hypotonia, and elevated urinary organic acids. Key symptoms not reported: metabolic acidosis, developmental delay.

+3. Propionic acidemia: Consistent with seizures, hypotonia, and elevated urinary organic acids. Key symptoms not reported: metabolic acidosis, vomiting, lethargy.

+4. Maple syrup urine disease: Consistent with seizures, hypotonia, and elevated urinary organic acids. Key symptom not reported: maple syrup odor.

+5. Recurrent metabolic encephalomyopathic crises-rhabdomyolysis-cardiac arrhythmia-intellectual disability syndrome: Consistent with seizures and hypotonia. Key symptoms not reported: rhabdomyolysis, cardiac arrhythmia, intellectual disability.",Hereditary metabolic disorders
['Medium chain acyl-CoA dehydrogenase deficiency'],"+1: Mitochondrial trifunctional protein deficiency: Delayed speech and language development, abnormality of prenatal development or birth, death in infancy/childhood, decreased plasma free carnitine, and decreased 3-hydroxyacyl-CoA dehydrogenase level are consistent with this disorder, which is a severe fatty acid oxidation defect.

+2: Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency: The decreased 3-hydroxyacyl-CoA dehydrogenase level and other symptoms are consistent with this fatty acid oxidation disorder, which can lead to metabolic crises and potentially fatal outcomes.

+3: Carnitine palmitoyltransferase II deficiency: The decreased plasma free carnitine and other symptoms could be explained by this disorder, which impairs the transport of long-chain fatty acids into the mitochondria for oxidation.

+4: Carnitine-acylcarnitine translocase deficiency: This disorder, which affects the transport of acylcarnitines across the mitochondrial membrane, could potentially explain the decreased plasma free carnitine and other symptoms.

+5: Very long-chain acyl-CoA dehydrogenase deficiency: While the decreased 3-hydroxyacyl-CoA dehydrogenase level is not a typical finding, this fatty acid oxidation disorder could potentially explain some of the patient's symptoms, particularly if there are additional clinical or laboratory findings suggestive of this condition.",Hereditary metabolic disorders
['Maple syrup urine disease'],"+1. Maple syrup urine disease (MSUD): Consistent with seizures, hypotonia, metabolic acidosis, hypervalinemia, hyperleucinemia, hyperisoleucinemia, and body odor. Key symptom not reported: maple syrup odor.

+2. Propionic acidemia: Consistent with seizures, hypotonia, metabolic acidosis, and feeding difficulties. Key symptoms not reported: vomiting, lethargy, and protein avoidance.

+3. Methylmalonic acidemia: Consistent with seizures, hypotonia, metabolic acidosis, and feeding difficulties. Key symptoms not reported: vomiting, lethargy, and protein avoidance.

+4. Mitochondrial disorder: Consistent with seizures, hypotonia, metabolic acidosis, and multi-organ involvement. Key symptoms not reported: lactic acidosis, muscle weakness, and specific organ involvement.

+5. Zellweger syndrome: Consistent with seizures, hypotonia, and metabolic abnormalities. Key symptoms not reported: characteristic facial features, liver dysfunction, and skeletal abnormalities.",Hereditary metabolic disorders
['Propionic acidemia'],"+1. Methylmalonic acidemia: Consistent with intellectual disability, anemia, hyperammonemia, cerebral atrophy, increased blood urea nitrogen, elevated creatinine, abnormal carnitine levels, and elevated urinary carboxylic acid. Key symptoms not reported: metabolic acidosis, ketosis.

+2. Ornithine transcarbamylase deficiency: Consistent with intellectual disability, psychosis, hyperammonemia, cerebral atrophy, increased blood urea nitrogen, and elevated creatinine. Key symptoms not reported: vomiting, lethargy, protein avoidance.

+3. Acute intermittent porphyria: Consistent with psychosis, intellectual disability, anemia, abnormal circulating porphyrin concentration, and body odor. Key symptoms not reported: abdominal pain, neuropathy, and specific porphyrin abnormalities.

+4. Mitochondrial disorder (e.g., MELAS, Leigh syndrome): Consistent with intellectual disability, psychosis, cerebral atrophy, anemia, hearing impairment, and elevated urinary carboxylic acid. Key symptoms not reported: seizures, lactic acidosis, and specific mitochondrial enzyme deficiencies.

+5. Mucopolysaccharidosis (e.g., Hurler syndrome): Consistent with intellectual disability, severe short stature, kyphoscoliosis, hearing impairment, and death in adolescence/early adulthood. Key symptoms not reported: coarse facial features, hepatosplenomegaly, and specific enzyme deficiencies.",Hereditary metabolic disorders
['L-2-hydroxyglutaric aciduria'],"+1. L-2-hydroxyglutaric aciduria: Characterized by intellectual disability, seizures, ataxia, and the presence of elevated L-2-hydroxyglutaric acid levels in the urine and other body fluids. The patient's symptoms are consistent with this diagnosis.

+2. Combined D-2- and L-2-hydroxyglutaric aciduria: A more severe form of L-2-hydroxyglutaric aciduria, with similar symptoms but often earlier onset and more severe neurological involvement. The patient's symptoms are consistent with this diagnosis, but the presence of D-2-hydroxyglutaric acid is not specified.

+3. Malonic aciduria: A disorder of fatty acid and amino acid metabolism that can also lead to elevated L-2-hydroxyglutaric acid levels. Symptoms include developmental delay, seizures, hypotonia, and metabolic acidosis, which are consistent with the patient's presentation.

+4. Mitochondrial disorder: Various mitochondrial disorders can present with a combination of neurological symptoms, such as intellectual disability, seizures, ataxia, and tremor. However, the presence of L-2-hydroxyglutaric aciduria is not a typical finding in most mitochondrial disorders.

+5. Organic acidemia: A group of inherited metabolic disorders characterized by the accumulation of organic acids, which can lead to neurological symptoms similar to the patient's presentation. However, the specific finding of L-2-hydroxyglutaric aciduria is not commonly associated with most organic acidemias.",Hereditary metabolic disorders
['Canavan disease'],"+1. Maple syrup urine disease (MSUD): Characterized by motor delay, abnormal circulating aspartate family amino acid concentration (elevated leucine, isoleucine, and valine), and potentially fatal if untreated.

+2. Urea cycle disorders (e.g., ornithine transcarbamylase deficiency, citrullinemia): Characterized by motor delay, abnormal circulating aspartate family amino acid concentration (elevated ammonia and other toxic metabolites), and potentially fatal if untreated.

+3. Organic acidemias (e.g., methylmalonic acidemia, propionic acidemia, isovaleric acidemia): Characterized by motor delay, abnormal circulating aspartate family amino acid concentration (elevated organic acids), and potentially fatal if untreated.

+4. Mitochondrial disorders: Characterized by motor delay, potentially abnormal circulating aspartate family amino acid concentration, and potentially fatal if untreated. Additional symptoms may include muscle weakness, seizures, and organ dysfunction.

+5. Nonketotic hyperglycinemia: Characterized by motor delay, abnormal circulating aspartate family amino acid concentration (elevated glycine), and potentially fatal if untreated. Additional symptoms may include seizures, apnea, and intellectual disability.",Hereditary metabolic disorders
['Citrullinemia type I'],"+1. Citrullinemia type I: Consistent with hyperammonemia, elevated plasma citrulline, neonatal death, and increased total bilirubin. Key symptoms not reported include oroticaciduria and hypoargininemia.

+2. Recurrent metabolic encephalomyopathic crises-rhabdomyolysis-cardiac arrhythmia-intellectual disability syndrome: Consistent with hyperammonemia and increased total bilirubin. However, the patient did not report symptoms like seizures, intellectual disability, rhabdomyolysis, or cardiac arrhythmias.

+3. Classic galactosemia: Consistent with neonatal death and increased total bilirubin. However, the patient did not report symptoms like jaundice, hypotonia, vomiting, or feeding difficulties.

+4. Fabry disease: Consistent with neonatal death. However, the patient did not report symptoms like proteinuria, angiokeratoma, or other characteristic features of Fabry disease.

+5. TMEM199-CDG: Consistent with neonatal death and increased total bilirubin. However, the patient did not report symptoms like hepatic steatosis, hypercholesterolemia, or abnormal protein glycosylation.",Hereditary metabolic disorders
['3-hydroxy-3-methylglutaric aciduria'],"+1. Methylmalonic acidemia: Consistent with metabolic acidosis, hypoglycemia, hyperammonemia, vomiting, lethargy, and elevated methylmalonic acid levels (a dicarboxylic acid). May not explain the 3-methylglutaric aciduria.

+2. Propionic acidemia: Consistent with metabolic acidosis, hypoglycemia, hyperammonemia, vomiting, lethargy, and elevated propionylcarnitine and propionate levels. May not explain the 3-methylglutaric aciduria.

+3. Isovaleric acidemia: Consistent with metabolic acidosis, hypoglycemia, vomiting, lethargy, and elevated isovalerylcarnitine and isovaleric acid levels. May not explain the hyperammonemia or 3-methylglutaric aciduria.

+4. Mitochondrial DNA depletion syndrome: Consistent with metabolic acidosis, hypoglycemia, hepatomegaly, lethargy, and multi-system involvement. May not explain the specific organic acid elevations.

+5. Ornithine transcarbamylase deficiency: Consistent with hyperammonemia, lethargy, vomiting, and metabolic decompensation. May not explain the organic aciduria or hypoglycemia.",Hereditary metabolic disorders
['Cystinuria'],"+1. Niemann-Pick disease type C: Seizures, splenomegaly, respiratory insufficiency. Key symptom not reported: hepatomegaly.

+2. Gaucher disease: Seizures, splenomegaly, respiratory issues. Key symptom not reported: hepatomegaly.

+3. Mitochondrial disorder: Seizures, multi-organ involvement (splenomegaly, respiratory insufficiency). Additional symptoms like lactic acidosis, muscle weakness, or developmental delay may be present but not reported.

+4. Congenital infection (e.g., CMV, toxoplasmosis): Seizures, hepatosplenomegaly, respiratory distress. Additional symptoms like chorioretinitis, rash, or hearing loss may be present but not reported.

+5. Peroxisomal disorder (e.g., Zellweger spectrum): Seizures, hepatosplenomegaly, respiratory issues. Additional symptoms like dysmorphic features, developmental delay, or renal cysts may be present but not reported.",Hereditary metabolic disorders
['Vitamin B12-unresponsive methylmalonic acidemia'],"+1. Methylmalonic acidemia (MMA): Consistent with intellectual disability, motor delay, generalized hypotonia, hyperammonemia, vomiting, increased blood urea nitrogen, abnormal amino acid levels, and methylmalonic aciduria. Key symptoms not reported: metabolic acidosis, ketosis.

+2. Propionic acidemia: Consistent with intellectual disability, motor delay, generalized hypotonia, hyperammonemia, vomiting, increased blood urea nitrogen, abnormal amino acid levels, methylmalonic aciduria, and recurrent viral infections. Key symptoms not reported: metabolic acidosis, ketosis, protein intolerance.

+3. Urea cycle disorders (e.g., ornithine transcarbamylase deficiency, carbamoyl phosphate synthetase I deficiency): Consistent with intellectual disability, hyperammonemia, vomiting, increased blood urea nitrogen, and hypoproteinemia. Key symptoms not reported: respiratory alkalosis, lethargy, seizures.

+4. Maple syrup urine disease (MSUD): Consistent with intellectual disability, motor delay, generalized hypotonia, hyperammonemia, vomiting, abnormal branched-chain amino acid levels (valine, isoleucine, leucine), and feeding difficulties. Key symptoms not reported: maple syrup odor, metabolic acidosis, ketosis.

+5. Glutaric acidemia type II: Consistent with intellectual disability, motor delay, generalized hypotonia, hyperammonemia, vomiting, increased blood urea nitrogen, and abnormal amino acid levels. Key symptoms not reported: metabolic acidosis, ketosis, hypoglycemia.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Tyrosinemia type I: Hypertyrosinemia, elevated urinary carboxylic acid, death in infancy/childhood. Key symptoms not reported: liver disease, kidney problems, neurological issues.

+2. Phenylketonuria (PKU): Hyperphenylalaninemia. Key symptoms not reported: developmental delays, neurological symptoms.

+3. Maple syrup urine disease (MSUD): Elevated urinary carboxylic acid. Key symptoms not reported: maple syrup odor, specific metabolic abnormalities.

+4. Organic acidemia: Elevated urinary carboxylic acid. Key symptoms not reported: specific metabolic abnormalities, other associated symptoms.

+5. Amino acid metabolism disorder: Hypertyrosinemia, hyperphenylalaninemia, elevated urinary carboxylic acid. Key symptoms not reported: specific metabolic abnormalities, other associated symptoms.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Tyrosinemia: Intellectual disability, hypertyrosinemia, death in infancy/early childhood if untreated. Key symptom not reported: liver disease.

+2. Phenylketonuria (PKU): Intellectual disability, hyperphenylalaninemia. Key symptoms not reported: musty odor, fair skin, and blue eyes.

+3. Maple syrup urine disease (MSUD): Intellectual disability, abnormality of prenatal development or birth, potentially neonatal death if untreated. Key symptom not reported: maple syrup odor.

+4. Mitochondrial disorder: Intellectual disability, abnormality of prenatal development or birth, potentially early mortality. Additional symptoms would be needed to identify a specific mitochondrial disorder.

+5. Congenital disorder of glycosylation (CDG): A group of metabolic disorders affecting glycosylation, which can cause intellectual disability, abnormal prenatal development, and potentially early mortality. Additional symptoms would be needed to identify a specific CDG.",Hereditary metabolic disorders
['Ornithine transcarbamylase deficiency'],"+1: Ornithine transcarbamylase deficiency (OTC deficiency): Consistent with hyperammonemia, oroticaciduria, vomiting, and early onset of severe symptoms. Key symptom not reported: episodic lethargy or coma.

+2: Citrullinemia type I: Consistent with hyperammonemia, oroticaciduria, and abnormality of the coagulation cascade. Key symptoms not reported: elevated plasma citrulline, hypoargininemia, hyperprolinemia.

+3: Severe liver disease: Consistent with abnormal bleeding, abnormality of the coagulation cascade, and vomiting. Key symptoms not reported: jaundice, ascites, or other signs of liver failure.

+4: Coagulation factor deficiency: Consistent with abnormal bleeding and abnormality of the coagulation cascade. Key symptoms not reported: prolonged bleeding times, easy bruising, or specific factor deficiency.

+5: Urea cycle disorder (unspecified): Consistent with hyperammonemia, vomiting, and early onset of severe symptoms. Additional testing would be needed to identify the specific enzyme deficiency.",Hereditary metabolic disorders
['L-2-hydroxyglutaric aciduria'],"+1: L-2-hydroxyglutaric aciduria: Consistent with intellectual disability, generalized hypotonia, abnormal cerebral morphology, abnormal myelination, and L-2-hydroxyglutaric acidemia. Key symptoms not reported: seizures, macrocephaly.

+2: Urea cycle disorder (e.g., citrullinemia, argininosuccinic aciduria): Consistent with intellectual disability, hyperammonemia, abnormal cerebral morphology. Key symptoms not reported: specific metabolic abnormalities associated with the disorder.

+3: Organic acidemia (e.g., methylmalonic acidemia, propionic acidemia): Consistent with intellectual disability, generalized hypotonia, abnormal cerebral morphology. Key symptoms not reported: specific metabolic abnormalities associated with the disorder.

+4: Leukodystrophy (e.g., metachromatic leukodystrophy, Krabbe disease): Consistent with intellectual disability, abnormal cerebral morphology, abnormal myelination. Key symptoms not reported: specific neurological or metabolic abnormalities associated with the disorder.

+5: Recurrent metabolic encephalomyopathic crises-rhabdomyolysis-cardiac arrhythmia-intellectual disability syndrome: Consistent with intellectual disability, hyperammonemia, abnormal cerebral morphology. Key symptoms not reported: rhabdomyolysis, cardiac arrhythmia, specific metabolic abnormalities.",Hereditary metabolic disorders
['PMM2-CDG'],"+1. Niemann-Pick disease type C: Consistent with intellectual disability, ataxia, cerebellar atrophy, stroke-like episodes, and early death. Key symptoms not reported: hepatosplenomegaly, vertical supranuclear gaze palsy.

+2. Chronic visceral acid sphingomyelinase deficiency: Consistent with intellectual disability, ataxia, cerebellar atrophy, stroke-like episodes, and early death. Key symptoms not reported: hepatosplenomegaly, pulmonary involvement.

+3. Congenital disorders of glycosylation (CDG): Consistent with intellectual disability, ataxia, and cerebellar abnormalities. Specific type of CDG would need to be determined based on additional testing.

+4. Mitochondrial disorder: Consistent with intellectual disability, ataxia, cerebellar atrophy, and early death. Specific mitochondrial disorder would need to be identified through genetic and biochemical testing.

+5. Leukodystrophy: Consistent with intellectual disability, ataxia, and progressive neurological deterioration. Specific type of leukodystrophy would need to be determined based on neuroimaging and genetic testing.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Tyrosinemia type I: Characterized by hypertyrosinemia, neonatal death, and liver and kidney problems. The patient did not report specific liver or kidney issues.

+2. Phenylketonuria (PKU): Characterized by hyperphenylalaninemia, which the patient exhibited, but no mention of intellectual disability or seizures.

+3. Maple syrup urine disease (MSUD): A disorder of branched-chain amino acid metabolism, which could potentially explain the hypertyrosinemia and hyperphenylalaninemia, but the patient did not report the characteristic maple syrup odor or other typical symptoms.

+4. Homocystinuria: An inherited disorder of methionine metabolism, which can lead to elevated levels of homocysteine and other amino acids, including tyrosine and phenylalanine. However, the patient did not report any of the typical symptoms, such as developmental delays, lens dislocation, or thrombosis.

+5. Non-ketotic hyperglycinemia: A rare disorder of glycine metabolism that can present with neonatal seizures, lethargy, and respiratory distress. While not directly related to tyrosine or phenylalanine metabolism, it could potentially explain the severe neonatal presentation.",Hereditary metabolic disorders
['Propionic acidemia'],"+1. Maple syrup urine disease (MSUD): Consistent with intellectual disability, seizures, lethargy, hypotonia, hyperammonemia, increased branched-chain amino acids (leucine, isoleucine, valine). Key symptom not reported: Maple syrup odor.

+2. Nonketotic hyperglycinemia: Consistent with intellectual disability, seizures, lethargy, hypotonia, hyperglycinemia. Key symptoms not reported: Apnea, hiccups.

+3. Glutaric aciduria type I: Consistent with intellectual disability, seizures, hypotonia, hyperammonemia, increased lactate, acidosis. Key symptoms not reported: Macrocephaly, dystonia.

+4. Propionic acidemia: Consistent with intellectual disability, seizures, lethargy, hypotonia, hyperammonemia, increased lactate, acidosis, vomiting, protein intolerance. Key symptoms not reported: Ketosis, pancytopenia.

+5. Mitochondrial disorders (e.g., Leigh syndrome, MELAS): Consistent with intellectual disability, seizures, hypotonia, increased lactate, recurrent infections, hearing impairment, neonatal/childhood death. Key symptoms not reported: Specific neuroimaging findings, organ-specific manifestations.",Hereditary metabolic disorders
['Wilson disease'],"+1. Wilson's disease: Consistent with polydipsia, elevated liver enzymes, decreased ceruloplasmin and copper levels. Neurological symptoms and Kayser-Fleischer rings (copper deposits in the cornea) are common but not reported.

+2. TMEM199-CDG (Congenital disorder of glycosylation): Consistent with elevated liver enzymes, decreased ceruloplasmin and copper levels, and potentially fatal outcome. Polydipsia is not a typical symptom.

+3. Copper deficiency: Consistent with decreased copper levels and potentially fatal outcome. However, the cause of copper deficiency and the elevated liver enzymes are not explained.

+4. Liver cirrhosis: Consistent with elevated liver enzymes and potentially fatal outcome. However, the cause of liver cirrhosis and the decreased copper levels are not explained.

+5. Metabolic disorder (unspecified): The combination of symptoms suggests a metabolic disorder involving copper metabolism and liver dysfunction, but the specific condition cannot be determined based on the provided information.",Hereditary metabolic disorders
['Ornithine transcarbamylase deficiency'],"+1. Urea cycle disorder: Consistent with hyperglutaminemia, oroticaciduria, and neonatal death. Key symptoms like hyperammonemia may not have been reported.
+2. Organic acidemia: Consistent with lethargy, hypotonia, vomiting, and metabolic abnormalities. Specific organic acid levels may not have been provided.
+3. Mitochondrial disorder: Consistent with seizures, hypotonia, vomiting, and metabolic disturbances. Additional symptoms like lactic acidosis or muscle weakness may not have been reported.
+4. Peroxisomal disorder: Consistent with seizures, hypotonia, and metabolic abnormalities. Additional symptoms like dysmorphic features or liver dysfunction may not have been reported.
+5. Recurrent metabolic encephalomyopathic crises-rhabdomyolysis-cardiac arrhythmia-intellectual disability syndrome: Consistent with seizures, lethargy, and metabolic disturbances. However, key symptoms like rhabdomyolysis, arrhythmia, and intellectual disability were not reported.",Hereditary metabolic disorders
['Classic galactosemia'],"+1. Classic galactosemia: Microcephaly, delayed speech and language development, intellectual disability, motor delay, generalized hypotonia, feeding difficulties, hypergalactosemia, abnormality of galactoside metabolism. Key symptoms not reported: jaundice, hepatomegaly, vomiting.

+2. Galactosemia variant: Microcephaly, delayed speech and language development, intellectual disability, motor delay, generalized hypotonia, feeding difficulties, hypergalactosemia, abnormality of galactoside metabolism. Specific enzyme deficiency may vary.

+3. Lysosomal storage disorder: Microcephaly, delayed speech and language development, intellectual disability, motor delay, generalized hypotonia, feeding difficulties, abnormality of prenatal development or birth, death in infancy/childhood. Key symptoms not reported: organomegaly, skeletal abnormalities, coarse facial features.

+4. Peroxisomal disorder: Microcephaly, delayed speech and language development, intellectual disability, motor delay, generalized hypotonia, feeding difficulties, abnormality of prenatal development or birth, death in infancy/childhood. Key symptoms not reported: seizures, hearing/vision loss, skeletal abnormalities.

+5. Mitochondrial disorder: Microcephaly, delayed speech and language development, intellectual disability, motor delay, generalized hypotonia, feeding difficulties, death in infancy/childhood, elevated alkaline phosphatase. Key symptoms not reported: seizures, lactic acidosis, multi-system involvement.",Hereditary metabolic disorders
['Biotinidase deficiency'],"+1. Urea cycle disorder: Hyperammonemia is a key symptom, consistent with a defect in the urea cycle. Obesity and abnormal foot morphology could be associated features. Death in childhood suggests a severe, life-threatening condition if untreated.

+2. Organic acidemia: Disorders like methylmalonic acidemia or propionic acidemia can also cause hyperammonemia due to disruptions in amino acid metabolism. The other symptoms could potentially fit, but hyperammonemia is not always a prominent feature.

+3. Fatty acid oxidation disorder (e.g., MCADD): Hyperammonemia can occur in some fatty acid oxidation disorders, although it is not a typical presenting symptom. The other symptoms are non-specific but could potentially be seen.

+4. Lysosomal storage disorder: While not directly causing hyperammonemia, some lysosomal storage disorders (e.g., mucopolysaccharidoses) can present with obesity, abnormal skeletal features, and potentially life-threatening complications. However, hyperammonemia is not a common feature.

+5. Mitochondrial disorder: Certain mitochondrial disorders can lead to metabolic decompensation and hyperammonemia, although the other symptoms provided are not strongly suggestive of a primary mitochondrial disorder.",Hereditary metabolic disorders
['Canavan disease'],"+1. Maple syrup urine disease (MSUD): Consistent with hyperactivity, abnormal circulating aspartate family amino acid concentration, feeding difficulties. MSUD is characterized by elevated levels of branched-chain amino acids (leucine, isoleucine, and valine) due to a deficiency in the enzyme that breaks them down.

+2. Phenylketonuria (PKU): Consistent with hyperactivity, abnormal circulating aspartate family amino acid concentration, feeding difficulties. PKU is caused by a deficiency in the enzyme that breaks down the amino acid phenylalanine, leading to its accumulation and potential neurological damage.

+3. Krabbe disease: Consistent with abnormal myelination, death in infancy. Krabbe disease is a rare genetic disorder that affects the myelin sheath, leading to progressive neurological deterioration and often death in infancy or early childhood.

+4. Metachromatic leukodystrophy: Consistent with abnormal myelination, death in infancy. This is a genetic disorder that affects the metabolism of certain lipids, leading to the destruction of the myelin sheath and progressive neurological symptoms.

+5. Mitochondrial disorders: Consistent with feeding difficulties, abnormal circulating aspartate family amino acid concentration, death in infancy. Mitochondrial disorders can affect energy production and lead to a wide range of symptoms, including feeding difficulties, developmental delays, and abnormal metabolic profiles.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Phenylketonuria (PKU): Characterized by hyperphenylalaninemia due to deficiency of the enzyme phenylalanine hydroxylase, leading to intellectual disability, seizures, and other complications if untreated. Consistent with the reported symptoms.

+2. Biopterin defects: A group of disorders affecting the synthesis or recycling of tetrahydrobiopterin, a cofactor required for phenylalanine hydroxylase activity, also causing hyperphenylalaninemia and neurological symptoms.

+3. Transient neonatal hyperphenylalaninemia: A temporary elevation of phenylalanine levels in newborns, often resolving without treatment. However, the reported neonatal death makes this less likely.

+4. Maple syrup urine disease (MSUD): An inherited disorder of branched-chain amino acid metabolism, characterized by elevated levels of leucine, isoleucine, and valine. While not directly related to phenylalanine, MSUD can also present with neonatal death and metabolic abnormalities.

+5. Organic acidemias: A group of inherited metabolic disorders involving the breakdown of certain amino acids and fatty acids, some of which can present with neonatal death and metabolic abnormalities, although hyperphenylalaninemia is not a typical feature.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Phenylketonuria (PKU): Hyperphenylalaninemia, delayed speech and language development, intellectual disability, and potential for severe complications if untreated.

+2. Tyrosinemia: Hypertyrosinemia, potential for liver and kidney dysfunction, neurological symptoms, and high mortality rates in severe forms.

+3. Maple syrup urine disease (MSUD): Elevated levels of branched-chain amino acids (leucine, isoleucine, valine), neurological symptoms, coma, and potential for early death if untreated.

+4. Homocystinuria: Elevated homocysteine levels, intellectual disability, skeletal abnormalities, and potential for thrombotic events and other complications.

+5. Glutaric aciduria type I: Elevated glutaric acid levels, macrocephaly, dystonia, and potential for brain damage and neurological complications.",Hereditary metabolic disorders
[],"+1. Congenital disorders of glycosylation (CDG): Consistent with nephritis, cardiomyopathy, hypotonia, and early lethality. Key symptoms not reported include developmental delay and seizures.

+2. Fabry disease: Consistent with nephritis, cardiomyopathy, and hypotonia. Key symptoms not reported include angiokeratomas, acroparesthesias, and corneal opacities.

+3. Pompe disease: Consistent with cardiomyopathy, hypotonia, and early lethality. Key symptoms not reported include respiratory distress and muscle weakness.

+4. Mitochondrial disorders: Consistent with cardiomyopathy, hypotonia, and multi-organ involvement. Key symptoms not reported include lactic acidosis and neurological manifestations.

+5. Fetal Gaucher disease: Consistent with cardiomyopathy and early lethality. Key symptoms not reported include hepatosplenomegaly, thrombocytopenia, and ichthyosis.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Tyrosinemia type I: Consistent with hypertyrosinemia, irritability, spasticity, hyperreflexia, and potential for early death. Key symptom not reported: liver failure.

+2. Phenylketonuria (PKU): Consistent with hyperphenylalaninemia, irritability, spasticity, hyperreflexia, and potential for early death. Key symptom not reported: intellectual disability.

+3. Maple syrup urine disease (MSUD): Consistent with irritability, spasticity, hyperreflexia, recurrent viral infections, and potential for early death. Key symptom not reported: maple syrup odor in urine.

+4. Glutaric aciduria type I: Consistent with irritability, spasticity, hyperreflexia, and potential for early death. Key symptoms not reported: macrocephaly, dystonia, and subdural hemorrhage.

+5. Methylmalonic acidemia: Consistent with irritability, spasticity, hyperreflexia, recurrent viral infections, and potential for early death. Key symptom not reported: metabolic acidosis.",Hereditary metabolic disorders
['Medium chain acyl-CoA dehydrogenase deficiency'],"+1. Carnitine deficiency: Abnormal circulating carnitine concentration is a key symptom, and this condition can lead to prenatal abnormalities and neonatal death. However, other symptoms associated with carnitine deficiency, such as hypoglycemia, cardiomyopathy, or muscle weakness, are not reported.

+2. Fatty acid oxidation disorders (e.g., VLCAD deficiency, LCHAD deficiency): These conditions can present with abnormal circulating carnitine levels, prenatal abnormalities, and neonatal death. Specific symptoms may include hypoglycemia, cardiomyopathy, and liver dysfunction, which are not mentioned in the given symptoms.

+3. Organic acidemias (e.g., methylmalonic acidemia, propionic acidemia): These metabolic disorders can cause prenatal abnormalities, neonatal death, and potentially abnormal carnitine levels. Additional symptoms like metabolic acidosis, hyperammonemia, or ketosis are often present but not reported in this case.

+4. Mitochondrial disorders: Some mitochondrial disorders can present with prenatal abnormalities, neonatal death, and potentially abnormal carnitine levels. However, other common features like lactic acidosis, muscle weakness, or neurological symptoms are not mentioned.

+5. Congenital disorders of glycosylation (CDG): Certain types of CDG can be associated with prenatal abnormalities, neonatal death, and potentially abnormal carnitine levels. However, additional symptoms like developmental delay, hypotonia, or coagulopathy are often present but not reported here.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Phenylketonuria (PKU): Delayed speech and language development, hyperphenylalaninemia, potential abnormality of prenatal development. Key symptom not reported: intellectual disability, seizures, musty odor.

+2. Tyrosinemia type I: Delayed speech and language development, hypertyrosinemia, potential abnormality of prenatal development, death in infancy/childhood. Key symptoms not reported: liver disease, renal tubular dysfunction, rickets.

+3. Maple syrup urine disease (MSUD): Delayed speech and language development, generalized hypotonia, potential abnormality of prenatal development, death in infancy/childhood. Key symptoms not reported: maple syrup odor, lethargy, vomiting.

+4. Non-ketotic hyperglycinemia: Delayed speech and language development, generalized hypotonia, potential abnormality of prenatal development, death in infancy/childhood. Key symptoms not reported: seizures, apnea, hiccups.

+5. Glutaric aciduria type I: Delayed speech and language development, generalized hypotonia, potential abnormality of prenatal development, death in infancy/childhood. Key symptoms not reported: macrocephaly, dystonia, metabolic acidosis.",Hereditary metabolic disorders
['Glutaryl-CoA dehydrogenase deficiency'],"+1. Glutaric acidemia type 1 (GA1): Consistent with seizures, encephalopathy, opisthotonus, glutaric aciduria, elevated glutaric acid levels, decreased carnitine, and elevated urinary carboxylic acids. This is a severe disorder of organic acid metabolism caused by a deficiency of the enzyme glutaryl-CoA dehydrogenase.

+2. Recurrent metabolic encephalomyopathic crises-rhabdomyolysis-cardiac arrhythmia-intellectual disability syndrome: While consistent with seizures and encephalopathy, the patient does not exhibit the characteristic rhabdomyolysis, cardiac arrhythmias, or intellectual disability associated with this condition.

+3. Chronic visceral acid sphingomyelinase deficiency (Niemann-Pick disease type C): This condition can present with seizures and encephalopathy, but the patient does not exhibit the characteristic hepatosplenomegaly, lung involvement, or other systemic manifestations.

+4. Fabry disease: While Fabry disease can cause neurological symptoms, the patient's presentation is not consistent with the typical manifestations of this lysosomal storage disorder, such as proteinuria, cardiomyopathy, or angiokeratomas.

+5. TMEM199-CDG (Congenital disorder of glycosylation): This condition can cause seizures and developmental delay, but the patient's symptoms do not align with the characteristic liver involvement, coagulopathy, and abnormal glycosylation seen in TMEM199-CDG.",Hereditary metabolic disorders
[],"+1. Mitochondrial disorder: Consistent with neurological symptoms (seizures, intellectual disability, hypotonia), metabolic acidosis, multi-organ involvement. Key symptoms not reported: specific mitochondrial markers (e.g., lactic acidosis, elevated lactate levels).

+2. Organic acidemia: Consistent with metabolic acidosis, hyperkalemia, neurological symptoms. Key symptoms not reported: specific metabolic markers (e.g., elevated organic acids in urine/blood).

+3. Peroxisomal disorder: Consistent with neurological symptoms, hearing impairment, fair/white hair. Key symptoms not reported: specific peroxisomal markers (e.g., elevated very long-chain fatty acids).

+4. Leukodystrophy: Consistent with spastic diplegia, intellectual disability (suggesting white matter involvement). Key symptoms not reported: specific neuroimaging findings.

+5. Congenital disorder of glycosylation (CDG): Consistent with multi-system involvement, intellectual disability. Key symptoms not reported: specific glycosylation markers (e.g., abnormal transferrin isoforms).",Hereditary metabolic disorders
['PMM2-CDG'],"+1. Niemann-Pick disease type C: Consistent with intellectual disability, ataxia, cerebellar atrophy, hypotonia, hepatic fibrosis, and premature death. Key symptoms not reported: vertical supranuclear gaze palsy, seizures, and splenomegaly.

+2. Chronic visceral acid sphingomyelinase deficiency: Consistent with intellectual disability, ataxia, cerebellar atrophy, hypotonia, cirrhosis, hepatic fibrosis, thromboembolism, reduced antithrombin III activity, and premature death. Key symptoms not reported: splenomegaly, pancytopenia, and pulmonary involvement.

+3. Recurrent metabolic encephalomyopathic crises-rhabdomyolysis-cardiac arrhythmia-intellectual disability syndrome: Consistent with intellectual disability, ataxia, hypotonia, and premature death. Key symptoms not reported: seizures, metabolic acidosis, hypoglycemia, rhabdomyolysis, and cardiac arrhythmias.

+4. Mucolipidosis type IV: Consistent with intellectual disability, cerebellar atrophy, hypotonia, and premature death. Key symptoms not reported: microcephaly, megalocornea, optic disc pallor, and nystagmus.

+5. TMEM199-CDG: Consistent with intellectual disability, hypotonia, cirrhosis, hepatic fibrosis, and premature death. Key symptoms not reported: hepatosplenomegaly, abnormal coagulation, and abnormal glycosylation.",Hereditary metabolic disorders
['Canavan disease'],"+1. Inborn error of metabolism: Consistent with seizures, hypotonia, feeding difficulties, and abnormal amino acid levels. Key symptoms not reported include metabolic acidosis, hyperammonemia, or specific metabolic abnormalities.

+2. Pyridoxine-dependent epilepsy: Consistent with intractable seizures, hypotonia, and feeding difficulties in infancy. Response to pyridoxine supplementation not mentioned.

+3. Neurodegenerative disorder (e.g., infantile neuroaxonal dystrophy, Leigh syndrome): Consistent with seizures, hypotonia, and feeding difficulties in infancy. Specific neurodegenerative features not described.

+4. Structural brain abnormality or injury: Consistent with seizures, hypotonia, and feeding difficulties. No specific structural abnormalities or injuries mentioned.

+5. Severe epileptic encephalopathy: Consistent with intractable seizures, hypotonia, and feeding difficulties in infancy. Specific etiology or features not described.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Tyrosinemia type I: Hypertyrosinemia, gastrointestinal inflammation, and death in infancy are consistent with this disorder caused by a deficiency of the enzyme fumarylacetoacetate hydrolase.

+2. Phenylketonuria (PKU): Hyperphenylalaninemia is a key feature of this disorder caused by a deficiency of the enzyme phenylalanine hydroxylase, but the patient does not have reported neurological symptoms.

+3. Maple syrup urine disease (MSUD): A deficiency of the branched-chain alpha-keto acid dehydrogenase complex can lead to accumulation of amino acids and their byproducts, but the patient does not have the characteristic maple syrup odor or reported neurological symptoms.

+4. Urea cycle disorder: Disorders of the urea cycle, such as ornithine transcarbamylase deficiency or citrullinemia, can lead to hyperammonemia, which can cause gastrointestinal inflammation and neurological problems. However, the patient does not have reported hyperammonemia or neurological symptoms.

+5. Organic acidemia: A group of inherited disorders caused by deficiencies in enzymes involved in the metabolism of amino acids and fatty acids, leading to accumulation of organic acids. Some organic acidemias can present with gastrointestinal symptoms and metabolic acidosis, but the patient does not have reported acidosis or other specific symptoms.",Hereditary metabolic disorders
['Maple syrup urine disease'],"+1. Maple syrup urine disease (MSUD): Consistent with hyperleucinemia, metabolic acidosis, neurological symptoms (ataxia, coma, reduced reflexes), and potential early mortality. Key symptom not reported: Characteristic maple syrup odor in urine and body fluids.

+2. Leukodystrophies: Consistent with abnormal cerebral white matter morphology, neurological symptoms (ataxia, coma, reduced reflexes), and potential early mortality. Key symptoms not reported: Specific neurological deficits depending on the type of leukodystrophy.

+3. Mitochondrial disorders: Consistent with metabolic acidosis, neurological symptoms (ataxia, coma, reduced reflexes), and potential multi-organ involvement. Key symptoms not reported: Specific organ dysfunctions depending on the type of mitochondrial disorder.

+4. Immunodeficiency disorders: Consistent with recurrent viral infections, potentially explaining some of the other symptoms. Key symptoms not reported: Specific infections or immune abnormalities.

+5. Organic acidemias: A group of metabolic disorders characterized by the accumulation of organic acids, which could potentially explain the metabolic acidosis and neurological symptoms. Key symptoms not reported: Specific organic acid elevations or other metabolic abnormalities.",Hereditary metabolic disorders
['Acute intermittent porphyria'],"+1. Acute intermittent porphyria (AIP): Abdominal pain, elevated urinary delta-aminolevulinic acid, potentially leading to death in childhood. Key symptom not reported: Neurological symptoms like seizures, psychosis, or neuropathy.

+2. Hereditary coproporphyria (HCP): Abdominal pain, elevated urinary delta-aminolevulinic acid, potentially leading to death in childhood. Key symptom not reported: Photosensitivity or skin lesions.

+3. Lead poisoning: Abdominal pain, elevated urinary delta-aminolevulinic acid. Key symptoms not reported: Neurological symptoms, anemia, or other signs of lead toxicity.

+4. Aminolevulinic acid dehydratase deficiency porphyria: Abdominal pain, elevated urinary delta-aminolevulinic acid. Key symptom not reported: Neurological symptoms or photosensitivity.

+5. Congenital erythropoietic porphyria: Abdominal pain, elevated urinary delta-aminolevulinic acid. Key symptoms not reported: Photosensitivity, skin lesions, or hemolytic anemia.",Hereditary metabolic disorders
['Vitamin B12-unresponsive methylmalonic acidemia'],"+1: Methylmalonic acidemia (mut deficiency): Consistent with metabolic acidosis, methylmalonic aciduria, and potentially seizures and early death. Key symptom not reported: hyperammonemia.

+2: Methylmalonic acidemia (cblA deficiency): Consistent with metabolic acidosis, methylmalonic aciduria, and potentially seizures and early death. Key symptom not reported: hyperammonemia.

+3: Methylmalonic acidemia (cblB deficiency): Consistent with metabolic acidosis, methylmalonic aciduria, and potentially seizures and early death. Key symptom not reported: hyperammonemia.

+4: Methylmalonic acidemia (cblC deficiency): Consistent with metabolic acidosis, methylmalonic aciduria, and potentially seizures and early death. Key symptom not reported: hyperammonemia.

+5: Methylmalonic acidemia (cblD deficiency): Consistent with metabolic acidosis, methylmalonic aciduria, and potentially seizures and early death. Key symptom not reported: hyperammonemia.",Hereditary metabolic disorders
['Alkaptonuria'],"+1. Organic acidemia: Consistent with seizures, lethargy, hypotonia, growth delay, and dark urine. May not present with sleep abnormalities or early death.

+2. Mitochondrial disorder: Consistent with seizures, lethargy, hypotonia, growth delay, and potential multi-organ involvement. May not present with dark urine or sleep abnormalities.

+3. Lysosomal storage disorder (e.g., Gaucher disease, Niemann-Pick disease): Consistent with seizures, lethargy, hypotonia, growth delay, and potential multi-organ involvement. May not present with dark urine or sleep abnormalities.

+4. Zellweger syndrome: Consistent with seizures, hypotonia, growth delay, and potential multi-organ involvement. May not present with lethargy, dark urine, or sleep abnormalities.

+5. Smith-Lemli-Opitz syndrome: Consistent with seizures, hypotonia, growth delay, and potential multi-organ involvement. May not present with lethargy, dark urine, or sleep abnormalities.",Hereditary metabolic disorders
['Maple syrup urine disease'],"+1. Maple syrup urine disease (MSUD): Seizures, death in infancy, aminoaciduria, and abnormal circulating levels of leucine, isoleucine, and valine are consistent with this disorder. Key symptom not reported: Maple syrup odor in urine and body fluids.

+2. Isovaleric acidemia: Seizures, death in infancy, and aminoaciduria are consistent with this disorder. Key symptoms not reported: Distinctive sweaty feet odor, vomiting, and lethargy.

+3. Methylmalonic acidemia: Seizures, death in infancy, and aminoaciduria are consistent with this disorder. Key symptoms not reported: Metabolic acidosis, lethargy, and developmental delays.

+4. Propionic acidemia: Seizures, death in infancy, and aminoaciduria are consistent with this disorder. Key symptoms not reported: Metabolic acidosis, vomiting, and lethargy.

+5. Glutaric acidemia type II: Seizures, death in infancy, and aminoaciduria are consistent with this disorder. Key symptoms not reported: Metabolic acidosis, hypoglycemia, and progressive neurological deterioration.",Hereditary metabolic disorders
['Very long chain acyl-CoA dehydrogenase deficiency'],"+1. Mitochondrial disorder: Consistent with lactic acidosis, hypoglycemia, organ involvement, and early mortality. Key symptoms not reported: muscle weakness, seizures, developmental delay.

+2. Fatty acid oxidation disorder (e.g., MCADD): Consistent with hypoglycemia, dicarboxylic aciduria, and metabolic decompensation. Key symptoms not reported: vomiting, lethargy during fasting or illness.

+3. Organic acidemia (e.g., methylmalonic acidemia, propionic acidemia): Consistent with metabolic acidosis, hypoglycemia, and elevated lactate. Key symptoms not reported: protein avoidance, developmental delay, hyperammonemia.

+4. Glycogen storage disease (e.g., von Gierke disease): Consistent with hypoglycemia, lactic acidosis, and hepatomegaly. Key symptoms not reported: growth retardation, hyperlipidemia, bleeding tendency.

+5. Severe combined immunodeficiency: Consistent with recurrent viral infections and early mortality. Key symptoms not reported: chronic diarrhea, failure to thrive, opportunistic infections.",Hereditary metabolic disorders
['3-hydroxy-3-methylglutaric aciduria'],"+1. Glutaric acidemia type I (GA1): Characterized by elevated levels of glutaric acid and 3-methylglutaric acid, seizures, progressive neurological deterioration, metabolic acidosis, and hypoglycemia. The patient exhibits most of these key symptoms.

+2. Methylmalonic acidemia: An organic acidemia involving the breakdown of certain amino acids, which can lead to metabolic acidosis, hypoglycemia, lethargy, seizures, and elevated organic acids in urine. The patient's symptoms are consistent with this condition.

+3. Propionic acidemia: Another organic acidemia that can cause metabolic acidosis, hypoglycemia, vomiting, lethargy, and elevated levels of organic acids in urine and blood. The patient's symptoms align with this disorder.

+4. Mitochondrial disorders (e.g., MELAS, Leigh syndrome): Certain mitochondrial disorders can present with metabolic acidosis, hypoglycemia, seizures, neurological deterioration, and elevated organic acids. The patient's symptoms could potentially fit these conditions.

+5. Maple syrup urine disease (MSUD): A rare inherited disorder of amino acid metabolism that can cause metabolic acidosis, lethargy, seizures, and elevated levels of branched-chain amino acids in urine and blood. The patient's symptoms are consistent with this condition, although the specific organic acids mentioned are not typical of MSUD.",Hereditary metabolic disorders
['MODY'],"+1. Acute intermittent porphyria: Consistent with abnormal circulating porphyrin concentration, hypoglycemia. Key symptom not reported: abdominal pain, neurological symptoms.

+2. Hereditary fructose intolerance: Consistent with hypoglycemia, glycosuria. Key symptom not reported: fructose intolerance, liver and kidney problems.

+3. Glycogen storage disease: Consistent with hypoglycemia, glycosuria. Key symptoms may vary depending on the specific type.

+4. Diabetes mellitus (type 1 or type 2): Consistent with hypoglycemia, glycosuria. Abnormal porphyrin levels not typically associated with diabetes.

+5. Porphyria (other types): Consistent with abnormal circulating porphyrin concentration. Additional symptoms may vary depending on the specific type.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Phenylketonuria (PKU): Characterized by hyperphenylalaninemia due to deficiency of the enzyme phenylalanine hydroxylase, leading to intellectual disability, seizures, and other complications if untreated. Consistent with the reported symptoms.

+2. Biopterin defects: A group of disorders affecting the synthesis or recycling of tetrahydrobiopterin, a cofactor required for phenylalanine hydroxylase activity, also causing hyperphenylalaninemia and neurological symptoms.

+3. Maple syrup urine disease (MSUD): An inherited disorder of branched-chain amino acid metabolism, characterized by elevated levels of leucine, isoleucine, and valine. While not directly related to phenylalanine, MSUD can also present with neonatal death and metabolic abnormalities.

+4. Transient neonatal hyperphenylalaninemia: A temporary elevation of phenylalanine levels in newborns, often resolving within a few weeks without treatment. However, the reported neonatal death makes this less likely.

+5. Non-ketotic hyperglycinemia: A rare inherited disorder of glycine metabolism, characterized by elevated glycine levels in the brain and body fluids, leading to severe neurological symptoms and potential neonatal death. While not directly related to phenylalanine, it is another metabolic disorder that can present with neonatal death.",Hereditary metabolic disorders
['Glutaryl-CoA dehydrogenase deficiency'],"+1. Glutaryl-CoA dehydrogenase deficiency: Consistent with hydrocephalus, macrocephaly, seizures, lethargy, dystonia, cerebral atrophy, and glutaric aciduria. Key symptom not reported: subdural hemorrhage.

+2. Krabbe disease: Consistent with hydrocephalus, macrocephaly, seizures, lethargy, cerebral atrophy. Key symptoms not reported: vision loss, muscle weakness, and peripheral neuropathy.

+3. Metachromatic leukodystrophy: Consistent with hydrocephalus, macrocephaly, seizures, lethargy, cerebral atrophy. Key symptoms not reported: muscle weakness, peripheral neuropathy, and cognitive decline.

+4. Infantile neuroaxonal dystrophy: Consistent with macrocephaly, seizures, lethargy, dystonia, cerebral atrophy. Key symptoms not reported: hypotonia, developmental delay, and optic atrophy.

+5. Neuronal ceroid lipofuscinosis: Consistent with seizures, lethargy, cerebral atrophy. Key symptoms not reported: vision loss, cognitive decline, and motor dysfunction.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Tyrosinemia type I: Characterized by hypertyrosinemia, abnormality of prenatal development or birth, neonatal death, death in infancy, and death in childhood. Key symptoms not reported: liver failure, kidney dysfunction, neurological problems.

+2. Phenylketonuria (PKU): Characterized by hyperphenylalaninemia, abnormality of prenatal development or birth, neonatal death, death in infancy, and death in childhood. Key symptoms not reported: intellectual disability, seizures, neurological problems.

+3. Maple syrup urine disease (MSUD): Characterized by abnormality of prenatal development or birth, neonatal death, death in infancy, and death in childhood. Key symptoms not reported: buildup of branched-chain amino acids, coma, neurological problems.

+4. Homocystinuria: A disorder of methionine metabolism, characterized by abnormality of prenatal development or birth, neonatal death, death in infancy, and death in childhood. Key symptoms not reported: elevated homocysteine levels, intellectual disability, skeletal abnormalities.

+5. Glutaric aciduria type I: A disorder of lysine and tryptophan metabolism, characterized by abnormality of prenatal development or birth, neonatal death, death in infancy, and death in childhood. Key symptoms not reported: elevated glutaric acid levels, neurological problems, metabolic acidosis.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Tyrosinemia type I: Consistent with hypertyrosinemia, hyperphenylalaninemia, and potential liver dysfunction leading to complications like preeclampsia and early death. Key symptoms not reported include liver failure, kidney dysfunction, and neurological symptoms.

+2. Phenylketonuria (PKU): Consistent with hyperphenylalaninemia, but does not typically cause hypertyrosinemia or preeclampsia. Key symptoms not reported include intellectual disability, seizures, and developmental delays.

+3. Tyrosinemia type II: Consistent with hypertyrosinemia, but does not typically cause hyperphenylalaninemia or preeclampsia. Key symptoms not reported include eye and skin lesions, and neurological symptoms.

+4. Maple syrup urine disease (MSUD): Consistent with elevated levels of branched-chain amino acids like leucine, isoleucine, and valine (not reported), but does not typically cause hypertyrosinemia or hyperphenylalaninemia. Key symptoms not reported include maple syrup odor, lethargy, and developmental delays.

+5. Homocystinuria: Consistent with potential liver dysfunction (not reported), but does not typically cause hypertyrosinemia or hyperphenylalaninemia. Key symptoms not reported include intellectual disability, skeletal abnormalities, and thrombotic events.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Tyrosinemia type I: Consistent with hypertyrosinemia, elevated urinary carboxylic acid, and potential neonatal death or death in early adulthood. Key symptoms not reported: liver failure, kidney disease, neurological problems.

+2. Phenylketonuria (PKU): Consistent with hyperphenylalaninemia and potential abnormality of prenatal development or birth. Key symptoms not reported: intellectual disability, seizures, behavioral problems.

+3. Maple syrup urine disease (MSUD): Consistent with elevated urinary carboxylic acid and potential neonatal death or death in early adulthood. Key symptoms not reported: maple syrup odor, lethargy, poor feeding, seizures.

+4. Glutaric aciduria type I: Consistent with elevated urinary carboxylic acid and potential abnormality of prenatal development or birth. Key symptoms not reported: macrocephaly, dystonia, cerebral atrophy.

+5. Methylmalonic acidemia: Consistent with elevated urinary carboxylic acid and potential abnormality of prenatal development or birth. Key symptoms not reported: lethargy, vomiting, dehydration, metabolic acidosis.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Tyrosinemia type I: Characterized by hypertyrosinemia, abnormality of prenatal development or birth, and potential for neonatal death or death in infancy/childhood if untreated. Key symptoms not reported: liver dysfunction, kidney dysfunction, neurological problems.

+2. Phenylketonuria (PKU): Characterized by hyperphenylalaninemia, and potential for intellectual disability, seizures, and neurological problems if untreated. Key symptoms not reported: developmental delay, seizures, intellectual disability.

+3. Maple syrup urine disease (MSUD): Characterized by accumulation of branched-chain amino acids, and potential for severe neurological problems and death if untreated. Key symptoms not reported: maple syrup odor in urine, lethargy, poor feeding, vomiting.

+4. Homocystinuria: Characterized by accumulation of homocysteine and methionine, and potential for intellectual disability, skeletal abnormalities, and other complications. Key symptoms not reported: intellectual disability, skeletal abnormalities, thrombosis.

+5. Non-ketotic hyperglycinemia: A rare disorder caused by a deficiency of the glycine cleavage system, leading to accumulation of glycine in the body. It can cause seizures, intellectual disability, and respiratory problems. Key symptoms not reported: seizures, intellectual disability, respiratory problems.",Hereditary metabolic disorders
['Hereditary orotic aciduria'],"+1. Lysosomal storage disorder: Consistent with hepatosplenomegaly, lethargy, and early death. However, the skin rash and abnormal urine findings are atypical.

+2. Urea cycle disorder: Matches the abnormal urine findings (ornithinuria, oroticaciduria) and lethargy, but does not fully explain the organomegaly, skin rash, and early death.

+3. Inborn error of amino acid metabolism: Could account for the abnormal urine findings (hyperglycinuria, cystinuria), neurological symptoms, and lethargy, but the skin rash, organomegaly, and early death are less common.

+4. Severe combined immunodeficiency: Consistent with recurrent infections (pneumonia), skin rash, and early death, but does not explain the abnormal urine findings and organomegaly.

+5. Congenital infection: Fever, skin rash, and early death could potentially be explained by a congenital infection, but the abnormal urine findings and organomegaly are not typical.",Hereditary metabolic disorders
['Holocarboxylase synthetase deficiency'],"+1. Propionic acidemia: Consistent with propionyl-CoA carboxylase deficiency, metabolic acidosis, hyperammonemia, aminoaciduria, and elevated organic acids. Key symptoms not reported: vomiting, lethargy, and developmental delay.

+2. Methylmalonic acidemia: Consistent with metabolic acidosis, hyperammonemia, aminoaciduria, and elevated organic acids. Key symptoms not reported: vomiting, lethargy, and developmental delay.

+3. Isovaleric acidemia: Consistent with metabolic acidosis, hyperammonemia, and elevated organic acids. Key symptoms not reported: vomiting, lethargy, and developmental delay.

+4. Glutaric acidemia type II: Consistent with metabolic acidosis, hyperammonemia, and elevated organic acids. Key symptoms not reported: vomiting, lethargy, and developmental delay.

+5. Multiple carboxylase deficiency: Consistent with metabolic acidosis, hyperammonemia, aminoaciduria, and elevated organic acids. Key symptoms not reported: vomiting, lethargy, and developmental delay.",Hereditary metabolic disorders
['Ornithine transcarbamylase deficiency'],"+1. Citrullinemia: Hyperammonemia, oroticaciduria, vomiting, lethargy, ataxia, consistent with a urea cycle disorder. Key symptom not reported: elevated plasma citrulline.

+2. Ornithine transcarbamylase deficiency: Hyperammonemia, lethargy, ataxia, vomiting, consistent with a urea cycle disorder. Key symptom not reported: elevated plasma glutamine.

+3. Carbamoyl phosphate synthetase I deficiency: Hyperammonemia, lethargy, vomiting, consistent with a urea cycle disorder. Key symptom not reported: elevated plasma glutamine.

+4. Methylmalonic acidemia: Hyperammonemia, lethargy, vomiting, consistent with an organic acidemia. Key symptoms not reported: metabolic acidosis, ketosis, developmental delay.

+5. Propionic acidemia: Hyperammonemia, lethargy, vomiting, consistent with an organic acidemia. Key symptoms not reported: metabolic acidosis, ketosis, developmental delay.",Hereditary metabolic disorders
[],"+1. Long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency: Consistent with vomiting, ethylmalonic aciduria, abnormal carnitine levels, and decreased 3-hydroxyacyl-CoA dehydrogenase level. This disorder can lead to life-threatening metabolic crises and early death if not managed properly.

+2. Mitochondrial trifunctional protein (MTP) deficiency: A broader category of disorders that includes LCHAD deficiency. Consistent with the same symptoms as LCHAD deficiency, as MTP is involved in the beta-oxidation of long-chain fatty acids.

+3. Glutaric aciduria type II: Consistent with ethylmalonic aciduria and abnormal carnitine levels. However, this disorder typically presents with additional symptoms like metabolic acidosis, hypoglycemia, and neurological manifestations, which are not reported in this case.

+4. Multiple acyl-CoA dehydrogenase deficiency (MADD): A disorder of fatty acid oxidation that can present with ethylmalonic aciduria and abnormal carnitine levels. However, it is typically associated with more severe and earlier onset of symptoms compared to the patient's presentation.

+5. Carnitine palmitoyltransferase (CPT) deficiency: Consistent with abnormal carnitine levels and potential fatty acid oxidation defect. However, it is less likely as the primary enzyme deficiency is not directly related to the reported decreased 3-hydroxyacyl-CoA dehydrogenase level.",Hereditary metabolic disorders
['Smith-Lemli-Opitz syndrome'],"+1. Smith-Lemli-Opitz syndrome (SLOS): Low-set ears, wide nasal bridge, anteverted nares, ptosis, syndactyly, intellectual disability, motor delay, generalized hypotonia, feeding difficulties, hypocholesterolemia, elevated 8-dehydrocholesterol, elevated circulating 7-dehydrocholesterol concentration. Key symptoms not reported: structural brain abnormalities, behavioral problems.

+2. Zellweger syndrome: Low-set ears, wide nasal bridge, anteverted nares, ptosis, syndactyly, intellectual disability, motor delay, generalized hypotonia, feeding difficulties, death in infancy. Key symptoms not reported: hepatomegaly, renal cysts, retinal abnormalities.

+3. Desmosterolosis: Intellectual disability, motor delay, generalized hypotonia, feeding difficulties, hypocholesterolemia, elevated circulating desmosterol concentration. Key symptoms not reported: macrocephaly, ambiguous genitalia, photosensitivity.

+4. Lathosterolosis: Intellectual disability, motor delay, generalized hypotonia, feeding difficulties, hypocholesterolemia, elevated circulating lathosterol concentration. Key symptoms not reported: ambiguous genitalia, liver dysfunction, photosensitivity.

+5. Congenital disorder of glycosylation (CDG): Intellectual disability, motor delay, generalized hypotonia, feeding difficulties, hypocholesterolemia. Key symptoms not reported: coagulopathy, liver dysfunction, specific biochemical abnormalities associated with different CDG subtypes.",Hereditary metabolic disorders
['L-2-hydroxyglutaric aciduria'],"+1. L-2-hydroxyglutaric aciduria: Consistent with the presence of L-2-hydroxyglutaric aciduria, intellectual disability, ataxia, tremor, cerebral atrophy, and abnormal basal ganglia morphology. Early death is also a common feature.

+2. Leigh syndrome: Consistent with intellectual disability, ataxia, tremor, cerebral atrophy, and abnormal basal ganglia morphology. However, the presence of L-2-hydroxyglutaric aciduria is not a typical finding.

+3. Mitochondrial disorders: Consistent with intellectual disability, ataxia, tremor, cerebral atrophy, and abnormal basal ganglia morphology. Early death is also a common feature in severe cases. However, the presence of L-2-hydroxyglutaric aciduria is not a typical finding.

+4. Glutaric aciduria type 1: Consistent with intellectual disability, ataxia, cerebral atrophy, and abnormal basal ganglia morphology. However, the presence of L-2-hydroxyglutaric aciduria and early death are not typical features.

+5. Neuronal ceroid lipofuscinosis: Consistent with intellectual disability, ataxia, cerebral atrophy, and early death. However, the presence of L-2-hydroxyglutaric aciduria and abnormal basal ganglia morphology are not typical features.",Hereditary metabolic disorders
['3-hydroxy-3-methylglutaric aciduria'],"+1. Glutaric aciduria type II (Multiple acyl-CoA dehydrogenase deficiency): Consistent with metabolic acidosis, dicarboxylic aciduria, and early mortality. However, seizures and opisthotonus are not typical features.

+2. Methylmalonic acidemia: Consistent with metabolic acidosis, seizures, and early mortality. However, dicarboxylic aciduria and 3-methylglutaconic aciduria are not typical features.

+3. Propionic acidemia: Consistent with metabolic acidosis, seizures, and early mortality. However, dicarboxylic aciduria and 3-methylglutaconic aciduria are not typical features.

+4. Mitochondrial disorders: Consistent with metabolic acidosis, seizures, hypotonia, and early mortality. However, dicarboxylic aciduria and 3-methylglutaconic aciduria are not typical features.

+5. Organic acidemias (e.g., isovaleric acidemia, methylmalonic acidemia, propionic acidemia): Consistent with metabolic acidosis, seizures, and early mortality. However, dicarboxylic aciduria and 3-methylglutaconic aciduria are not typical features.",Hereditary metabolic disorders
['L-2-hydroxyglutaric aciduria'],"+1. Inherited metabolic disorder (e.g., L-2-hydroxyglutaric aciduria): Consistent with L-2-hydroxyglutaric aciduria, seizures, and potential neurological involvement. Key symptoms not reported include developmental delay, intellectual disability, or specific metabolic abnormalities.

+2. Inflammatory or autoimmune disorder: Consistent with skin rash, elevated C-reactive protein, and potential multi-system involvement. Key symptoms not reported include specific autoantibodies, organ involvement, or other characteristic features.

+3. Infectious disease: Consistent with fever and elevated C-reactive protein. Key symptoms not reported include respiratory distress, gastrointestinal symptoms, or other specific signs of infection.

+4. Nutritional deficiency (e.g., iron deficiency): Consistent with decreased iron concentration. Key symptoms not reported include specific signs of iron deficiency anemia or other nutritional deficiencies.

+5. Neonatal sepsis or systemic inflammatory response syndrome (SIRS): Consistent with fever, elevated C-reactive protein, and potential multi-system involvement. Key symptoms not reported include specific signs of infection or organ dysfunction.",Hereditary metabolic disorders
['X-linked hypophosphatemia'],"+1. Hereditary hypophosphatemic rickets with hypercalciuria: Characterized by hypophosphatemia, abnormal limb bone morphology, elevated alkaline phosphatase, and nephritis (kidney inflammation). Consistent with the patient's symptoms.

+2. Fanconi syndrome: Presents with hypophosphatemia, bone deformities, and kidney dysfunction (nephritis). The abnormal circulating hormone concentration could be related to associated endocrine abnormalities.

+3. Cystinosis: A lysosomal storage disorder that can cause nephritis, bone abnormalities, and endocrine disturbances. The early onset and potential for death in infancy or childhood is consistent with the severe form of this condition.

+4. Hypophosphatemic rickets: Characterized by hypophosphatemia, abnormal bone development, and elevated alkaline phosphatase. However, nephritis is not a typical feature of this disorder.

+5. Vitamin D-resistant rickets: Presents with hypophosphatemia, bone deformities, and elevated alkaline phosphatase. Nephritis is not commonly reported in this condition.",Hereditary metabolic disorders
['Propionic acidemia'],"+1. Nonketotic hyperglycinemia (NKH): Characterized by hyperglycinemia, hyperglycinuria, hyperammonemia, and developmental delay, consistent with the patient's symptoms. However, the skin rash and leukopenia are not typical features of NKH.

+2. Urea cycle disorder: Hyperammonemia, abnormal amino acid levels, and developmental delay are consistent with these disorders, but hyperglycinemia and hyperglycinuria are not typical features.

+3. Organic acidemia: Elevated urinary carboxylic acids, hyperammonemia, and developmental delay are consistent with these disorders, but hyperglycinemia and hyperglycinuria are not characteristic features.

+4. Glycine encephalopathy: A rare disorder of glycine metabolism, characterized by hyperglycinemia, hyperglycinuria, and developmental delay, consistent with the patient's symptoms. However, the skin rash, leukopenia, and abnormal amino acid levels are not typical features.

+5. Aminoacidopathy: A general term for disorders involving abnormal amino acid metabolism, which could explain the abnormal amino acid levels and hyperammonemia. However, the specific combination of symptoms, including hyperglycinemia and hyperglycinuria, is not fully explained by this broad category.",Hereditary metabolic disorders
"['Methylmalonic acidemia with homocystinuria, type cblC']","+1. Methylmalonic acidemia: Delayed speech and language development, generalized hypotonia, death in infancy/childhood, hyperhomocystinemia, abnormal cerebral white matter morphology, gastrointestinal inflammation, decreased plasma free carnitine, methylmalonic aciduria.
+2. Propionic acidemia: Generalized hypotonia, death in infancy/childhood, hyperhomocystinemia, gastrointestinal inflammation, methylmalonic aciduria. Key symptoms not reported: vomiting, lethargy, metabolic acidosis.
+3. Remethylation disorders (e.g., cobalamin deficiencies): Hyperhomocystinemia, methylmalonic aciduria. May not fully explain other symptoms like developmental delays, hypotonia, and gastrointestinal inflammation.
+4. Glutaric acidemia type II: Generalized hypotonia, abnormal cerebral white matter morphology, gastrointestinal inflammation, decreased plasma free carnitine. Key symptoms not reported: metabolic acidosis, macrocephaly, dystonia.
+5. Organic acidemias (e.g., isovaleric acidemia, methylmalonic acidemia with homocystinuria): Generalized hypotonia, gastrointestinal inflammation, decreased plasma free carnitine, methylmalonic aciduria. May not fully explain developmental delays and cerebral white matter abnormalities.",Hereditary metabolic disorders
['Biotinidase deficiency'],"+1. Organic acidemia: Consistent with elevated urinary carboxylic acid and potential neonatal/early infantile presentation. Key symptoms not reported: metabolic acidosis, vomiting, lethargy.

+2. Fatty acid oxidation disorder: Consistent with elevated urinary carboxylic acid and potential neonatal/early infantile presentation. Key symptoms not reported: hypoglycemia, metabolic acidosis.

+3. Mitochondrial disorder: Consistent with elevated urinary carboxylic acid and potential neonatal/early infantile presentation. Key symptoms not reported: lactic acidosis, multi-organ dysfunction.

+4. Recurrent metabolic encephalomyopathic crises-rhabdomyolysis-cardiac arrhythmia-intellectual disability syndrome: Consistent with potential neonatal/early infantile presentation, but key symptoms (e.g., rhabdomyolysis, arrhythmia, intellectual disability) not reported.

+5. Classic galactosemia: Consistent with potential neonatal/early infantile presentation, but key symptoms (e.g., jaundice, hypotonia, vomiting, hypergalactosemia) not reported.",Hereditary metabolic disorders
['Carbamoyl-phosphate synthetase 1 deficiency'],"+1. Urea cycle disorder: Consistent with hyperammonemia, lethargy, and potential neonatal onset. Key symptom not reported: episodic vomiting or protein aversion.

+2. Organic acidemia: Consistent with lethargy, hypotonia, and potential neonatal onset. Key symptoms not reported: metabolic acidosis, ketosis, or specific metabolite elevations.

+3. Mitochondrial disorder: Consistent with hypotonia, lethargy, and multi-system involvement. Key symptoms not reported: lactic acidosis, seizures, or specific organ involvement (e.g., cardiomyopathy).

+4. Leukodystrophy (e.g., Krabbe disease): Consistent with progressive neurological deterioration and potential early death. Key symptoms not reported: vision loss, peripheral neuropathy, or specific MRI findings.

+5. Neuronal ceroid lipofuscinosis: Consistent with progressive neurological deterioration and potential early death. Key symptoms not reported: seizures, vision loss, or specific patterns of brain atrophy on MRI.",Hereditary metabolic disorders
['Vitamin B12-unresponsive methylmalonic acidemia'],"+1. Methylmalonic acidemia: Consistent with metabolic acidosis, decreased methylmalonyl-CoA mutase activity, and early death. Key symptoms not reported include vomiting, lethargy, and developmental delays.

+2. Propionic acidemia: Consistent with metabolic acidosis and early death. However, decreased methylmalonyl-CoA mutase activity is more specific to methylmalonic acidemia.

+3. Isovaleric acidemia: Consistent with metabolic acidosis and early death. However, the enzyme deficiency is not directly related to methylmalonyl-CoA mutase.

+4. Glutaric acidemia type II: Consistent with metabolic acidosis and early death. However, the enzyme deficiency is not directly related to methylmalonyl-CoA mutase.

+5. Multiple carboxylase deficiency: Consistent with metabolic acidosis and early death. However, the specific enzyme deficiency (methylmalonyl-CoA mutase) is not typically associated with this condition.",Hereditary metabolic disorders
[],"+1. Congenital porphyria: Consistent with abnormal circulating porphyrin concentration, hemolytic anemia, and potential neurological symptoms (hyperactivity, spasticity). Key symptoms not reported: photosensitivity, abdominal pain.

+2. Mitochondrial disorder: Consistent with metabolic acidosis, increased lactate dehydrogenase, and potential multi-organ involvement. Key symptoms not reported: specific neurological manifestations (e.g., seizures, developmental delay).

+3. Severe combined immunodeficiency (SCID): Consistent with recurrent viral infections and potential immune dysfunction. Key symptoms not reported: chronic diarrhea, failure to thrive.

+4. Hereditary hemolytic anemia: Consistent with hemolytic anemia and potential metabolic complications. Key symptoms not reported: jaundice, splenomegaly.

+5. Inborn error of metabolism: Consistent with metabolic acidosis, potential neurological symptoms, and potential multi-organ involvement. Key symptoms not reported: specific metabolic abnormalities (e.g., hypoglycemia, hyperammonemia).",Hereditary metabolic disorders
['Neonatal intrahepatic cholestasis due to citrin deficiency'],"+1. Citrullinemia type I: Elevated plasma citrulline, hyperammonemia, respiratory distress, and neonatal onset are consistent with this urea cycle disorder caused by a deficiency in the argininosuccinate synthetase enzyme.

+2. Argininosuccinic aciduria: Characterized by elevated citrulline and ammonia levels due to a deficiency in the argininosuccinate lyase enzyme, which can present with similar symptoms.

+3. Carbamoyl phosphate synthetase I deficiency: Another urea cycle disorder that can cause hyperammonemia, respiratory distress, and neonatal onset, although elevated citrulline levels are not a typical finding.

+4. Recurrent metabolic encephalomyopathic crises-rhabdomyolysis-cardiac arrhythmia-intellectual disability syndrome: While this condition can present with hyperammonemia and respiratory distress, the absence of other characteristic symptoms (e.g., seizures, intellectual disability, rhabdomyolysis) makes it less likely in this case.

+5. Classic galactosemia: A metabolic disorder that can cause neonatal complications, but the symptoms provided do not align with the typical presentation of galactosemia (e.g., jaundice, vomiting, hyperbilirubinemia).",Hereditary metabolic disorders
[],"+1. Methylmalonic acidemia: Consistent with methylmalonic acidemia, aciduria, and decreased methylmalonyl-CoA mutase activity. Key symptoms not reported: specific neurological manifestations like developmental delay or movement disorders.

+2. Mitochondrial encephalomyopathy: Consistent with neurological symptoms (intellectual disability, seizures, coma, hypotonia), lactic acidosis, and multi-organ involvement. Key symptoms not reported: specific mitochondrial myopathy or other organ-specific manifestations.

+3. Organic acidemia (e.g., propionic acidemia, isovaleric acidemia): Consistent with metabolic derangements, acidemia, and neurological symptoms. Key symptoms not reported: specific metabolic aciduria or other biochemical abnormalities associated with the specific disorder.

+4. Urea cycle disorder (e.g., citrullinemia, argininosuccinic aciduria): Consistent with hyperammonemia and multi-organ involvement. Key symptoms not reported: specific biochemical abnormalities or neurological manifestations associated with the specific disorder.

+5. Lysosomal storage disorder (e.g., mucopolysaccharidosis, glycoprotein storage disorder): Consistent with neurological symptoms, skeletal abnormalities, and multi-organ involvement. Key symptoms not reported: specific clinical or biochemical features associated with the specific disorder.",Hereditary metabolic disorders
['Dihydropteridine reductase deficiency'],"+1. Phenylketonuria (PKU): Microcephaly, intellectual disability, seizures, hyperphenylalaninemia. Key symptom not reported: fair skin, light hair, and blue eyes.

+2. Tyrosinemia type I: Microcephaly, intellectual disability, seizures, hypertyrosinemia, neonatal death. Key symptom not reported: liver disease or failure.

+3. Zellweger syndrome: Microcephaly, intellectual disability, seizures, generalized hypotonia, cerebral atrophy, abnormal cerebral white matter morphology. Key symptom not reported: characteristic facial features.

+4. Neuronal ceroid lipofuscinosis (NCL): Microcephaly, intellectual disability, seizures, motor delay, cerebral atrophy, death in childhood. Key symptom not reported: vision loss or retinal degeneration.

+5. GM1/GM2 gangliosidosis: Microcephaly, intellectual disability, seizures, generalized hypotonia, cerebral atrophy, death in infancy. Key symptom not reported: cherry-red spot on the macula.",Hereditary metabolic disorders
[],"+1. Mitochondrial disorder: Cytochrome C oxidase-negative muscle fibers, feeding difficulties, functional abnormality of the gastrointestinal tract. Key symptoms not reported: neurological manifestations, lactic acidosis.

+2. Organic acidemia: Ethylmalonic aciduria, glycosuria. Key symptoms not reported: metabolic acidosis, hyperammonemia, developmental delay.

+3. Glycine encephalopathy: Abnormal circulating glycine concentration, feeding difficulties. Key symptoms not reported: seizures, intellectual disability, hypotonia.

+4. Metabolic disorder with skin manifestations: Skin rash (erythematous plaque, macule, papule), death in infancy. Key symptoms not reported: specific metabolic abnormalities or other organ involvement.

+5. Severe combined immunodeficiency: Death in infancy, feeding difficulties, functional abnormality of the gastrointestinal tract. Key symptoms not reported: recurrent infections, lymphopenia, failure to thrive.",Hereditary metabolic disorders
['Carbamoyl-phosphate synthetase 1 deficiency'],"+1. Citrullinemia type I: Consistent with hyperammonemia, cerebral edema, oroticaciduria, hypoargininemia, and low plasma citrulline levels. This disorder is caused by a deficiency of the enzyme argininosuccinate synthetase in the urea cycle.

+2. Argininosuccinic aciduria: Another urea cycle disorder caused by a deficiency of the enzyme argininosuccinate lyase. It can present with similar symptoms, including hyperammonemia, seizures, and cerebral edema. However, the patient's low plasma citrulline levels are more specific for citrullinemia type I.

+3. Carbamoyl phosphate synthetase I deficiency: A urea cycle disorder that can also cause hyperammonemia, seizures, and cerebral edema. However, the absence of reported low plasma citrulline levels makes this diagnosis less likely.

+4. Ornithine transcarbamylase deficiency: Another urea cycle defect that can present with hyperammonemia and neurological symptoms. However, the presence of oroticaciduria and low plasma citrulline levels are not typical features of this disorder.

+5. Transient hyperammonemia of the newborn: A temporary condition in newborns caused by immature liver enzymes or other factors. While hyperammonemia is present, the severity of symptoms (e.g., cerebral edema, neonatal death) and specific metabolic abnormalities (e.g., oroticaciduria, hypoargininemia) make this diagnosis less likely in this case.",Hereditary metabolic disorders
['Canavan disease'],"+1. Urea cycle disorder: Seizures, hyperammonemia, aminoaciduria, abnormal amino acid levels (consistent with the patient's symptoms). Key symptom not reported: Lethargy, vomiting.

+2. Organic acidemia: Seizures, aminoaciduria, abnormal amino acid levels (consistent with the patient's symptoms). Key symptoms not reported: Metabolic acidosis, ketosis, developmental delay.

+3. Glycine encephalopathy: Seizures, abnormal glycine concentration (consistent with the patient's symptoms). Key symptoms not reported: Developmental delay, hypotonia, respiratory distress.

+4. Porphyria: Skin rash (consistent with the patient's symptoms). Key symptoms not reported: Abdominal pain, neurological symptoms, photosensitivity.

+5. Lysosomal storage disorder: Skin rash, seizures (consistent with the patient's symptoms). Key symptoms not reported: Organomegaly, developmental delay, skeletal abnormalities.",Hereditary metabolic disorders
['Maple syrup urine disease'],"+1. Maple syrup urine disease (MSUD): Consistent with hypervalinemia, hyperleucinemia, hyperisoleucinemia, seizures, feeding difficulties, and potentially fatal in infancy. Key symptom not reported: Maple syrup odor in urine and body fluids.

+2. Propionic acidemia: Consistent with seizures, feeding difficulties, respiratory insufficiency, and potentially fatal in infancy. Key symptoms not reported: Metabolic acidosis, vomiting, lethargy.

+3. Methylmalonic acidemia: Consistent with seizures, feeding difficulties, respiratory insufficiency, and potentially fatal in infancy. Key symptoms not reported: Metabolic acidosis, vomiting, lethargy.

+4. Organic acidemia: A group of inherited disorders characterized by the accumulation of organic acids, consistent with seizures, feeding difficulties, respiratory insufficiency, and potentially fatal in infancy. Key symptoms not reported: Metabolic acidosis, vomiting, lethargy.

+5. Urea cycle disorder: A group of inherited disorders affecting the metabolism of nitrogen, consistent with seizures, feeding difficulties, respiratory insufficiency, and potentially fatal in infancy. Key symptoms not reported: Hyperammonemia, vomiting, lethargy.",Hereditary metabolic disorders
['Medium chain acyl-CoA dehydrogenase deficiency'],"+1. Mitochondrial fatty acid oxidation disorder (e.g., LCHAD deficiency, VLCAD deficiency): Consistent with abnormal circulating carnitine concentration, decreased 3-hydroxyacyl-CoA dehydrogenase level, and potentially fatal complications in infancy/childhood. Key symptoms not reported: metabolic crises, hypoglycemia, hepatic dysfunction.

+2. Carnitine deficiency disorder: Consistent with abnormal circulating carnitine concentration and potentially fatal complications in infancy/childhood. Key symptoms not reported: metabolic crises, hypoglycemia, cardiomyopathy.

+3. Organic acidemia (e.g., propionic acidemia, methylmalonic acidemia): Consistent with potentially fatal complications in infancy/childhood and disruption of fatty acid oxidation. Key symptoms not reported: metabolic acidosis, hyperammonemia, ketosis.

+4. Mitochondrial respiratory chain disorder: Consistent with potentially fatal complications in infancy/childhood and disruption of energy metabolism. Key symptoms not reported: lactic acidosis, neurological symptoms, multi-organ involvement.

+5. Peroxisomal disorder (e.g., Zellweger syndrome): Consistent with potentially fatal complications in infancy/childhood and disruption of fatty acid oxidation. Key symptoms not reported: neurological abnormalities, liver dysfunction, dysmorphic features.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Phenylketonuria (PKU): Intellectual disability, seizures, hyperphenylalaninemia. Key symptom not reported: musty odor, eczema, fair skin/hair.

+2. Tyrosinemia: Intellectual disability, seizures, hypertyrosinemia. Additional information on liver function and other metabolic markers could help confirm.

+3. Leukodystrophy: Intellectual disability, seizures, abnormal cerebral white matter morphology. Specific neuroimaging and biochemical findings needed for diagnosis.

+4. Mitochondrial disorder: Intellectual disability, seizures, metabolic abnormalities. Muscle biopsy, genetic testing, or evaluation of mitochondrial function could help identify the specific disorder.

+5. Organic acidemia: Intellectual disability, seizures, metabolic abnormalities, early mortality. Specific organic acid analysis and enzyme assays could diagnose the particular organic acidemia.",Hereditary metabolic disorders
['Wilson disease'],"+1. Wilson's disease: Generalized hypotonia, splenomegaly, hepatomegaly, elevated circulating hepatic transaminase concentration, decreased circulating ceruloplasmin concentration, increased urinary copper concentration, abnormal circulating amino acid concentrations, copper accumulation in liver, death in childhood or adolescence. Key symptoms not reported: Kayser-Fleischer rings (corneal copper deposits), neurological symptoms (tremors, dysarthria, psychiatric disturbances).

+2. TMEM199-CDG (Congenital disorder of glycosylation type IIc): Generalized hypotonia, splenomegaly, hepatomegaly, elevated circulating hepatic transaminase concentration, decreased circulating ceruloplasmin concentration, decreased circulating copper concentration. Key symptoms not reported: Hepatic steatosis, hypercholesterolemia, abnormal protein glycosylation.

+3. Chronic visceral acid sphingomyelinase deficiency (Niemann-Pick disease type B): Splenomegaly, hepatomegaly, elevated circulating hepatic transaminase concentration, death in childhood or adolescence. Key symptoms not reported: Thrombocytopenia, leukopenia, anemia, pulmonary involvement.

+4. Niemann-Pick disease type C: Splenomegaly, hepatomegaly, elevated circulating hepatic transaminase concentration, death in childhood or adolescence. Key symptoms not reported: Neurological symptoms (ataxia, vertical supranuclear gaze palsy, dysarthria), psychiatric disturbances.

+5. Fetal Gaucher disease: Generalized hypotonia, hepatosplenomegaly, thrombocytopenia, decreased body weight, death in infancy. Key symptoms not reported: Congenital nonbullous ichthyosiform erythroderma, decreased beta-glucocerebrosidase level.",Hereditary metabolic disorders
['PMM2-CDG'],"+1. Pontocerebellar hypoplasia: Consistent with cerebellar agenesis/atrophy, intellectual disability, hypotonia, and abnormal facial/skull morphology. Often leads to early death.

+2. Congenital muscular dystrophy: Consistent with generalized hypotonia, intellectual disability, and brain malformations in some forms. May not fully explain cerebellar agenesis.

+3. Congenital disorder of glycosylation: Consistent with intellectual disability, hypotonia, and dysmorphic features. Specific types can involve cerebellar abnormalities.

+4. Chromosomal abnormality or syndrome: Intellectual disability, congenital malformations, and dysmorphic features could suggest an underlying chromosomal or syndromic disorder.

+5. Congenital brain malformation syndrome: The combination of cerebellar agenesis, intellectual disability, and dysmorphic features may indicate a specific syndrome affecting brain development.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Tyrosinemia type I: Characterized by hypertyrosinemia, abnormality of prenatal development, and potential death in infancy or adolescence. Key symptoms not reported: liver and kidney problems, neurological issues.

+2. Phenylketonuria (PKU): Characterized by hyperphenylalaninemia, abnormality of prenatal development, and potential death in infancy or adolescence. Key symptoms not reported: intellectual disability, seizures, neurological problems.

+3. Maple syrup urine disease (MSUD): Characterized by abnormality of prenatal development and potential death in infancy or adolescence. Key symptoms not reported: buildup of leucine, isoleucine, and valine, neurological problems.

+4. Homocystinuria: A rare inherited disorder characterized by abnormality of prenatal development and potential death in infancy or adolescence. Key symptoms not reported: elevated homocysteine levels, intellectual disability, skeletal abnormalities.

+5. Glutaric aciduria type I: A rare inherited disorder characterized by abnormality of prenatal development and potential death in infancy or adolescence. Key symptoms not reported: elevated glutaric acid levels, neurological problems, metabolic acidosis.",Hereditary metabolic disorders
['Glutaryl-CoA dehydrogenase deficiency'],"+1. Glutaric acidemia type 1 (GA1): Consistent with macrocephaly, hypotonia, abnormal cerebral morphology, glutaric aciduria, and abnormal lysine and carnitine levels. Key symptoms not reported: seizures, dystonia, and movement disorders.

+2. Methylmalonic acidemia: Consistent with metabolic acidosis, hypotonia, and cerebral abnormalities. Key symptoms not reported: developmental delay, failure to thrive, and recurrent vomiting.

+3. Propionic acidemia: Consistent with metabolic acidosis, hypotonia, and cerebral abnormalities. Key symptoms not reported: developmental delay, failure to thrive, and protein avoidance.

+4. Mitochondrial disorder: Consistent with increased lactate levels and hypotonia. Key symptoms not reported: specific organ involvement (e.g., cardiomyopathy, myopathy, or neurological deficits).

+5. Organic acidemia, unspecified: Consistent with metabolic acidosis, hypotonia, and cerebral abnormalities. Additional testing would be needed to identify the specific disorder.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Tyrosinemia type I (Fumarylacetoacetate hydrolase deficiency): Consistent with hypertyrosinemia, abnormality of prenatal development, and potential for neonatal/infant/childhood death if untreated.
+2. Phenylketonuria (Phenylalanine hydroxylase deficiency): Consistent with hyperphenylalaninemia, abnormality of prenatal development, and potential for developmental delays and neurological complications if untreated.
+3. Maple syrup urine disease (Branched-chain ketoacid dehydrogenase deficiency): Consistent with abnormality of prenatal development and potential for neonatal/infant death if untreated. Key symptoms of maple syrup odor and ketoacidosis are not reported.
+4. Homocystinuria (Cystathionine beta-synthase deficiency): Consistent with abnormality of prenatal development and potential for developmental delays and neurological complications if untreated. Key symptoms of homocystinuria, such as ectopia lentis and skeletal abnormalities, are not reported.
+5. Alkaptonuria (Homogentisate 1,2-dioxygenase deficiency): Consistent with abnormality of prenatal development. Key symptoms of alkaptonuria, such as dark urine and ochronosis, are not reported.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Tyrosinemia type I: Hypertyrosinemia, feeding difficulties, potential for early death. Key symptoms not reported: liver failure, kidney problems, neurological issues.

+2. Phenylketonuria (PKU): Hyperphenylalaninemia, microcephaly, developmental delays. Key symptoms not reported: intellectual disability, seizures, fair skin and hair.

+3. Zellweger spectrum disorder: Microcephaly, developmental delays, feeding problems, prenatal abnormalities, effusions, potential for early death. Key symptoms not reported: hypotonia, seizures, liver dysfunction.

+4. Mitochondrial disorder: Developmental delays, feeding issues, organ failures (effusions), potential for early death. Key symptoms not reported: specific organ involvement (e.g., brain, muscle, heart), lactic acidosis.

+5. Severe combined immunodeficiency (SCID): Small for gestational age, feeding difficulties, potential for early death. Key symptoms not reported: recurrent infections, failure to thrive, lymphopenia.",Hereditary metabolic disorders
['Ornithine transcarbamylase deficiency'],"+1. Ornithine transcarbamylase deficiency (OTC deficiency): Consistent with hyperammonemia, vomiting, and oroticaciduria. May not present with hyperglutaminemia.

+2. Carbamoyl phosphate synthetase I deficiency (CPS1 deficiency): Consistent with hyperammonemia, vomiting, and oroticaciduria. May not present with hyperglutaminemia.

+3. Citrullinemia type I: Consistent with hyperammonemia, vomiting, oroticaciduria, and hyperglutaminemia.

+4. Argininosuccinic aciduria (ASA): Consistent with hyperammonemia, vomiting, and oroticaciduria. May not present with hyperglutaminemia.

+5. Argininemia: Consistent with hyperammonemia and vomiting. May not present with oroticaciduria or hyperglutaminemia.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Phenylketonuria (PKU): Hyperphenylalaninemia, abnormal circulating tyrosine concentration. Key symptom not reported: intellectual disability, seizures, developmental delay.

+2. Maple syrup urine disease (MSUD): Elevated urinary carboxylic acid, abnormal circulating amino acid concentrations. Key symptoms not reported: maple syrup odor, lethargy, vomiting, coma.

+3. Propionic acidemia: Elevated urinary carboxylic acid, abnormality of prenatal development or birth, death in infancy. Key symptoms not reported: metabolic acidosis, vomiting, lethargy, hypotonia.

+4. Methylmalonic acidemia: Elevated urinary carboxylic acid, abnormality of prenatal development or birth, death in infancy. Key symptoms not reported: metabolic acidosis, vomiting, lethargy, hypotonia.

+5. Glutaric acidemia type II: Elevated urinary carboxylic acid, abnormality of prenatal development or birth, death in infancy. Key symptoms not reported: metabolic acidosis, hypoglycemia, hypotonia, seizures.",Hereditary metabolic disorders
['Pearson syndrome'],"+1. Lysosomal storage disorder: Consistent with the multi-organ involvement, including enlarged kidney, hematological abnormalities, neurological symptoms, and progressive deterioration leading to death in infancy/childhood. Key symptoms not reported: specific organ manifestations may vary depending on the type of lysosomal storage disorder.

+2. Mitochondrial disorder: Consistent with the multi-organ dysfunction, lactic acidosis, neurological symptoms (lethargy, coma), and potential cardiac involvement (congestive heart failure). Key symptoms not reported: specific organ manifestations and severity may vary.

+3. Organic acidemia (e.g., methylmalonic acidemia, propionic acidemia): Consistent with the metabolic acidosis, hypoglycemia, lethargy, coma, and elevated lactate/pyruvate levels. Key symptoms not reported: specific organ involvement is less common in organic acidemias.

+4. Congenital disorder of glycosylation (CDG): Consistent with the multi-organ involvement, including neurological symptoms, and potential kidney and gastrointestinal manifestations. Key symptoms not reported: specific organ manifestations may vary depending on the type of CDG.

+5. Severe combined immunodeficiency (SCID): Consistent with the recurrent viral infections and potential hematological abnormalities. Key symptoms not reported: the majority of the reported symptoms are not typical for SCID.",Hereditary metabolic disorders
['Smith-Lemli-Opitz syndrome'],"+1. Smith-Lemli-Opitz syndrome: Consistent with broad/long philtrum, anteverted nares, syndactyly, generalized hypotonia, feeding difficulties, hypocholesterolemia, elevated 7-dehydrocholesterol and 8-dehydrocholesterol levels, and neonatal death. Key symptoms not reported include intellectual disability and structural brain abnormalities.

+2. Desmosterolosis: A rare cholesterol biosynthesis disorder caused by a deficiency of the enzyme 3-hydroxysterol-24-reductase. Consistent with dysmorphic facial features, syndactyly, hypotonia, and elevated cholesterol precursors. However, the specific biochemical abnormalities (elevated desmosterol levels) were not reported.

+3. Lathosterolosis: Another cholesterol biosynthesis disorder caused by a deficiency of the enzyme 3-hydroxysteroid-5-desaturase. Consistent with dysmorphic features, syndactyly, hypotonia, and elevated cholesterol precursors. However, the specific biochemical abnormality (elevated lathosterol levels) was not reported.

+4. Zellweger spectrum disorder: A group of peroxisomal biogenesis disorders that can present with dysmorphic features, hypotonia, and liver dysfunction. Consistent with some of the patient's symptoms, but the characteristic biochemical abnormalities (elevated very long chain fatty acids, phytanic acid, etc.) were not reported.

+5. Congenital disorders of glycosylation (CDG): A group of disorders affecting the glycosylation of proteins. Some types of CDG can present with dysmorphic features, hypotonia, and failure to thrive. However, the specific biochemical abnormalities (abnormal glycosylation patterns) were not reported in this case.",Hereditary metabolic disorders
['Acute intermittent porphyria'],"+1. Chronic visceral acid sphingomyelinase deficiency (Niemann-Pick disease type B): Consistent with recurrent viral infections, vomiting, and abdominal pain. Key symptoms not reported: hepatosplenomegaly, failure to thrive.

+2. Niemann-Pick disease type C: Consistent with recurrent viral infections, vomiting, and abdominal pain. Key symptoms not reported: hepatosplenomegaly, neurological symptoms.

+3. Severe combined immunodeficiency (SCID): Consistent with recurrent viral infections. Key symptoms not reported: failure to thrive, diarrhea, opportunistic infections.

+4. Glycogen storage disease type IV (Andersen disease): Consistent with recurrent viral infections, vomiting, and abdominal pain. Key symptoms not reported: liver dysfunction, muscle weakness, hypoglycemia.

+5. Chronic granulomatous disease: Consistent with recurrent viral infections. Key symptoms not reported: pneumonia, abscesses, failure to thrive.",Hereditary metabolic disorders
['Citrullinemia type I'],"+1. Citrullinemia type I: Consistent with hyperammonemia, elevated plasma citrulline, argininuria, and neonatal death. Key symptom not reported: oroticaciduria.

+2. Argininosuccinic aciduria: Consistent with hyperammonemia, metabolic acidosis, hyperglycinuria, and neonatal death. Key symptom not reported: elevated anion gap.

+3. Carbamoyl phosphate synthetase I deficiency: Consistent with hyperammonemia, metabolic acidosis, and neonatal death. Key symptoms not reported: respiratory alkalosis, low citrulline levels.

+4. Ornithine transcarbamylase deficiency: Consistent with hyperammonemia, metabolic acidosis, and neonatal death. Key symptoms not reported: orotic aciduria, protein avoidance.

+5. Arginase deficiency: Consistent with hyperammonemia, argininuria, and neonatal death. Key symptoms not reported: spastic diplegia, progressive neurological impairment.",Hereditary metabolic disorders
[],"+1. Methylmalonic acidemia (MMA): Delayed speech and language development, lethargy, generalized hypotonia, hyperammonemia, hyperhomocystinemia, methylmalonic acidemia, methylmalonic aciduria, decreased plasma free carnitine. Key symptoms not reported: vomiting, failure to thrive, metabolic acidosis.

+2. Cobalamin (vitamin B12) deficiency or disorders: Delayed speech and language development, lethargy, generalized hypotonia, hyperammonemia, hyperhomocystinemia, methylmalonic acidemia, methylmalonic aciduria. Key symptoms not reported: macrocytic anemia, glossitis, neurological symptoms (e.g., peripheral neuropathy, subacute combined degeneration of the spinal cord).

+3. Propionic acidemia: Delayed speech and language development, lethargy, generalized hypotonia, hyperammonemia, hyperhomocystinemia, methylmalonic acidemia, methylmalonic aciduria. Key symptoms not reported: vomiting, ketoacidosis, protein avoidance, neutropenia, thrombocytopenia.

+4. Disorders of intracellular cobalamin metabolism: Delayed speech and language development, lethargy, generalized hypotonia, hyperammonemia, hyperhomocystinemia, methylmalonic acidemia, methylmalonic aciduria. Key symptoms not reported: developmental regression, seizures, microcephaly.

+5. Disorders of carnitine metabolism: Delayed speech and language development, lethargy, generalized hypotonia, hyperammonemia, decreased plasma free carnitine. Key symptoms not reported: cardiomyopathy, skeletal muscle weakness, hypoglycemia, metabolic acidosis.",Hereditary metabolic disorders
['Very long chain acyl-CoA dehydrogenase deficiency'],"+1. Organic acidemia: Consistent with hyperammonemia, abnormal amino acid levels, and potential metabolic acidosis. Key symptoms not reported: vomiting, lethargy, metabolic acidosis.

+2. Fatty acid oxidation disorder: Consistent with decreased plasma free carnitine, hypotonia, and potential metabolic decompensation. Key symptoms not reported: hypoglycemia, hepatomegaly, cardiomyopathy.

+3. Urea cycle disorder: Consistent with hyperammonemia and potential for neonatal onset and early lethality. Key symptoms not reported: vomiting, lethargy, respiratory alkalosis.

+4. Mitochondrial disorder: Consistent with hypotonia, elevated creatine kinase, and potential multi-system involvement. Key symptoms not reported: lactic acidosis, seizures, developmental delay.

+5. Congenital disorder of glycosylation (CDG): Consistent with hypotonia and multi-system involvement. Key symptoms not reported: developmental delay, failure to thrive, coagulopathy.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Tyrosinemia type I: Consistent with hypertyrosinemia, abnormality of prenatal development, and death in infancy. Key symptoms not reported: liver failure, kidney dysfunction.

+2. Phenylketonuria (PKU): Consistent with hyperphenylalaninemia and potential intellectual disability (not explicitly stated). Key symptoms not reported: seizures, musty odor.

+3. Maple syrup urine disease (MSUD): Consistent with neonatal death and potential respiratory distress (upper airway obstruction). Key symptoms not reported: maple syrup odor, lethargy, poor feeding.

+4. Congenital disorders of glycosylation (CDG): Consistent with abnormality of prenatal development and potential multi-organ involvement. Key symptoms not reported: specific organ manifestations vary by type of CDG.

+5. Severe combined immunodeficiency (SCID): Consistent with recurrent infections (chronic pulmonary obstruction) and potential failure to thrive (not explicitly stated). Key symptoms not reported: opportunistic infections, lymphopenia.",Hereditary metabolic disorders
['Medium chain acyl-CoA dehydrogenase deficiency'],"+1. Fatty acid oxidation disorder (e.g., LCHAD deficiency, VLCAD deficiency): Consistent with decreased 3-hydroxyacyl-CoA dehydrogenase level, hypoglycemia, metabolic acidosis, cardiomyopathy, and liver dysfunction. Key symptoms not reported: cardiomyopathy, liver dysfunction.

+2. Carnitine deficiency: Consistent with decreased plasma free carnitine, which can lead to metabolic derangements and symptoms. Key symptoms not reported: cardiomyopathy, liver dysfunction.

+3. Vitamin B12 deficiency: Consistent with abnormal circulating vitamin B12 concentration, which can cause various neurological and hematological abnormalities. Key symptoms not reported: neurological symptoms, hematological abnormalities.

+4. Mitochondrial disorder: Consistent with metabolic derangements, multi-organ involvement, and potential energy deficiency. Key symptoms not reported: specific neurological or muscular symptoms.

+5. Congenital disorder of glycosylation (CDG): Consistent with multi-organ involvement and potential metabolic abnormalities. Key symptoms not reported: specific neurological or developmental symptoms.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Tyrosinemia type I: Hypertyrosinemia, death in infancy/childhood/adolescence, recurrent viral infections. Key symptom not reported: liver failure.

+2. Phenylketonuria (PKU): Hyperphenylalaninemia, death in infancy/childhood/adolescence, recurrent viral infections. Key symptom not reported: intellectual disability, seizures.

+3. Maple syrup urine disease (MSUD): Death in infancy/childhood/adolescence, recurrent viral infections. Key symptoms not reported: maple syrup odor, lethargy, coma.

+4. Urea cycle disorders (e.g., ornithine transcarbamylase deficiency): Death in infancy/childhood/adolescence, recurrent viral infections. Key symptoms not reported: hyperammonemia, vomiting, lethargy.

+5. Organic acidemias (e.g., methylmalonic acidemia, propionic acidemia): Death in infancy/childhood/adolescence, recurrent viral infections. Key symptoms not reported: metabolic acidosis, vomiting, lethargy.",Hereditary metabolic disorders
['3-methylcrotonyl-CoA carboxylase deficiency'],"+1. Glycine encephalopathy (non-ketotic hyperglycinemia): Consistent with abnormal circulating glycine concentration. May not present with aminoaciduria or elevated urinary carboxylic acid.

+2. Methylmalonic acidemia: Consistent with elevated urinary carboxylic acid and aminoaciduria. May not present with abnormal circulating glycine concentration.

+3. Propionic acidemia: Consistent with elevated urinary carboxylic acid and aminoaciduria. May not present with abnormal circulating glycine concentration.

+4. Isovaleric acidemia: Consistent with elevated urinary carboxylic acid and aminoaciduria. May not present with abnormal circulating glycine concentration.

+5. Other organic acidemias: Consistent with elevated urinary carboxylic acid and aminoaciduria. May or may not present with abnormal circulating glycine concentration, depending on the specific disorder.",Hereditary metabolic disorders
['Succinic semialdehyde dehydrogenase deficiency'],"+1. Glutaric aciduria type 1: Consistent with elevated urinary carboxylic acid, seizures, hypotonia, and developmental delays. Key symptoms not reported: macrocephaly, dystonia, and subdural hemorrhages.

+2. Maple syrup urine disease (MSUD): Consistent with seizures, ataxia, hypotonia, and developmental delays. Key symptom not reported: maple syrup odor in urine and sweat.

+3. Mitochondrial disorder: Consistent with seizures, hypotonia, developmental delays, and elevated urinary carboxylic acid (potential marker of mitochondrial dysfunction). Specific mitochondrial disorder cannot be determined without additional testing.

+4. Leukodystrophy: Consistent with seizures, ataxia, and developmental delays. Metabolic abnormalities like elevated urinary carboxylic acid are not typically seen.

+5. Peroxisomal disorder: Consistent with neurological symptoms and potential metabolic abnormalities. Specific peroxisomal disorder cannot be determined without additional testing.",Hereditary metabolic disorders
['Argininosuccinic aciduria'],"+1. Organic acidemia: Consistent with metabolic acidosis, vomiting, and potentially fatal course in infancy. Key symptoms not reported: specific metabolic abnormalities, neurological symptoms.

+2. Fatty acid oxidation disorder: Consistent with metabolic acidosis, hepatomegaly, and potentially fatal course in infancy. Key symptoms not reported: hypoglycemia, cardiomyopathy.

+3. Mitochondrial disorder: Consistent with metabolic acidosis, multi-organ involvement (liver, cardiorespiratory), and potentially fatal course in infancy. Key symptoms not reported: neurological symptoms, lactic acidosis.

+4. Glycogen storage disease (GSD) type I (von Gierke disease): Consistent with metabolic acidosis, hepatomegaly, and potentially fatal course in infancy. Key symptoms not reported: hypoglycemia, growth retardation.

+5. Lysosomal storage disorder (e.g., Gaucher disease, Niemann-Pick disease): Consistent with hepatomegaly and potentially fatal course in infancy. Key symptoms not reported: neurological symptoms, organomegaly (splenomegaly).",Hereditary metabolic disorders
['Gyrate atrophy of choroid and retina'],"+1. Nonketotic hyperglycinemia: Consistent with hyperglycinemia, feeding difficulties, severe short stature, and neurological symptoms (blindness, headache). May not fully explain the hyperammonemia or hypoargininemia.

+2. Citrullinemia type I: Consistent with hyperammonemia, hypoargininemia, and hyperornithinemia. May not explain the hyperglycinemia, blindness, or malabsorption.

+3. Argininosuccinic aciduria: Consistent with hyperammonemia, hypoargininemia, and hyperornithinemia. May not explain the hyperglycinemia, blindness, or malabsorption.

+4. Cystic fibrosis: Consistent with malabsorption, feeding difficulties, and growth failure. May not fully account for the metabolic abnormalities (hyperammonemia, hyperglycinemia, etc.).

+5. Glycine encephalopathy: Consistent with hyperglycinemia, neurological symptoms (blindness, headache), and severe short stature. May not explain the hyperammonemia, hypoargininemia, or malabsorption.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Phenylketonuria (PKU): Characterized by hyperphenylalaninemia, which can lead to developmental delays, seizures, and intellectual disability if untreated. The patient did not report any specific neurological symptoms.

+2. Tyrosinemia type I: A severe form of tyrosinemia characterized by hypertyrosinemia, liver and kidney dysfunction, and potentially death in infancy if untreated. The patient did not report any specific liver or kidney symptoms.

+3. Maple syrup urine disease (MSUD): Characterized by the accumulation of branched-chain amino acids, including leucine, isoleucine, and valine, leading to metabolic decompensation, neurological symptoms, and potentially death if untreated. The patient did not report any specific neurological symptoms.

+4. Homocystinuria: A genetic disorder involving the metabolism of the amino acid homocysteine, which can lead to developmental delays, intellectual disability, and other complications if untreated. The patient did not report any specific symptoms related to homocystinuria.

+5. Glutaric aciduria type I: A genetic disorder involving the metabolism of glutaric acid, which can lead to metabolic decompensation, neurological symptoms, and potentially death if untreated. The patient did not report any specific neurological symptoms.",Hereditary metabolic disorders
['Carbamoyl-phosphate synthetase 1 deficiency'],"+1. Urea cycle disorder: Hyperammonemia, cerebral edema, neonatal death, and feeding difficulties are consistent with a severe urea cycle defect. Key symptoms like citrullinemia or argininosuccinic aciduria were not reported.

+2. Organic acidemia: Conditions like methylmalonic acidemia or propionic acidemia can present with hyperammonemia, cerebral edema, and neurological symptoms due to the accumulation of toxic organic acids. Specific organic acid levels were not provided.

+3. Mitochondrial disorder: Defects in mitochondrial energy production can cause multi-system dysfunction, including hypotonia, feeding difficulties, and neurological impairment. Specific findings like lactic acidosis or elevated lactate levels were not mentioned.

+4. Nonketotic hyperglycinemia: This rare inherited disorder of glycine metabolism can present with hypotonia, lethargy, apnea, and seizures in the neonatal period. Elevated glycine levels in body fluids are characteristic but were not reported.

+5. Maple syrup urine disease: An inherited disorder of branched-chain amino acid metabolism, it can present with poor feeding, lethargy, and cerebral edema in the neonatal period. The characteristic maple syrup odor and elevated branched-chain amino acids were not described.",Hereditary metabolic disorders
['Canavan disease'],"+1. Leukodystrophy (e.g., Krabbe disease, metachromatic leukodystrophy): Consistent with blindness, seizures, hypotonia, abnormal myelination, and neonatal death. Key symptom not reported: specific pattern of neurological deterioration.

+2. Organic acidemia (e.g., maple syrup urine disease, propionic acidemia): Consistent with seizures, hypotonia, abnormal amino acid levels, and neonatal death. Key symptoms not reported: specific metabolic abnormalities, maple syrup odor.

+3. Peroxisomal disorder (e.g., Zellweger syndrome, rhizomelic chondrodysplasia punctata): Consistent with blindness, seizures, hypotonia, abnormal myelination, and neonatal death. Key symptoms not reported: skeletal abnormalities, liver dysfunction.

+4. Mitochondrial disorder: Consistent with seizures, hypotonia, hearing impairment, and multi-system involvement. Key symptoms not reported: specific metabolic abnormalities, muscle weakness.

+5. Congenital disorder of glycosylation (CDG): Consistent with seizures, hypotonia, and multi-system involvement. Key symptoms not reported: specific glycosylation abnormalities, developmental delays.",Hereditary metabolic disorders
"['Methylmalonic acidemia with homocystinuria, type cblC']","+1. Methylmalonic acidemia: Consistent with methylmalonic aciduria, intellectual disability, neurological symptoms (hydrocephalus, microcephaly, strabismus, nystagmus, dyskinesia). Key symptom not reported: recurrent vomiting, lethargy, failure to thrive.

+2. Homocystinuria: Consistent with hyperhomocystinemia, intellectual disability, neurological symptoms. Key symptoms not reported: ectopia lentis, marfanoid habitus, thrombosis.

+3. Mitochondrial disorders: Consistent with intellectual disability, neurological symptoms (hydrocephalus, microcephaly, strabismus, nystagmus, dyskinesia), abnormal circulating carnitine concentration. Key symptoms not reported: lactic acidosis, muscle weakness, seizures.

+4. Cobalamin C deficiency: Consistent with methylmalonic aciduria, hyperhomocystinemia, intellectual disability, neurological symptoms. Key symptoms not reported: megaloblastic anemia, failure to thrive, seizures.

+5. Glutaric aciduria type II: Consistent with intellectual disability, neurological symptoms (hydrocephalus, microcephaly, dyskinesia). Key symptoms not reported: metabolic acidosis, hypoglycemia, organic aciduria.",Hereditary metabolic disorders
['Medium chain acyl-CoA dehydrogenase deficiency'],"+1. Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency (LCHADD): Consistent with decreased 3-hydroxyacyl-CoA dehydrogenase level, vomiting, and potential neonatal death. Key symptom not reported: hypoglycemia.

+2. Carnitine palmitoyltransferase deficiency: Consistent with abnormal circulating carnitine concentration, vomiting, and potential neonatal death. Key symptoms not reported: hypoketotic hypoglycemia, liver dysfunction.

+3. Mitochondrial fatty acid oxidation disorders: Consistent with vomiting, gastrointestinal inflammation, and potential neonatal death. Key symptoms not reported: hypoglycemia, metabolic acidosis.

+4. Organic acidemias: Consistent with vomiting, gastrointestinal inflammation, and potential neonatal death. Key symptoms not reported: metabolic acidosis, hyperammonemia.

+5. Severe combined immunodeficiency (SCID): Consistent with abnormality of prenatal development or birth and potential neonatal death. Key symptoms not reported: recurrent infections, failure to thrive.",Hereditary metabolic disorders
['Biotinidase deficiency'],"+1. Urea cycle disorder: Consistent with hyperammonemia, metabolic acidosis, and potentially fatal neonatal presentation. Key symptoms like vomiting, lethargy, or seizures may not be reported.

+2. Organic acidemia: Matches metabolic acidosis, hyperammonemia, and potentially severe neonatal course. Specific symptoms like ketoacidosis, hypoglycemia, or developmental delay may not be mentioned.

+3. Mitochondrial disorder: Generalized hypotonia and metabolic acidosis are consistent. However, other common features like lactic acidosis, seizures, or neurological regression are not reported.

+4. Severe congenital myopathy: Generalized hypotonia and potentially fatal neonatal course fit. But additional symptoms like respiratory distress, feeding difficulties, or specific muscle biopsy findings are not provided.

+5. Severe combined immunodeficiency (SCID): Leukopenia could indicate an immune disorder like SCID, which can be life-threatening in infancy. However, other key symptoms like recurrent infections or failure to thrive are not reported.",Hereditary metabolic disorders
['Tyrosinemia type 2'],"+1. Tyrosinemia type II (Richner-Hanhart syndrome): Keratitis, conjunctivitis, photophobia, hyperkeratosis, intellectual disability, seizures, hypertyrosinemia. Does not typically lead to death in childhood.

+2. Mucolipidosis II (I-cell disease): Intellectual disability, seizures, hyperkeratosis. Does not typically present with keratitis, conjunctivitis, photophobia, or hypertyrosinemia.

+3. Galactosialidosis: Intellectual disability, seizures, keratitis (corneal clouding). Does not typically present with conjunctivitis, photophobia, hyperkeratosis, or hypertyrosinemia.

+4. Congenital disorders of glycosylation (CDG): Intellectual disability, seizures, keratitis, conjunctivitis, hyperkeratosis. Does not typically present with hypertyrosinemia.

+5. Leukocyte adhesion deficiency type 1: Keratitis, conjunctivitis, photophobia, intellectual disability, seizures. Does not typically present with hyperkeratosis or hypertyrosinemia.",Hereditary metabolic disorders
['Phenylketonuria'],"+1. Phenylketonuria (PKU): Characterized by hyperphenylalaninemia, abnormal circulating tyrosine concentration, and potential for severe developmental and neurological complications if untreated. The patient did not report any specific neurological or developmental symptoms.

+2. Tyrosinemia type I: A disorder of tyrosine metabolism, which could explain the abnormal circulating tyrosine concentration. However, hyperphenylalaninemia is not a typical feature of this condition.

+3. Maple syrup urine disease (MSUD): An inborn error of branched-chain amino acid metabolism, which can present with abnormal amino acid levels and potentially lead to neonatal death or early mortality if untreated. The patient did not report the characteristic maple syrup odor or other specific symptoms of MSUD.

+4. Non-ketotic hyperglycinemia: A rare disorder of glycine metabolism that can cause neonatal seizures, apnea, and developmental delay, potentially leading to early death. The patient did not report any specific neurological symptoms.

+5. Homocystinuria: A disorder of methionine metabolism that can cause developmental delay, intellectual disability, and other complications if untreated. However, the patient did not report any specific symptoms associated with homocystinuria.",Hereditary metabolic disorders
[],"+1. Methylmalonic acidemia: Consistent with hyperammonemia, seizures, neonatal death, and 3-hydroxydicarboxylic aciduria. Key symptom not reported: metabolic acidosis.

+2. Propionic acidemia: Consistent with hyperammonemia, seizures, neonatal death, and 3-hydroxydicarboxylic aciduria (3-hydroxypropionic acid). Key symptom not reported: metabolic acidosis.

+3. Isovaleric acidemia: Consistent with hyperammonemia, seizures, and neonatal death. Key symptoms not reported: metabolic acidosis, presence of isovaleric acid in urine.

+4. Ornithine transcarbamylase deficiency (urea cycle disorder): Consistent with hyperammonemia, seizures, and neonatal death. Key symptom not reported: elevated orotic acid levels.

+5. Carbamoyl phosphate synthetase I deficiency (urea cycle disorder): Consistent with hyperammonemia, seizures, and neonatal death. Key symptom not reported: elevated orotic acid levels.",Hereditary metabolic disorders
['Alkaptonuria'],"+1. Urea cycle disorder: Consistent with vomiting, dark urine (due to elevated ammonia levels), and potential for death in infancy if untreated. Key symptoms not reported: neurological symptoms, hyperammonemia.

+2. Organic acidemia: Consistent with vomiting, dark urine (due to the presence of organic acids), and potential for death in infancy if untreated. Key symptoms not reported: metabolic acidosis, ketosis, developmental delay.

+3. Biliary atresia: Consistent with vomiting, dark urine (due to elevated bilirubin levels), and potential for death in infancy if not treated with surgical intervention. Key symptoms not reported: jaundice, pale stools, hepatomegaly.

+4. Neonatal hepatitis: Consistent with vomiting, dark urine (due to elevated bilirubin levels), and potential for death in infancy if severe. Key symptoms not reported: jaundice, hepatomegaly, coagulopathy.

+5. Sepsis: Consistent with vomiting, dark urine (due to hemolysis or rhabdomyolysis), and potential for death in infancy if not treated promptly. Key symptoms not reported: fever, lethargy, respiratory distress.",Hereditary metabolic disorders
['Maple syrup urine disease'],"+1. Maple syrup urine disease (MSUD): Consistent with seizures, lethargy, metabolic acidosis, hyperammonemia, elevated branched-chain amino acids (valinemia, leucinemia, isoleucinemia), and feeding difficulties. Key symptoms not reported: maple syrup odor in urine and cerumen.

+2. Isovaleric acidemia: Consistent with seizures, lethargy, metabolic acidosis, hyperammonemia, and elevated urinary carboxylic acid. Key symptoms not reported: distinctive sweaty feet odor.

+3. Methylmalonic acidemia: Consistent with seizures, lethargy, metabolic acidosis, hyperammonemia, and elevated urinary carboxylic acid. Key symptoms not reported: developmental delay, hypotonia, and renal complications.

+4. Propionic acidemia: Consistent with seizures, lethargy, metabolic acidosis, hyperammonemia, and elevated urinary carboxylic acid. Key symptoms not reported: developmental delay, hypotonia, and protein avoidance.

+5. Glutaric acidemia type II: Consistent with seizures, lethargy, metabolic acidosis, hyperammonemia, and elevated urinary carboxylic acid. Key symptoms not reported: hypoglycemia and macrocephaly.",Hereditary metabolic disorders
['Ornithine transcarbamylase deficiency'],"+1. Citrullinemia type I: Consistent with hyperammonemia, cerebral edema, oroticaciduria, elevated plasma citrulline, and abnormal amino acid levels. Key symptoms like hypoglycemia and athetosis are not typical.

+2. Urea cycle disorder (e.g., OTC deficiency, CPS1D): Consistent with hyperammonemia, cerebral edema, and abnormal amino acid levels. Does not fully explain hypoglycemia, athetosis, and other symptoms.

+3. Organic acidemia (e.g., propionic acidemia, methylmalonic acidemia): Consistent with metabolic derangements, hypoglycemia, and neurological symptoms. Specific metabolic abnormalities not described.

+4. Recurrent metabolic encephalomyopathic crises-rhabdomyolysis-cardiac arrhythmia-intellectual disability syndrome: Consistent with hypoglycemia, hyperammonemia, and abnormal creatine kinase levels. Does not explain oroticaciduria, aminoaciduria, or other symptoms.

+5. Galactosemia: Consistent with hypoglycemia, vomiting, and liver dysfunction. Does not explain hyperammonemia, cerebral edema, or abnormal amino acid levels.",Hereditary metabolic disorders
